Compounds for the Degradation of EGFR Kinase
Novel bifunctional compounds targeting EGFR mutations via E3 ubiquitin ligases address the limitations of existing EGFR-targeting PROTACs by effectively degrading Del19, L858R, Del19/T790M, L858R/T790M, and L858R/T790M/C797S mutations, providing a therapeutic approach for non-small cell lung cancer.
Patent Information
- Application Number
- JP2024529800
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-10-25
- Filing Date
- 2022-11-29
- Publication Date
- 2024-11-12
AI Technical Summary
Existing EGFR-targeting PROTACs fail to degrade all major EGFR mutations such as Del19, L858R, Del19/T790M, L858R/T790M, and L858R/T790M/C797S, necessitating the development of novel compounds that can effectively target and degrade these mutations.
Novel bifunctional compounds are conjugated with an EGFR inhibitor moiety and an E3 ligase ligand moiety to recruit target proteins to E3 ubiquitin ligases for degradation, providing a method for treating diseases affected by EGFR modulation.
The compounds effectively target and degrade various EGFR mutations, offering a potential solution for overcoming drug resistance in non-small cell lung cancer by recruiting EGFR proteins to the ubiquitin-proteasome pathway for degradation.
Smart Images

Figure 2024541758000001 
Figure 2024541758000002 
Figure 2024541758000003
Abstract
Description
[Technical Field]
[0001] Disclosed herein are novel bifunctional compounds formed by conjugating an EGFR inhibitor moiety with an E3 ligase ligand moiety, which function to recruit target proteins to E3 ubiquitin ligases for degradation, as well as methods for their preparation and use. [Background technology]
[0002] Protein degradation-targeting chimeras (PROTACs) consist of two covalently linked protein-binding molecules: one capable of binding to an E3 ubiquitin ligase, and the other capable of binding to a protein of interest (POI) that is targeted for degradation (Sakamoto KM et al., Proc. Natl. Acad. Sci. 2001, 98:8554-9; Sakamoto KM et al., Methods Enzymol. 2005, 399:833-847). Rather than inhibiting the enzymatic activity of the target protein, they recruit E3 ligase to specific unwanted proteins, resulting in ubiquitination of the target protein and subsequent degradation by the proteasome. The entire process of ubiquitination and proteasomal degradation is known as the ubiquitin-proteasome pathway (UPP) (Ardley H. et al., Essays Biochem. 2005, 41, 15-30; Komander D. et al., Biochem. 2012, 81, 203-229; Grice G. Lett. et al., Cell Rep. 2015, 12, 545-553; Swatek K. Nett. et al., Cell Res. 2016, 26, 399-422). The proteasome is a protein complex that degrades unnecessary, misfolded, or abnormal proteins into small peptides to maintain cellular health and productivity. Ubiquitin ligases, also known as E3 ubiquitin ligases, directly catalyze the transfer of ubiquitin from E2s to target proteins for degradation.Although the human genome encodes over 600 putative E3 ligases, only a limited number of E3 ubiquitin ligases have been widely applied by small molecule PROTAC technology: cereblon (CRBN), von Hippel-Lindau disease (VHL), mouse double minute 2 homolog (MDM2), cellular inhibitor of apoptosis proteins (cIAP) (Philipp O. et al., Chem. Biol. 2017, 12, 2570-2578), recombinant human RING finger protein 114 (RNF114) (Spradlin, J. Net et al., Nat. Chem. Biol. 2019, 15, 747-755), and DDB1 and CUL4-associated factor 16 (DCAF16) (Zhang, X. et al., Nat. Chem. Biol. 2019, 15, 737-746). For example, cereblon (CRBN) forms an E3 ubiquitin ligase complex with damaged DNA-binding protein 1 (DDB1) and cullin-4A (CUL4A), which ubiquitinates several other proteins and subsequently degrades them via the proteasome (Yi-An Chen, et al., Scientific Reports 2015, 5, 1-13). Immunomodulatory drugs (IMiDs), such as thalidomide, lenalidomide, and pomalidomide, inhibit CRL4A. CRBNIt functions as a monovalent promoter of PPIs by binding to the cereblon (CRBN) subunit of the E3 ligase complex and recruiting new substrate proteins (Matyskiela, ME et al., Nat Chem Biol 2018, 14, 981-987). Consequently, the ability of thalidomide and its derivatives to recruit CRBN has been widely applied in proteolytic targeting chimeras (PROTACs)-related research (Christopher T. et al., ACS Chem. Biol. 2019, 14, 342-347; Honorine L. et al., ACS Cent. Sci. 2016, 2, 927-934). PROTACs have great potential to eliminate protein targets and non-enzyme proteins that are "undruggable" by conventional inhibitors (Chu TT. et al., Cell Chem Biol. 2016;23:453-461. Qin C. et al., J Med Chem 2018;61:6685-6704. Winter GE. et al., Science 2015;348:1376-1381.).In recent years, PROTACs have been reported as useful modulators for promoting the selective degradation of a wide range of target proteins in anti-tumor research (Lu J. et al., Chem Biol. 2015;22(6):755-763; Ottis P. et al., Chem Biol. 2017;12(4):892-898; Crews CM et al., J Med Chem. 2018;61(2):403-404; Neklesa TK et al., Pharmacol Ther. 2017,174:138-144; Cermakova K. et al., Molecules, 2018.23(8); An S. et al., BioMedicine, 2018; Lebraud H. et al., Essays Biochem. 2017;61(5):517-527; Sun YH et al., Cell Res.2018;28:779-81;Toure M.et al.,Angew Chem Int Ed Engl.2016;55(6):1966-1973;Yonghui Sun et al.,Leukemia,volume 33,pages 2105-2110(2019);Shaodong Liu et al.,Medicinal Chemistry Research,volume 29 pages 802-808(2020); Patent publications, for example, US20160045607, US20170008904, US20180050021, US20180072711, WO2002020740, WO2014108452, WO2016146985, WO2016149668, WO2016197032, WO2016197114, WO2017011590, WO2017030814, WO 2017079267, WO2017182418, WO2017197036, WO2017197046, WO2017197051, WO2017197056, WO2017201449, WO2018071606, WO2021178920, WO2021127283, WO2021127190, WO202111871 and WO202111913.
[0003] The epidermal growth factor receptor (EGFR), a member of the ErbB family, is a transmembrane receptor tyrosine kinase (RTK) that plays a fundamental role in cell proliferation, differentiation, and motility (Y. Yarden, et al., Nat. Rev. Mol. Cell Biol. 2001;2:127-137). Homodimerization or heterodimerization of EGFR with other ErbB family members activates the cytoplasmic tyrosine kinase domain, initiating intracellular signal transduction. Overexpression or activating mutations of EGFR are associated with the development of many types of cancer, including pancreatic cancer, breast cancer, glioblastoma multiforme, head and neck cancer, and non-small cell lung cancer (Yewale C., et al., Biomaterials. 2013,34(34):8690-8707). Activating mutations in the EGFR tyrosine kinase domain (L858R mutation and exon 19 deletion) have been identified as oncogenic drivers of NSCLC (Konduri, K., et al. Cancer Discovery 2016, 6(6), 601-611). The first-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib, have been approved for patients with NSCLC harboring EGFR-activating mutations (M. Maemondo, N. Engl. J. Med. 362(2010)2380-2388). While most patients with EGFR-mutant NSCLC respond to these therapies, resistance typically develops after an average of one year of treatment. Acquired resistance to gefitinib and erlotinib has several mechanisms, including a secondary threonine 790 to methionine 790 mutation (T790M), also known as the "gatekeeper" T790M mutation (Xu Y., et al. Cancer Biol Ther. 2010, 9(8):572-582). Therefore, the second-generation EGFR-TKI afatinib and the third-generation EGFR-TKI osimertinib (AZD9291) were developed as irreversible EGFR inhibitors that bind to Cys797 for the treatment of patients with the T790M mutation. Notably, osimertinib, which largely avoids wild-type EGFR, achieved higher clinical response rates in NSCLC patients with EGF-RT790M mutation.However, several recent studies have reported a tertiary Cys797 to Ser797 (C797S) point mutation in osimertinib-treated patients (Thress KS, et al. Nat. Med. 2015, 21(6):560-562). There is a need for drugs that can overcome EGFR (C797S) resistance in non-small cell lung cancer (NSCLC). PROTACs targeting EGFR serve as a potential strategy to overcome drug resistance mediated by these mutations, as disclosed or discussed in patent publications such as WO2018119441, WO2019149922, WO2019183523, WO2019121562, US20190106417, WO202157882, WO2021123087, WO2021133809, WO2021168074, WO2021208918 and WO2021216440.
[0004] However, several EGFR-targeting PROTACs designed to degrade EGFR mutant proteins have been published (Zhang X., et al. Eur. J. Med. Chem. 2020, 192, 112199; Zhang H, et al. Eur. J. Med. Chem. 2020, 189, 112061; Lu X. Med. Res. Rev. 2018, 38(5):1550-1581; He K., et al. Bioorg. Med. Chem. Lett. 2020, 15, 127167). Most of the published molecules are based on first-, second-, or third-generation EGFR inhibitors (WO2021023233, WO2019121562, and WO2018119441) or allosteric EGFR inhibitors (WO2021127561). However, there was no data demonstrating that EGFR-targeting PROTACs degrade all major EGFR mutations, such as Del19, L858R, Del19 / T790M, L858R / T790M, Del19 / T790M / C797S, and L858R / T790M / C797S.
[0005] The present application provides novel bifunctional compounds and compositions for the treatment of serious diseases. Summary of the Invention [Problem to be solved by the invention]
[0006] One object of the present invention is to provide compounds and derivatives formed by conjugating an EGFR inhibitor moiety with an E3 ligase ligand moiety, which function to recruit target proteins to E3 ubiquitin ligases for degradation, as well as methods for their preparation and use. [Means for solving the problem]
[0007] The compounds described herein or salts thereof are useful for treating diseases that may be affected by EGFR modulation. The present invention provides the use of the compounds described herein or pharmaceutically acceptable salts thereof in the manufacture of a medicament for treating a disease that may be affected by EGFR modulation. The present invention further provides the compounds described herein or pharmaceutically acceptable salts thereof for use in treating a disease that may be affected by EGFR modulation. The present application further provides a method of treating a proliferative disease, comprising administering to a subject in need thereof a therapeutically effective amount of a compound described herein or a pharmaceutically acceptable salt thereof.
[0008] Aspect 1: A compound of formula (I):
[0009] [ka]
[0010] (I)
[0011] or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a deuterated analog thereof, or a prodrug thereof,
[0012] During the ceremony:
[0013] R 3 and R4 are each independently absent, hydrogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl or -C 3-8 is cycloalkyl; -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl or -C 3-8 Each cycloalkyl can be hydrogen, halogen, -C 1-8 Alkoxy, -C 3-8 optionally substituted with at least one substituent selected from cycloalkyl or -CN;
[0014] R 1a , R 1b , R 1c , R 1d , R 5a , R 5b , R 6a , R 6b , R 7a , R 7b , R 2 , R 8 , R 9 and R 10 are each independently absent, hydrogen, halogen, or -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 Alkoxy, - C3-8 cycloalkyl or -CN, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 Alkoxy, or -C 3-8 Each cycloalkyl can be hydrogen, halogen, -C 1-8 Alkoxy, -C 3-8 optionally substituted with at least one substituent selected from cycloalkyl or —CN;
[0015] [ka] is optionally O or NR a may be substituted with;
[0016] R 1a , R 1b , R 1c , R 1d , R 5a , R 5b , R 6a , R 6b , R 7a and R 7b two pairs or adjacent substituents from the group consisting of:
[0017] R 11a , R 11b , R 11c , R 11d , R 12a , R 12b , R 12c and R 12d are each independently absent, oxo, hydrogen, halogen, or -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 Alkoxy or -C 3-8 is cycloalkyl; -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 Alkoxy or -C 3-8 Each cycloalkyl can be hydrogen, halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 optionally substituted with at least one substituent selected from alkoxy or —CN; or
[0018] R 11a and R 12aform a 3- to 12-membered ring together with the carbon atom to which they are attached, said ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; said ring containing hydrogen, halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 optionally substituted with at least one substituent selected from alkoxy or -CN;
[0019] R 11b and R 12b form a 3- to 12-membered ring together with the carbon atom to which they are attached, said ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; said ring containing hydrogen, halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 optionally substituted with at least one substituent selected from alkoxy or -CN;
[0020] R 11c and R 12c form a 3- to 12-membered ring together with the carbon atom to which they are attached, said ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; said ring containing hydrogen, halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 optionally substituted with at least one substituent selected from alkoxy or -CN;
[0021] R 11d and R 12d form a 3- to 12-membered ring together with the carbon atom to which they are attached, said ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; said ring containing hydrogen, halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8optionally substituted with at least one substituent selected from alkoxy or -CN;
[0022] L 1 -O-, -NR a -, -C(O)-, * L1 -C(O)NR a -** L1 , * L1 -C(O)O-** L1 , * L1 -NR a C(O)-** L1 , * L1 -OC(O)-** L1 , [ka] are independently selected from [ka] Each of the L1c optionally replaced by:
[0023] In the formula, * L1 is the part [ka] and ** L1 is the part [ka] refers to the position to be attached;
[0024] L 2 -O-, -NR a -, -C(O)-, * L2 -C(O)NR a -** L2 , * L2 -C(O)O-** L2 , * L2 -NR a C(O)-** L2 , * L2 -OC(O)-** L2 , [ka] are independently selected from [ka] Each of the L2c optionally replaced by:
[0025] In the formula, * L2 is the part [ka] and ** L2 is the part [ka] refers to the position to be attached;
[0026] L 3 -O-, -NR a -, -C(O)-, * L3 -C(O)NR a -** L3 , * L3 -C(O)O-** L3 , * L3 -NR a C(O)-** L3 , * L3 -OC(O)-** L3 , [ka] are independently selected from [ka] Each of the L3c optionally replaced by:
[0027] In the formula, * L3 is the part [ka] and ** L3 is the part [ka] refers to the position to be attached;
[0028] R L1c , R L2c and R L3c each independently is absent, oxo (=O), halogen, hydroxy, -CN, -C1-C8 alkyl, -C1-C8 alkoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, C3-C8 cycloalkyl, 3- to 8-membered heterocyclyl, C6-C 12 aryl or 5- to 12-membered heteroaryl; said -C1-C8 alkyl, -C1-C8 alkoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, C3-C8 cycloalkyl, 3- to 8-membered heterocyclyl, C6-C 12 Each of the aryl and 5- to 12-membered heteroaryl has at least one substituent R Lca optionally replaced by
[0029] R Lca are independently absent, oxo (=O), halogen, hydroxy, -CN, -C1-C8 alkyl, -C1-C8 alkoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, C3-C8 cycloalkyl, 3- to 8-membered heterocyclyl, C6-C 12 aryl or 5-12 membered heteroaryl;
[0030] The Two R's L1c are taken together with the atoms to which they are attached to form a 3-12 membered ring, said ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; said ring is optionally substituted with at least one substituent halogen, hydroxy, -C1-C8 alkyl;
[0031] The Two R's L2care taken together with the atoms to which they are attached to form a 3-12 membered ring, said ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; said ring is optionally substituted with at least one substituent halogen, hydroxy, -C1-C8 alkyl;
[0032] The Two R's L3c are taken together with the atoms to which they are attached to form a 3-12 membered ring, said ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; said ring is optionally substituted with at least one substituent halogen, hydroxy, -C1-C8 alkyl;
[0033] [ka] teeth, [ka] Selected from;
[0034] Z 1 , Z 2 , and Z 3 are each independently N or CR z However, Z 1 , Z 2 , and Z 3 is not N at the same time;
[0035] R z is, in each occurrence, absent or a hydrogen, halogen, -C 1-8 Alkyl, -NR Za R Zb , -OR Za , -SR Za , C3-C8 cycloalkyl, 3- to 8-membered heterocyclyl, or CN; -C 1-8 Each of alkyl, C3-C8 cycloalkyl, and 3- to 8-membered heterocyclyl is selected from at least one R Zc optionally replaced by;
[0036] The part [ka] is Z 1 , Z 2 or Z 3 via any of the above. [ka] Connected to CR z and R z is absent;
[0037] R Za and R Zb are each independently absent, hydrogen, -C1-C8 alkyl, C3-C8 cycloalkyl, 3- to 8-membered heterocyclyl, C6-C 12 aryl, or 5- to 12-membered heteroaryl; 1~8 Alkyl, C3-C8 cycloalkyl, 3-8 membered heterocyclyl, C6-C 12 Each aryl or 5- to 12-membered heteroaryl may contain at least one substituent R Zd optionally replaced by;
[0038] R Zc and R Zd are each independently halogen, hydroxy, -C1 to C8 alkyl, -C 1~8 Alkoxy, C3-C8 cycloalkyl, 3-8 membered heterocyclyl, C6-C 12 aryl, or 5- to 12-membered heteroaryl;
[0039] R 13 and R 14 are absent, hydrogen, halogen, or -C, respectively. 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Alkynyl, -C 1~8 Alkoxy, -C3-C8 cycloalkyl, 3-8 membered heterocyclyl, -C6-C 12 Aryl, 5-12 membered heteroaryl, -CN, -SO2R 13a , -SO2NR 13a R13 b, -COR 13a , -CO2R 13a , -CONR 13a R 13b , -NR 13a R 13b , -NR 13a COR 13b , -NR 13a CO2R 13b , or -NR 13a SO2R 13b are independently selected from ;-C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 Alkoxy, -C3-C8 cycloalkyl, 3-8 membered heterocyclyl, -C6-C 12 Each of the aryl or 5- to 12-membered heteroaryl is selected from the group consisting of halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C3-C8 cycloalkyl, 3-8 membered heterocyclyl, C6-C 12 Aryl, 5-12 membered heteroaryl, oxo, -CN, -OR 13c , -SO2R 13c , -SO2NR 13c R 13d , -COR 13c , -CO2R 13c , -CONR 13c R 13d , -NR 13c R 13d , -NR 13c COR 13d , -NR 13c CO2R 13d , or -NR 13c SO2R 13d optionally replaced by;
[0040] In each occurrence, R 13a , R 13b , R 13c and R 13d are each independently absent, hydrogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8Alkynyl, C3-C8 cycloalkyl, 3-8 membered heterocyclyl, C6-C 12 aryl, or 5- to 12-membered heteroaryl;
[0041] L 4 , L 5 and L 6 are each independently absent, a single bond, -O-, or -NR a -,-(CR a R b ) n8 -, -O(CR a R b ) n8 -, -NR a (CR a R b ) n8 - or -C(O)-;
[0042] In each occurrence, X 1 , X 2 and X 7 are independently -CR a , or N;
[0043] In each occurrence, X 3 , X 4 and X 8 are each independently -NR a -, -O-, -S- and -CR a R b -Selected from;
[0044] In each occurrence, X 5 and X 6 are each independently absent, a single bond, -C(O)-, or -NR a - and -O-;
[0045] In each occurrence, R a and R b are each independently hydrogen, hydroxy, halogen, CN, -C1-C8 alkyl, -C1-C8 alkoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, -C3-C8 cycloalkyl, 3- to 8-membered heterocyclyl, -C6-C 12aryl or 5- to 12-membered heteroaryl; -C1-C8 alkyl, -C1-C8 alkoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, -C3-C8 cycloalkyl, 3- to 8-membered heterocyclyl, -C6-C 12 Each aryl or 5- to 12-membered heteroaryl may have at least one substituent, such as halogen, hydroxy, halogen, -C1-C8 alkyl, -C1-C8 alkoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, -C3-C8 cycloalkyl, 3- to 8-membered heterocyclyl, -C6-C 12 optionally substituted aryl or 5- to 12-membered heteroaryl; or
[0046] R a and R b are taken together with the carbon atoms to which they are attached to form a 3- to 12-membered ring, said ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; said ring containing at least one substituent, halogen, hydroxy, -C1-C8 alkyl, -C2-C8 alkenyl, -C2-C8 alkynyl, -C1-C8 alkoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, C3-C8 cycloalkyl, 3- to 8-membered heterocyclyl, C6-C 12 optionally substituted aryl or 5-12 membered heteroaryl;
[0047] m1, m2, m3, and m4 are each independently 0, 1, or 2; provided that m1+m2+m3+m4≦4;
[0048] m5, m6, and m7 each independently represent 0 or 1; provided that m5+m6+m7≧1;
[0049] n1, n2, n3, n4, and n5 are each independently 0, 1, 2, or 3;
[0050] n6, n7, and n8 are each independently 0, 1, 2, 3, or 4;
[0051] however,
[0052] L 1 , L 2 or L 3 For any one of X 1 If N, then X 5 is a single bond, is absent, is —C(O)—; and / or X 2 If N, then X 6 is a single bond, absent, or -C(O)-;
[0053] L 1 but [ka] If X 1 If N, then X 5 is a single bond, is absent, or is —C(O)—, and / or X 3 -CR a R b - and X 2 If N, then X 6 is a single bond, is absent, or is —C(O)—, and / or X 4 -CR a R b - and;
[0054] L 2 but [ka] If X 1 If N, then X 5 is a single bond, is absent, or is —C(O)—, and / or X 3 -CR a R b - and X 2 If N, then X 6 is a single bond, is absent, or is —C(O)—, and / or X 4 -CR a R b - and;
[0055] L 3 but [ka] If X 1 If N, then X 5 is a single bond, is absent, or is —C(O)—, and / or X 3 -CR a R b - and X 2 If N, then X 6 is a single bond, is absent, or is —C(O)—, and / or X 4 -CR a R b The compound,
[0056] Aspect 2: The compound of aspect 1, wherein the compound is selected from formula (II):
[0057] [ka]
[0058] where R 1a , R 1b , R 1c , R 1d , R 2 , R 3 , R 4 , R 5a , R 5b , R 6a , R 6b , R 7a , R 7b , R 8 , R 9 , R 10 , R 11a , R 11b , R 11c , R 11d , R 12a , R 12b , R 12c , R 12d , R 13 , R 14 , L 1 , L 2 , L 3 , L 4 , Z 1 , Z2 , Z 3 , X 7 , X 8 , m1, m2, m3, m4, m5, m6, m7 and n6 are defined as in embodiment 1.
[0059] Embodiment 3: The compound of any one of the preceding embodiments, wherein the compound is selected from Formula (III);
[0060] [ka]
[0061] where R 1a , R 1b , R 1c , R 1d , R 2 , R 3 , R 4 , R 5a , R 5b , R 6a , R 6b , R 7a , R 7b , R 8 , R 9 , R 10 , R 11a , R 11b , R 11c , R 11d , R 12a , R 12b , R 12c , R 12d , R 13 , L 1 , L 2 , L 3 , L 5 , L 6 , X 8 , m1, m2, m3, m4, m5, m6, m7, n6 and n7 are as defined in any one of the preceding aspects.
[0062] Embodiment 4: The compound of any one of the preceding embodiments, wherein the compound is selected from formula (IV);
[0063] [ka]
[0064] where R 1a , R 1b , R 1c , R 1d , R 2 , R 3 , R 4 , R 5a , R 5b , R 6a , R 6b , R 7a , R 7b , R 8 , R 9 , R 10 , R 11a , R 11b , R 11c , R 11d , R 12a , R 12b , R 12c , R 12d , R 13 , L 1 , L 2 , L 3 , L 5 , L 6 , X 8 , m1, m2, m3, m4, m5, m6, m7, n6 and n7 are as defined in any one of the preceding aspects.
[0065] Embodiment 5: The compound of any one of the preceding embodiments, wherein the compound is selected from Formula (Va), (Vb), (Vc), or (Vd);
[0066] [ka]
[0067] [ka]
[0068] [ka]
[0069] [ka]
[0070] where R 1a , R 1b , R 1c , R 1d , R 2 , R 3 , R 4 , R 5a , R 5b , R 6a , R 6b , R 7a , R 7b , R 8 , R 9 , R 10 , R 11a , R 11b , R 11c , R 11d , R 12a , R 12b , R 12c , R 12d , R 13 , R 14 , L 1 , L 2 , L 3 , L 6 , Z 1 , Z 2 , Z 3 , m1, m2, m3, m4, m5, m6, m7 and n7 are as defined in any one of the preceding aspects.
[0071] Embodiment 6: The compound of any one of the preceding embodiments, wherein the compound is selected from Formula (VIa), (VIb), (VIc), (VId), or (VIe);
[0072] [ka]
[0073] [ka]
[0074] [ka]
[0075] [ka]
[0076] [ka]
[0077] where R 1a , R 1b , R 1c , R 1d , R 2 , R 3 , R 4 , R 5a , R 5b , R 6a , R 6b , R 7a , R 7b , R 8 , R 9 , R 10 , R 11a , R 11b , R 11c , R 11d , R 12a , R 12b , R 12c , R 12d , R 13 , R 14 , L 1 , L 2 , L 3 , m1, m2, m3, m4, m5, m6, m7 and n7 are as defined in any one of the preceding aspects.
[0078] Embodiment 7: The compound of any one of the preceding embodiments, wherein the compound is selected from Formula (VIIa), (VIIb), (VIIc), (VIId), or (VIIe);
[0079] [ka]
[0080] [ka]
[0081] [ka]
[0082] [ka]
[0083] [ka]
[0084] where R 1a , R 1b , R 1c , R 1d , R 2 , R 3 , R 4 , R 5a , R 5b , R 6a , R 6b , R 7a , R 7b , R 8 , R 9 , R 10 , R 13 , R 14 , L 1 , L 2 , L 3 , m1, m2, m3, m4, m5, m6, m7 and n7 are as defined in any one of the preceding aspects.
[0085] Embodiment 8: The compound of any one of the preceding embodiments, wherein the compound is selected from Formula (VIIIa), (VIIIb), (VIIIc), or (VIIId);
[0086] [ka]
[0087] (VIIIa)
[0088] [ka]
[0089] (VIIIb)
[0090] [ka]
[0091] (VIIIc)
[0092] [ka]
[0093] (VIIId);
[0094] where R 1a , R 1b , R 1c , R 1d , R 2 , R 3 , R 4 , R 5a , R 5b , R 6a , R 6b , R 7a , R 7b , R 8 , R 9 , R 10 , R 11b , R 11c , R 11d , R 12b , R 12c , R 12d , R 13 , R 14 , L 2 , L 3 , m2, m3, m4, m6, m7 and degron are as defined in any one of the preceding aspects.
[0095] Embodiment 9. The compound of any one of the preceding embodiments, wherein m1 + m2 + m3 + m4 ≦3.
[0096] Embodiment 10. A compound according to any one of the preceding embodiments, wherein m1+m2+m3+m4=1, 2, or 3; preferably, m1+m2+m3+m4=1 or 2.
[0097] Embodiment 11. A compound according to any one of the preceding embodiments, comprising the moiety [ka] The compound, wherein the number of -CH2- is 4 or less, preferably 3 or less, and more preferably 2 or less.
[0098] Embodiment 12. A compound according to any one of the preceding embodiments, wherein R 3 and R 4 are each independently hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 The alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl is optionally substituted with at least one substituent selected from hydrogen, F, Cl, Br, I, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, or -CN.
[0099] Aspect 13. A compound according to any one of the preceding aspects, wherein R 3 and R4 are each independently hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl, and preferably R 3 are independently methyl or cyclopropyl, and R 4 is hydrogen.
[0100] Embodiment 14. A compound according to any one of the preceding embodiments, wherein R 1a , R 1b , R 1c , R 1d , R 5a , R 5b , R 6a , R 6b , R 7a , R 7b , R 2 , R 8 , R 9 and R 10 are each independently hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 alkynyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, or -CN; methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8wherein each of alkynyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl is optionally substituted with at least one substituent selected from hydrogen, F, Cl, Br, I, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, or —CN.
[0101] Embodiment 15. A compound according to any one of the preceding embodiments, wherein R 1a , R 1b , R 1c , R 1d , R 5a , R 5b , R 6a , R 6b , R 7a , R 7b , R 2 , R 8 , R 9 and R 10 are each independently hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -CF3, -CHF2, -CN, -CHOCH3, -CHOCHCH3, -CHCHOCH3-CHCH2OCH2CH3; preferably, R 1a , R 1b , R 1c , R 1d , R 5a , R 5b , R 6a , R 6b , R 7a , R 7b , R 2 , R 8 , R 9 and R 10are each independently hydrogen, F, Cl, methyl, methoxy, cyclopropyl, -CF3 or -CHF2, -CH2OCH3, and more preferably, R 2 is hydrogen, methyl, methoxy, cyclopropyl, or -CF3; R 8 is hydrogen, F, methyl, -CF3 or -CHF2; R 9 is hydrogen or F; R 10 is hydrogen, F, Cl, methyl or -CH2OCH3; R 1a , R 1b , R 1c , R 1d , R 5a , R 5b , R 6a , R 6b , R 7a and R 7b are each independently hydrogen, F or methyl.
[0102] Aspect 16. A compound according to any one of the preceding aspects, wherein (R 1a and R 1b ), (R 1c and R 1d ), (R 5a and R 5b ), (R 6a and R 6b ), (R 7a and R 7b ), (R 1a and R 1c ), (R 1a and R 1d ), (R 1b and R 1c ), (R 1b and R 1d ), (R 1a and R 5a ), (R 1a and R 5b ), (R 1b and R 5a ), (R 1b and R 5b ), (R 5a and R 6a ), (R 5a and R 6b ), (R 5b and R 6a), (R 5b and R 6b ), (R 6a and R 7a ), (R 6a and R 7b ), (R 6b and R 7a ) or (R 6b and R 7b ) together with the carbon atoms to which they are attached form a 3-, 4-, 5-, 6-, 7-, or 8-membered ring, said ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, said ring being optionally substituted with at least one substituent F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl.
[0103] Aspect 17. A compound according to any one of the preceding aspects, wherein the moiety [ka] but, [ka] [ka] The compound is selected from
[0104] Embodiment 18. A compound according to any one of the preceding embodiments, wherein R 11a , R 11b , R 11c , R 11d , R 12a , R 12b , R 12c and R 12d are each independently hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8alkynyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl are each selected from hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 optionally substituted with at least one substituent selected from alkynyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, or —CN; or
[0105] (R 11a and R 12a ), (R 11b and R 12b ), (R 11c and R 12c ) or (R 11d and R 12d ) together with the carbon atoms to which they are attached form a 3-, 4-, 5-, 6-, 7-, or 8-membered ring, said ring containing 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; said ring containing hydrogen, halogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 The compound is optionally substituted with at least one substituent selected from alkynyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, or -CN.
[0106] Embodiment 19. A compound according to any one of the preceding embodiments, wherein R 11a , R11b , R 11c , R 11d , R 12a , R 12b , R 12c and R 12d are each independently hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably, R 11a , R 11b , R 11c , R 11d , R 12a , R 12b , R 12c and R 12d are each independently hydrogen, F, Cl, Br, I, methyl, ethyl or propyl; more preferably, R 11a , R 11b , R 11c , R 11d , R 12a , R 12b , R 12c and R 12d are each independently hydrogen or methyl; or
[0107] (R 11a and R 12a ), (R 11b and R 12b ), (R 11c and R 12c ) or (R 11d and R 12d ) together with the carbon atoms to which they are attached form a 3-, 4-, 5-, 6-, 7-, or 8-membered ring, said ring containing 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; preferably, (R 11a and R 12a ), (R 11b and R 12b ), (R 11c and R 12c ) or (R 11d and R 12d) taken together with the carbon atom to which they are attached form a 3-, 4-, or 5-membered cycloalkyl ring.
[0108] Embodiment 20. A compound according to any one of the preceding embodiments, L1 -O-, -C(O)-, -N(R a )-, *L1 -C(O)N(R a )- **L1 , *L1 -C(O)O- **L1 , *L1 -N(R a )C(O)- **L1 , *L1 -OC(O)- **L1 , [ka] [ka] Selected from;
[0109] where: [ka] [ka] Each of the L1c optionally replaced by
[0110] R L1ceach independently represents oxo (=O), F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heterocyclyl. and each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, and 5- to 12-membered heteroaryl is selected from the group consisting of at least one R Lca optionally replaced by
[0111] R Lca are independently oxo (=O), F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl; or
[0112] The Two R's L1c together with the carbon atoms to which they are attached form a 3-, 4-, 5-, 6-, 7-, or 8-membered ring, said ring containing 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; said ring is optionally substituted with at least one substituent F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl;
[0113] R a is selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl, and each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl is , optionally substituted with at least one substituent halogen, hydroxy, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl.
[0114] Embodiment 21. A compound according to any one of the preceding embodiments, wherein L 1 is -O-, -N(CH3)-, -C(O)-, -NH-, *L1 -C(O)N(CH3)- **L1 , *L1 -C(O)NH- **L1 , *L1 -C(O)O- **L1 , *L1 -C(O)N(C2H5)- **L1 , *L1 -C(O)N(C3H7)- **L1 , *L1 -N(CH3)C(O)- **L1 , *L1 -NHC(O)- **L1 , *L1 -OC(O)- **L1 , *L1 -N(C2H5)C(O)- **L1 , *L1 -N(C3H7)C(O)- **L1 , [ka] [ka] [ka] [ka] [ka] [ka] [ka] The compound is selected from
[0115] Aspect 22. A compound according to any one of the preceding aspects, wherein L 2 -O-, -C(O)-, -N(R a )-, *L2 -C(O)N(R a )- **L2 , *L2 -C(O)O- **L2 , *L2 -N(R a )C(O)- **L2 , *L2 -OC(O)- **L2 , [ka] [ka] Selected from;
[0116] Here, the [ka] [ka] Each of theL2c optionally replaced by
[0117] R L2c each independently represents oxo (=O), F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heterocyclyl. and each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, and 5- to 12-membered heteroaryl is selected from the group consisting of at least one R Lca optionally replaced by
[0118] R Lca are independently oxo (=O), F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl; or
[0119] The Two R's L2ctogether with the carbon atoms to which they are attached form a 3-, 4-, 5-, 6-, 7-, or 8-membered ring, said ring containing 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; said ring is optionally substituted with at least one substituent F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl;
[0120] R a is selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl, and each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl is , optionally substituted with at least one substituent halogen, hydroxy, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl.
[0121] Aspect 23. A compound according to any one of the preceding aspects, wherein L 2 is -O-, -N(CH3)-, -C(O)-, -NH-, *L2 -C(O)N(CH3)- **L2 , *L2 -C(O)NH- **L2 , *L2 -C(O)O- **L2 , *L2 -C(O)N(C2H5)- **L2 , *L2 -C(O)N(C3H7)- **L2, *L2 -N(CH3)C(O)- **L2 , *L2 -NHC(O)- **L2 , *L2 -OC(O)- **L2 , *L2 -N(C2H5)C(O)- **L2 , *L2 -N(C3H7)C(O)- **L2 , [ka] [ka] [ka] [ka] [ka] [ka] [ka] The compound is selected from
[0122] Embodiment 24. A compound according to any one of the preceding embodiments, wherein L 3 However, -O-, -N(R a )-, -C(O)-, *L3 -C(O)N(R a )- **L3 , *L3 -C(O)O- **L3 , *L3 -N(R a )C(O)- **L3 , *L3 -OC(O)- **L3 , [ka] [ka] Selected from;
[0123] Here, the [ka] [ka] Each of the L3c optionally replaced by;
[0124] R L3c each independently represents oxo (=O), F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heterocyclyl. and each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, and 5- to 12-membered heteroaryl is selected from the group consisting of at least one R Lca optionally replaced by
[0125] R Lcaare independently oxo (=O), F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl; or
[0126] The Two R's L3c together with the carbon atoms to which they are attached form a 3-, 4-, 5-, 6-, 7-, or 8-membered ring, said ring containing 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; said ring is optionally substituted with at least one substituent F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl;
[0127] R a is selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl, and each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl is , optionally substituted with at least one substituent halogen, hydroxy, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl.
[0128] Embodiment 25. A compound according to any one of the preceding embodiments, wherein L 3 is -O-, -N(CH3)-, -C(O)-, -NH-, *L3 -C(O)N(CH3)- **L3 , *L3 -C(O)NH- **L3 , *L3 -C(O)O- **L3 , *L3 -C(O)N(C2H5)- **L3 , *L3 -C(O)N(C3H7)- **L3 , *L3 -N(CH3)C(O)- **L3 , *L3 -NHC(O)- **L3 , *L3 -OC(O)- **L3 , *L3 -N(C2H5)C(O)- **L3 , *L3 -N(C3H7)C(O)- **L3 , [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] The compound is selected from
[0129] Embodiment 26. A compound according to any one of the preceding embodiments, portion [ka] but, [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] The compound is selected from
[0130] Embodiment 27. A compound according to any one of the preceding embodiments, wherein L 4 is a single bond, -O-, -NR a -,-(CR a R b ) n8 -, -O(CR a R b ) n8 -, -NR a (CR a R b ) n8 - or -C(O)-;
[0131] In each occurrence, R a and R b are each independently selected from hydrogen, hydroxy, -F, -Cl, -Br, -I, -CN, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C-C alkenyl, -C-C alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl; wherein each of the C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl is optionally substituted with at least one substituent halogen, hydroxy, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl.
[0132] Embodiment 28. A compound according to any one of the preceding embodiments, wherein L 4 are independently selected from a single bond.
[0133] Embodiment 29. The compound of any one of the preceding embodiments, wherein X 7 But independently, -CR a , or N;
[0134] R aare independently selected from hydrogen, hydroxy, -F, -Cl, -Br, -I, -CN, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl; wherein each of alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl is optionally substituted with at least one substituent halogen, hydroxy, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl.
[0135] Embodiment 30. A compound according to any one of the preceding embodiments, wherein X 7 is independently selected from -CH, -C(CH), or N; preferably, X 7 are independently selected from —CH.
[0136] Embodiment 31. A compound according to any one of the preceding embodiments, wherein X 8 But independently, -NR a -, -O-, -S- and -CR a R b -Selected from;
[0137] In each occurrence, R a and R b are each independently selected from hydrogen, hydroxy, -F, -Cl, -Br, -I, -CN, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C-C alkenyl, -C-C alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl; wherein each of the C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl is optionally substituted with at least one substituent halogen, hydroxy, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl.
[0138] Aspect 32. A compound according to any one of the preceding aspects, wherein X 8 is independently selected from -NH- and -CH2-; preferably, X 8 is independently selected from -CH2-.
[0139] Embodiment 33. A compound according to any one of the preceding embodiments, [ka] teeth, [ka] is selected from; preferably [ka] teeth, [ka] The compound is selected from
[0140] Embodiment 34. A compound according to any one of the preceding embodiments, wherein Z 1 , Z 2 and Z 3 wherein at most one of the groups is N.
[0141] Embodiment 35. A compound according to any one of the preceding embodiments, wherein Z 1 , Z 2 and Z 3 However, each independently, CR z A compound which is
[0142] Embodiment 36. A compound according to any one of the preceding embodiments, wherein R Z is, in each occurrence, hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -NR Za R Zb , -OR Za , -SR Za , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, or CN; each of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and 3- to 8-membered heterocyclyl is selected from the group consisting of at least one R Zc optionally replaced by;
[0143] R Za and RZb are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl, and each of said hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl is optionally selected from at least one substituent R Zd optionally replaced by;
[0144] R Zc and R Zd are each independently -F, -Cl, -Br, -I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl.
[0145] Embodiment 37. A compound according to any one of the preceding embodiments, wherein R z is selected from H, -CH3, -C2H5, F, -CH2F, -CHF2, -CF3, -OCH3, -OC2H5, -C3H7, -OCH2F, -OCHF2, -OCH2CF3, -OCF3, -SCF3, -CF3 or -CH(OH)CH3.
[0146] Embodiment 38. A compound according to any one of the preceding embodiments, wherein R 13 and R 14are each independently hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, 3-8 membered heterocyclyl, -C6-C 12 Aryl, 5-12 membered heteroaryl, -CN, -SO2R 13a , -SO2NR 13a R 13b , -COR 13a , -CO2R 13a , -CONR 13a R 13b , -NR 13a R 13b , -NR 13a COR 13b , -NR 13a CO2R 13b , or -NR 13a SO2R 13b Selected from: methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, 3-8 membered heterocyclyl, -C6-C 12 Each of aryl and 5- to 12-membered heteroaryl is F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, 3-8 membered heterocyclyl, -C6-C 12 Aryl, 5-12 membered heteroaryl, oxo, -CN, -OR 13c, -SO2R 13c , -SO2NR 13c R 13d , -COR 13c , -CO2R 13c , -CONR 13c R 13d , -NR 13c R 13d , -NR 13c COR 13d , -NR 13c CO2R 13d , or -NR 13c SO2R 13d optionally replaced by;
[0147] R 13a , R 13b , R 13c and R 13d are each independently hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, 3-8 membered heterocyclyl, -C6-C 12 The compound is an aryl or a 5- to 12-membered heteroaryl.
[0148] Embodiment 39. A compound according to any one of the preceding embodiments, wherein R 13 and R 14 are each independently selected from hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, —CN, —CHF, —CHF, —CF, —OCHF, —OCHF, —OCHCF, —OCF, —SCF, or phenyl.
[0149] Embodiment 40. A compound according to any one of the preceding embodiments, [ka] but, [ka] The compound,
[0150] Embodiment 41. A compound according to any one of the preceding embodiments, wherein L 5 and L 6 are each independently a single bond, -O-, or -NR a -,-(CR a R b ) n8 -, -O(CR a R b ) n8 -, -NR a (CR a R b ) n8 - or -C(O)-;
[0151] X 8 -CR a R b - and;
[0152] In each occurrence, R a and R bare each independently selected from hydrogen, hydroxy, -F, -Cl, -Br, -I, -CN, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C-C alkenyl, -C-C alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl; wherein each of the C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl is optionally substituted with at least one substituent halogen, hydroxy, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl.
[0153] Embodiment 42. A compound according to any one of the preceding embodiments, wherein L 5 and L 6 are each independently a single bond, [ka] -O-, -NH-, -NMe-, -N(CH2CH3)-, -CH2-, -CHF-, -CF2-, -C(CH3)2- or CO- (preferably L 5 is -CO- or -CH2-, and L 6 teeth, [ka] -O-, -NH-, -NMe-, -N(CHCH)-, -CHF-, -CF, -C(CH)-, or -CO-;
[0154] where X 8 is CH2;
[0155] The compound wherein n6 is 0 or 1.
[0156] Embodiment 43. A compound according to any one of the preceding embodiments, wherein R 13 are each independently hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, 3-8 membered heterocyclyl, -C6-C 12 Aryl, 5-12 membered heteroaryl, -CN, -SO2R 13a , -SO2NR 13a R 13b , -COR 13a , -CO2R 13a , -CONR 13a R 13b , -NR 13a R 13b , -NR 13a COR 13b , -NR 13a CO2R 13b , or -NR 13a SO2R 13b Selected from: methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 2-8 Alkenyl, -C 2-8Alkynyl, 3-8 membered heterocyclyl, -C6-C 12 Each of aryl and 5- to 12-membered heteroaryl is F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, 3-8 membered heterocyclyl, -C6-C 12 Aryl, 5-12 membered heteroaryl, oxo, -CN, -OR 13c , -SO2R 13c , -SO2NR 13c R 13d , -COR 13c , -CO2R 13c , -CONR 13c R 13d , -NR 13c R 13d , -NR 13c COR 13d , -NR 13c CO2R 13d , or -NR 13c SO2R 13d optionally replaced by;
[0157] In each occurrence, R 13a , R 13b , R 13c and R 13d are each independently hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, 3-8 membered heterocyclyl, -C6-C 12 The compound is an aryl or a 5- to 12-membered heteroaryl.
[0158] Embodiment 44. A compound according to any one of the preceding embodiments, wherein R 13is independently selected from hydrogen, F, Cl, Br, I, CN, —C1-C8 alkyl, or —C1-C8 alkoxy, preferably R 13 are independently selected from hydrogen, F, Cl, Br, I, CN, -Me, -Et, -C3H7, -C4H9, -OMe, -OEt, -OC3H7 or -OC4H9;
[0159] wherein n7 is 0, 1, or 2.
[0160] Embodiment 45. A compound according to any one of the preceding embodiments, [ka] but, [ka] The compound,
[0161] Embodiment 46. A compound according to any one of the preceding embodiments, wherein L 5 and L 6 are each independently a single bond, -O-, or -NR a -,-(CR a R b ) n8 -, -O(CR a R b ) n8 -, -NR a (CR a R b ) n8 - or -C(O)-;
[0162] X 8 -CR a R b - and;
[0163] In each occurrence, R a and R bare each independently selected from hydrogen, hydroxy, -F, -Cl, -Br, -I, -CN, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C-C alkenyl, -C-C alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl; wherein each of the C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl is optionally substituted with at least one substituent halogen, hydroxy, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl.
[0164] Embodiment 47. A compound according to any one of the preceding embodiments, wherein L 5 and L 6 are each independently a single bond, [ka] -O-, -NH-, -NMe-, -N(CH2CH3)-, -CH2-, -CHF-, -CF2-, -C(CH3)2- or -CO- (preferably L 5 and L 6 are each independently —CO— or —CH—;
[0165] where X 8 is CH2;
[0166] The compound wherein n6 is 0 or 1.
[0167] Embodiment 48. A compound according to any one of the preceding embodiments, wherein R 13 are each independently hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, 3-8 membered heterocyclyl, -C6-C 12 Aryl, 5-12 membered heteroaryl, -CN, -SO2R 13a , -SO2NR 13a R 13b , -COR 13a , -CO2R 13a , -CONR 13a R 13b , -NR 13a R 13b , -NR 13a COR 13b , -NR 13a CO2R 13b , or -NR 13a SO2R 13b Selected from: methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, 3-8 membered heterocyclyl, -C6-C 12Each of aryl and 5- to 12-membered heteroaryl is F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, 3-8 membered heterocyclyl, -C6-C 12 Aryl, 5-12 membered heteroaryl, oxo, -CN, -OR 13c , -SO2R 13c , -SO2NR 13c R 13d , -COR 13c , -CO2R 13c , -CONR 13c R 13d , -NR 13c R 13d , -NR 13c COR 13d , -NR 13c CO2R 13d , or -NR 13c SO2R 13d optionally replaced by;
[0168] In each occurrence, R 13a , R 13b , R 13c and R 13d are each independently hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, 3-8 membered heterocyclyl, -C6-C 12 The compound is an aryl or a 5- to 12-membered heteroaryl.
[0169] Embodiment 49. A compound according to any one of the preceding embodiments, wherein R 13is independently selected from hydrogen, F, Cl, Br, I, CN, —C1-C8 alkyl, or —C1-C8 alkoxy, preferably R 13 are independently selected from hydrogen, F, Cl, Br, I, CN, -Me, -Et, -C3H7, -C4H9, -OMe, -OEt, -OC3H7 or -OC4H9;
[0170] wherein n7 is 0, 1, or 2.
[0171] Embodiment 50. A compound according to any one of the preceding embodiments, [ka] but, [ka] The compound is selected from
[0172] Embodiment 51. A compound according to any one of the preceding embodiments, wherein the moiety [ka] but, [ka] [ka] The compound,
[0173] Embodiment 52. The compound of any one of the preceding embodiments, selected from: [ka] [ka] [ka] [ka]
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
[0174] Embodiment 53. A pharmaceutical composition comprising the compound of any one of embodiments 1-52, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or prodrug thereof, in combination with a pharmaceutically acceptable excipient.
[0175] Embodiment 54. A method of treating a disease that can be affected by EGFR modulation, comprising administering to a subject in need thereof an effective amount of a compound according to any one of embodiments 1 to 52, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or prodrug thereof.
[0176] Embodiment 55. The method of embodiment 52, wherein the disease is selected from cancer, preferably pancreatic cancer, breast cancer, glioblastoma multiforme, head and neck cancer, or non-small cell lung cancer.
[0177] Embodiment 56. Use of a compound according to any one of embodiments 1 to 52, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or prodrug thereof, in the preparation of a medicament for treating a disease that can be affected by EGFR modulation.
[0178] Aspect 57. The use according to aspect 56, wherein the disease is cancer, preferably pancreatic cancer, breast cancer, glioblastoma multiforme, head and neck cancer, or non-small cell lung cancer.
[0179] Surprisingly, there is a linker-like structure between the EGFR binder moiety and the E3 ligase ligand moiety. [ka] It has been found that compounds having a DC moiety have superior activity to other compounds. Here, superior activity means that the compound has superior degradation activity and further means that the compound can degrade the target protein (here, EGFR protein) with high efficiency. 50 is less than 20 nm, preferably less than 10 nm, more preferably less than 5 nm, 3 nm, 2 nm or 1 nm. Dmax is greater than 60%, preferably greater than 70% or 80%. Preferably, m1, m2, m3 and m4 are each independently 0, 1 or 2, where m1+m2+m3+m4≦4, preferably m1+m2+m3+m4=1, 2 or 3, more preferably m1+m2+m3+m4=1 or 2.
[0180] In some particular embodiments, the linker is [ka] and L 1are independently -O-, -NR a -, [ka] Selected from; [ka] Each of the L1c optionally replaced by; In the formula, * L1 is a part [ka] and ** L1 is a part [ka] refers to the position to be attached; L 2 -O-, -NR a -, [ka] are independently selected from; [ka] Each of the L2c optionally replaced by; In the formula, * L2 is a part [ka] and ** L2 teeth, portion [ka] refers to the position to be attached; L 3 -O-, -NR a -, [ka] are independently selected from; [ka] Each of the L3c optionally replaced by; R 1a , R 1b , R 1c , R 1d , R 2 , R 3 , R 4 , R 5a , R 5b , R 6a , R 6b , R 7a , R 7b , R 8 , R 9 , R 10 , R 11a , R 11b , R 11c , R 11d , R 12a , R 12b , R 12c , R 12d , R 13 , R 14 , L 1 , L 2 , L 3 , L 4 , Z 1 , Z 2 , Z 3 , X 7 , X 8 , m1, m2, m3, m4, m5, m6, m7 and n6 are defined as preceding aspects.
[0181] In some particular embodiments, L 1 , L 2 or L 3 For any one of X 1 If N, then X 5 is a single bond, is absent, is —C(O)—; and / or X 2 If N, then X 6 is a single bond, absent, or -C(O)-; L 1 but [ka] If X 1 If N, then X 5 is a single bond, is absent, or is —C(O)—, and / or X 3 -CR a7 R b7 -and;X 2 If N, then X 6 is a single bond, is absent, or is —C(O)—, and / or X 4 -CR a7 R b7 and; L 2 but [ka] If X 1 If N, then X 5 is a single bond, is absent, or is —C(O)—, and / or X 3 -CR a7 R b7 and X 2 If N, then X 6 is a single bond, is absent, or is —C(O)—, and / or X 4 -CR a7 R b7 and; L 3 but [ka] If X 1 If N, then X 5 is a single bond, is absent, or is —C(O)—, and / or X 3 -CR a7 R b7 - and X 2 If N, then X 6 is a single bond, is absent, or is —C(O)—, and / or X 4 -CR a7 R b7 - and; L 1 but, [ka] When the formula is (I), n1, n2, n3, and n4 are each independently 1, 2, or 3; L 2 but, [ka] When the formula is (I), n1, n2, n3, and n4 are each independently 1, 2, or 3; L 3 but, [ka] When n1, n2, n3, and n4 are each independently 1, 2, or 3,
[0182] In some particular embodiments, L 1 is -O-, -N(R a )-, [ka] Selected from; where: [ka] Each of the L1c optionally replaced by; R L1ceach independently represents oxo (=O), F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heterocyclyl. and each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, and 5- to 12-membered heteroaryl is selected from the group consisting of at least one R Lca optionally replaced by R Lca are independently oxo (=O), F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl; or The Two R's L1c together with the carbon atoms to which they are attached form a 3-, 4-, 5-, 6-, 7-, or 8-membered ring, said ring containing 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; said ring is optionally substituted with at least one substituent F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl; R ais selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl, and each of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl is which is optionally substituted with at least one substituent halogen, hydroxy, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl.
[0183] In some particular embodiments, L 1 is -O-, -N(CH3)-, [ka] [ka] [ka] [ka] is selected from.
[0184] In some particular embodiments, L 2 is -O-, -N(R a )-, [ka] Selected from; where: [ka] Each of the L2c optionally replaced by; R L2c each independently represents oxo (=O), F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 1-membered heterocyclyl. 2-membered heteroaryl; and each of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, and 5- to 12-membered heteroaryl is selected from the group consisting of at least one R Lca optionally replaced by R Lca are independently oxo (=O), F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl; or The Two R's L2ctogether with the carbon atoms to which they are attached form a 3-, 4-, 5-, 6-, 7-, or 8-membered ring, the ring containing 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; the ring is optionally substituted with at least one substituent F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl; R a is selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl, and each of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl is which is optionally substituted with at least one substituent halogen, hydroxy, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl.
[0185] In some particular embodiments, L 2 is -O-, -N(CH3)-, [ka] [ka] [ka] [ka] is selected from.
[0186] In some particular embodiments, L 3 is -O-, -N(R a )-, [ka] Selected from; where: [ka] Each of the L3c optionally replaced by; R L3c each independently represents oxo (=O), F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 1-membered heterocyclyl. 2-membered heteroaryl; and each of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, and 5- to 12-membered heteroaryl is selected from the group consisting of at least one R Lca optionally replaced by R Lcaare independently oxo (=O), F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl; or The Two R's L3c together with the carbon atoms to which they are attached form a 3-, 4-, 5-, 6-, 7-, or 8-membered ring, said ring containing 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; said ring is optionally substituted with at least one substituent F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl; R a is selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl, and each of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl is which is optionally substituted with at least one substituent halogen, hydroxy, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl.
[0187] In some particular embodiments, L 3is -O-, -N(CH3)-, [ka] [ka] [ka] [ka] is selected from.
[0188] In some particular embodiments, the moiety [ka] teeth, [ka] [ka] [ka] [ka] is selected from.
[0189] Also, surprisingly, [ka] The compound having an E3 ligase ligand moiety has excellent binding activity to E3 ligase; and [ka] It was also found that compounds having an E3 ligase ligand moiety have excellent binding activity to E3 ligase.
[0190] For any of the parameters including, but not limited to, m1, m2, m3, m4, m5, m6, m7, n1, n2, n3, n4, n5, n6, n7, and n8, if any of these parameters is 0, it means that the group that the parameter limits is not present, is hydrogen, or is a single bond.
[0191] In some particular embodiments, L 1 , L 2 or L 3 For any one of X 1 If N, then X 5 is a single bond, is absent, is —C(O)—; and / or X 2 If N, then X 6 is a single bond, absent, or -C(O)-; L 1 but [ka] If X 1 If N, then X 5 is a single bond, is absent, or is —C(O)—, and / or X 3 -CR a7 R b7 -and;X 2 If N, then X 6 is a single bond, is absent, or is —C(O)—, and / or X 4 -CR a7 R b7 and; L 2 but [ka] If X 1 If N, then X 5 is a single bond, is absent, or is —C(O)—, and / or X 3 -CR a7 R b7 and X 2 If N, then X 6is a single bond, is absent, or is —C(O)—, and / or X 4 -CR a7 R b7 and; L 3 but [ka] If X 1 If N, then X 5 is a single bond, is absent, or is —C(O)—, and / or X 3 -CR a7 R b7 - and X 2 If N, then X 6 is a single bond, is absent, or is —C(O)—, and / or X 4 -CR a7 R b7 - and; L 1 but, [ka] When the formula is (I), n1, n2, n3, and n4 are each independently 1, 2, or 3; L 2 but, [ka] When the formula is (I), n1, n2, n3, and n4 are each independently 1, 2, or 3; L 3 but, [ka] When n1, n2, n3, and n4 are each independently 1, 2, or 3, DETAILED DESCRIPTION OF THE INVENTION
[0192] The following terms have the meanings indicated throughout this specification:
[0193] Unless otherwise defined elsewhere herein, all other technical and scientific terms used herein have the meaning commonly understood by one of ordinary skill in the art to which this invention belongs.
[0194] The following terms have the meanings indicated throughout this specification:
[0195] As used in this specification, including the appended claims, singular words such as "a," "an," and "the" include their corresponding plural references unless the context clearly dictates otherwise.
[0196] The term "or" means, and is used interchangeably with, the term "and / or," unless context clearly dictates otherwise.
[0197] The term "alkyl" includes hydrocarbon groups selected from linear and branched saturated hydrocarbon groups containing 1 to 18, for example, 1 to 12, further 1 to 10, further 1 to 8, or 1 to 6, or 1 to 4 carbon atoms. Alkyl groups containing 1 to 6 carbon atoms (i.e., C 1-6 Examples of alkyl include, but are not limited to, methyl, ethyl, 1-propyl or n-propyl ("n-Pr"), 2-propyl or isopropyl ("i-Pr"), 1-butyl or n-butyl ("n-Bu"), 2-methyl-1-propyl or isobutyl ("i-Bu"), 1-methylpropyl or s-butyl ("s-Bu"), 1,1-dimethylethyl or t-butyl ("t-Bu"), 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, and 3,3-dimethyl-2-butyl groups.
[0198] The term "propyl" includes 1-propyl or n-propyl ("n-Pr"), 2-propyl or isopropyl ("i-Pr").
[0199] The term "butyl" includes 1-butyl or n-butyl ("n-Bu"), 2-methyl-1-propyl or isobutyl ("i-Bu"), 1-methylpropyl or s-butyl ("s-Bu"), and 1,1-dimethylethyl or t-butyl ("t-Bu").
[0200] The term "pentyl" includes 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl.
[0201] The term "hexyl" includes 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl and 3,3-dimethyl-2-butyl.
[0202] The term "alkylene" refers to a divalent alkyl group formed by removing two hydrogens from an alkane. Alkylenes include, but are not limited to, methylene, ethylene, propylene, and the like.
[0203] The term "halogen" includes fluoro (F), chloro (Cl), bromo (Br), and iodo (I).
[0204] The term "alkenyl" includes hydrocarbon groups selected from straight and branched chain hydrocarbon groups containing at least one C=C double bond and 2 to 18, for example, 2 to 8, further for example, 2 to 6, carbon atoms. Alkenyl groups, for example, C 2-6Examples of alkenyl include, but are not limited to, ethenyl or vinyl, prop-1-enyl, prop-2-enyl, 2-methylprop-1-enyl, but-1-enyl, but-2-enyl, but-3-enyl, buta-1,3-dienyl, 2-methylbuta-1,3-dienyl, hex-1-enyl, hex-2-enyl, hex-3-enyl, hex-4-enyl, and hexa-1,3-dienyl groups.
[0205] The term "alkenylene" refers to a divalent alkenyl group formed by removing two hydrogens from an alkene. Alkenylene includes, but is not limited to, vinylidene, butenylene, and the like.
[0206] The term "alkynyl" includes hydrocarbon groups selected from straight and branched chain hydrocarbon groups containing at least one C≡C triple bond and 2 to 18, such as 2 to 8, further such as 2 to 6, carbon atoms. Alkynyl groups, such as C 2-6 Examples of alkynyl include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl (propargyl), 1-butynyl, 2-butynyl, and 3-butynyl groups.
[0207] The term "alkynylene" refers to a divalent alkynyl group formed by removing two hydrogens from an alkyne. Alkynylene includes, but is not limited to, ethynylene, and the like.
[0208] The term "cycloalkyl" includes hydrocarbon groups selected from saturated cyclic hydrocarbon groups, including monocyclic and polycyclic (e.g., bicyclic and tricyclic) groups, including fused, bridged, or spirocycloalkyls.
[0209] For example, the cycloalkyl group can contain 3 to 12, such as 3 to 10, further such as 3 to 8, further such as 3 to 6, 3 to 5, or 3 to 4 carbon atoms. Further, for example, the cycloalkyl group can be selected from monocyclic groups containing 3 to 12, such as 3 to 10, further such as 3 to 8, 3 to 6 carbon atoms. Examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, and cyclododecyl groups. In particular, saturated monocyclic cycloalkyls (e.g., C 3-8 Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups. In preferred embodiments, cycloalkyl is a monocyclic ring containing 3 to 6 carbon atoms (C ), such as, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. 3-6 (Abbreviated as cycloalkyl). Examples of bicyclic cycloalkyl groups include those having 7 to 12 ring atoms arranged as a fused bicyclic ring selected from [4,4], [4,5], [5,5], [5,6], and [6,6] ring systems, or as a bridged bicyclic ring selected from bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, and bicyclo[3.2.2]nonane. Further examples of bicyclic cycloalkyl groups include those arranged as a bicyclic ring selected from [5,6] and [6,6] ring systems.
[0210] The term "spirocycloalkyl" refers to a cyclic structure containing carbon atoms and formed by at least two rings that share one atom.
[0211] The term "fused cycloalkyl" includes bicyclic cycloalkyl groups, as defined herein, that are saturated and formed by two or more rings sharing two adjacent atoms.
[0212] The term "bridged cycloalkyl" refers to a cyclic structure containing carbon atoms and formed by two rings that share two non-adjacent atoms. The term "7-10 membered bridged cycloalkyl" refers to a cyclic structure containing 7-12 carbon atoms and formed by two rings that share two non-adjacent atoms.
[0213] Examples of fused cycloalkyl, fused cycloalkenyl, or fused cycloalkynyl include, but are not limited to, bicyclo[1.1.0]butyl, bicyclo[2.1.0]pentyl, bicyclo[3.1.0]hexyl, bicyclo[4.1.0]heptyl, bicyclo[3.3.0]octyl, bicyclo[4.2.0]octyl, decalin, and 3-8 membered benzocycloalkyl, benzoC 4-6 Examples include cycloalkenyl, 2,3-dihydro-1H-indenyl, 1H-indenyl, 1,2,3,4-tetralyl, 1,4-dihydronaphthyl, etc. Preferred embodiments are 8- to 9-membered fused rings, which refers to ring structures containing 8 to 9 ring atoms within the scope of the foregoing examples.
[0214] The term "aryl" used alone or in combination with other terms,
[0215] 5- and 6-membered carbocyclic aromatic rings, for example, phenyl;
[0216] Bicyclic ring systems, such as 7-12 membered bicyclic ring systems in which at least one ring is carbocyclic and aromatic, e.g., naphthyl and indanyl; and
[0217] Tricyclic ring systems, such as 10-15 membered tricyclic ring systems in which at least one ring is carbocyclic and aromatic, include groups selected from, for example, fluorenyl.
[0218] The terms "aromatic hydrocarbon ring" and "aryl" are used interchangeably throughout this disclosure. In some embodiments, a monocyclic or bicyclic aromatic hydrocarbon ring has 5 to 10 ring-forming carbon atoms (i.e., C 5-10aryl). Examples of monocyclic or bicyclic aromatic hydrocarbon rings include, but are not limited to, phenyl, naphth-1-yl, naphth-2-yl, anthracenyl, phenanthrenyl, and the like. In some embodiments, the aromatic hydrocarbon ring is a naphthalene ring (naphth-1-yl or naphth-2-yl) or a phenyl ring. In some embodiments, the aromatic hydrocarbon ring is a phenyl ring.
[0219] Specifically, the term "bicyclic fused aryl" refers to a bicyclic aryl ring as defined herein. An exemplary bicyclic fused aryl is naphthalene.
[0220] The term "heteroaryl" includes groups selected from:
[0221] a 5-, 6-, or 7-membered aromatic monocyclic ring containing at least one heteroatom, e.g., 1 to 4, or in some embodiments 1 to 3, and in some embodiments 1 to 2 heteroatoms, selected from nitrogen (N), sulfur (S), and oxygen (O), with the remaining ring atoms being carbon;
[0222] a 7-12 membered bicyclic ring containing at least one heteroatom selected from N, O, and S, e.g., 1 to 4, or in some embodiments 1 to 3, or in other embodiments 1 or 2 heteroatoms, the remaining ring atoms being carbon, and at least one ring being aromatic, with at least one heteroatom being in the aromatic ring; and
[0223] An 11-14 membered tricyclic ring containing at least one heteroatom selected from N, O, and S, for example, 1 to 4, or in some embodiments 1 to 3, or in other embodiments 1 or 2 heteroatoms, the remaining ring atoms being carbon, and at least one ring being aromatic, with at least one heteroatom being in the aromatic ring.
[0224] When the total number of S and O atoms in the heteroaryl group exceeds 1, these heteroatoms are not adjacent to one another. In some embodiments, the total number of S and O atoms in the heteroaryl group is 2 or less. In some embodiments, the total number of S and O atoms in the aromatic heterocycle is 1 or less. When a heteroaryl group contains two or more heteroatom ring members, the heteroatoms may be the same or different. Nitrogen atoms in the ring(s) of a heteroaryl group may be oxidized to form an N-oxide.
[0225] Specifically, the term "bicyclic fused heteroaryl" includes 7- to 12-membered, preferably 7- to 10-membered, and more preferably 9- or 10-membered fused bicyclic heteroaryl rings as defined herein. Typically, bicyclic fused heteroaryls are 5-membered / 5-membered, 5-membered / 6-membered, 6-membered / 6-membered, or 6-membered / 7-membered bicyclics. Groups can be attached to the remainder of the molecule via either ring.
[0226] "Heterocyclyl," "heterocycle," or "heterocyclic" are interchangeable and refer to a non-aromatic heterocyclyl group containing one or more heteroatoms selected from nitrogen, oxygen, or optionally oxidized sulfur as ring members, with the remaining ring members being carbon, and including monocyclic, fused, bridged, and spirocyclic rings, i.e., including monocyclic, heterocyclyl, bridged heterocyclyl, spiroheterocyclyl, and fused heterocyclic groups.
[0227] The term "H" or "hydrogen" as disclosed herein includes hydrogen and its non-radioactive isotope, deuterium.
[0228] The term "at least one substituent" as disclosed herein includes 1 to 4 substituents, such as 1 to 3, or even 1 or 2, as long as valence theory is satisfied. For example, "at least one substituent F" as disclosed herein includes 1 to 4, such as 1 to 3, or even 1 or 2 substituents F.
[0229] The term "divalent" refers to a linking group that can form covalent bonds with two other moieties. For example, a "divalent cycloalkyl group" refers to a cycloalkyl group obtained by removing two hydrogens from the corresponding cycloalkane to form the linking group. The terms "divalent aryl group," "divalent heterocyclyl group," or "divalent heteroaryl group" shall be understood similarly.
[0230] The compounds disclosed herein may have asymmetric centers and therefore may exist as enantiomers. "Enantiomer" refers to two stereoisomers of a compound that are non-superimposable mirror images of one another. When the compounds disclosed herein have two or more asymmetric centers, they may additionally exist as diastereomers. Enantiomers and diastereomers belong to a broader class of stereoisomers. All such possible stereoisomers are intended to be included, including substantially purely resolved enantiomers, racemic mixtures thereof, and mixtures of diastereomers. All stereoisomers of the compounds disclosed herein and / or their pharmaceutically acceptable salts are intended to be included. Unless otherwise specified, a reference to one isomer applies to any of the possible isomers. Whenever the isomeric composition is not specified, all possible isomers are included.
[0231] When compounds disclosed herein contain olefinic double bonds, unless otherwise specified, it is intended that such double bond include both E and Z geometric isomers.
[0232] When the compounds disclosed herein comprise a disubstituted cyclic ring system, the substituents found in such ring system can adopt cis and trans configuration.Cis configuration means that both substituents are found on the upper side of the arrangement of the two substituents on the carbon, while trans means that they are on the opposite side.For example, the disubstituted cyclic ring system can be a cyclohexyl or cyclobutyl ring.
[0233] It may be advantageous to separate reaction products from one another and / or from starting materials. The desired products of each step or series of steps are separated and / or purified (hereinafter, "separated") to the desired degree of homogeneity by techniques common in the art. Typically, such separations involve multiphase extraction, crystallization from a solvent or solvent mixture, distillation, sublimation, or chromatography. Chromatography can include any number of methods, including, for example, reverse-phase and normal-phase, size exclusion, ion exchange, high-, medium-, and low-pressure liquid chromatography methods and apparatus, small-scale analytical, simulated moving bed ("SMB"), and preparative thin- or thick-layer chromatography, as well as small-scale thin-layer and flash techniques. One skilled in the art can select and apply the techniques most likely to achieve the desired separation.
[0234] "Diastereomers" refer to stereoisomers of compounds that have two or more chiral centers but are not mirror images of one another. Diastereomeric mixtures can be separated into their individual diastereomers based on their physical chemical differences by methods well known to those skilled in the art, such as chromatography and / or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture to a diastereomeric mixture by reaction with a suitable optically active compound (e.g., a chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers, and converting the individual diastereoisomers into the corresponding pure enantiomers (e.g., by hydrolysis). Enantiomers can also be separated using a chiral HPLC column.
[0235] Single stereoisomers, e.g., substantially pure enantiomers, can be obtained by resolution of racemic mixtures using methods such as the formation of diastereomers with optically active resolving agents (Eliel, E. and Wilen, S. Stereochemistry of Organic Compounds. New York: John Wiley & Sons, Inc., 1994; Lochmuller, C.H., et al. 'Chromatographic resolution of enantiomers: Selective review.' J. Chromatogr., 113(3)(1975): pp. 283-302). Racemic mixtures of chiral compounds of the present invention can be separated and isolated by any suitable method, including: (1) formation of ionic diastereomeric salts with chiral compounds and separation by fractional crystallization or other methods; (2) formation of diastereomeric compounds with chiral derivatizing agents, separation of diastereomers, and conversion to pure stereoisomers; and (3) direct separation of substantially pure or enriched stereoisomers under chiral conditions. See Wainer, Irving W., Ed. Drug Stereochemistry: Analytical Methods and Pharmacology. New York: Marcel Dekker, Inc., 1993.
[0236] Some of the compounds disclosed herein may exist at different points of hydrogen attachment, called tautomers. For example, compounds containing a carbonyl -CHC(O)- group (keto form) may undergo tautomerism to form a hydroxyl -CH=C(OH)- group (enol form). Where applicable, both the keto and enol forms, as well as mixtures thereof, are intended to be included.
[0237] "Prodrug" refers to a derivative of an active drug that requires a transformation within the body to release the active drug. In some embodiments, the transformation is enzymatic. Prodrugs are often, but not necessarily, pharmacologically inactive until converted to the active drug.
[0238] "Deuterated analog" refers to a derivative of an active agent in which any hydrogen has been replaced with deuterium. In some embodiments, the deuteration site is on the warhead moiety. In some embodiments, the deuteration site is on the linker moiety. In some embodiments, the deuteration site is on the degron moiety.
[0239] "Pharmaceutically acceptable salt" refers to a salt that is suitable, within the scope of sound medical judgment, for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, and that corresponds to a reasonable benefit / risk ratio. Pharmaceutically acceptable salts can be prepared in situ during the final isolation and purification of the compounds disclosed herein, or separately by reacting a free base functional group with a suitable organic acid, or an acidic group with a suitable base. The term also includes salts of stereoisomers (such as enantiomers and / or diastereomers), tautomers, and prodrugs of the compounds of the invention.
[0240] In addition, if the compounds disclosed herein are obtained as acid addition salts, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the product is a free base, an addition salt, such as a pharmaceutically acceptable addition salt, can be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, according to conventional procedures for preparing acid addition salts from base compounds. Those skilled in the art will recognize a variety of synthetic methods that can be used without undue experimentation to prepare non-toxic pharmaceutically acceptable addition salts.
[0241] As used herein, the terms "administration," "administering," "treating," and "treatment," when applied to an animal, human, experimental subject, cell, tissue, organ, or biological fluid, refer to the contact of an exogenous pharmaceutical, therapeutic, diagnostic, or composition with the animal, human, subject, cell, tissue, organ, or biological fluid. Treatment of a cell encompasses contact of a reagent with the cell, as well as contact of a reagent with a fluid, where the fluid contacts the cell. The terms "administration" and "treatment" also refer to in vitro and ex vivo treatment, e.g., of a cell with a reagent, diagnostic, binding compound, or with another cell. As used herein, the term "subject" includes any organism, preferably an animal, more preferably a mammal (e.g., rat, mouse, dog, cat, and rabbit), and most preferably a human.
[0242] As used herein, the terms "treated," "treat," or "treatment" generally refer to achieving a desired pharmacological and / or physiological effect. The effect may be preventative, according to the total or partial prevention of a disease or its symptoms, and / or therapeutic, according to the partial or complete stabilization or cure of the disease and / or side effects due to the disease. As used herein, "treated," "treat," or "treatment" includes any treatment for a patient's disease: (a) prevention of a disease or condition in a patient who may be susceptible to, but has not yet been diagnosed with, the disease or condition; (b) inhibition of a symptom of the disease, i.e., prevention of its onset; or (c) amelioration of a symptom of the disease, i.e., causing a total or partial regression of the disease or condition.
[0243] The term "effective amount" or "therapeutically effective amount" refers to an amount of an active ingredient, such as a compound, that, when administered to a subject to treat a disease or at least one clinical symptom of a disease or disorder, is sufficient to affect such treatment for the disease, disorder, or condition. The term "therapeutically effective amount" can vary depending on the compound, the disease, disorder, and / or symptoms of the disease or disorder, the severity of the disease, disorder, and / or symptoms of the disease or disorder, the age of the subject being treated, and / or the weight of the subject being treated. The appropriate amount in any given case will be apparent to one of ordinary skill in the art or can be determined by routine experimentation. In some embodiments, a "therapeutically effective amount" is an amount of at least one compound disclosed herein and / or at least one stereoisomer, tautomer, or prodrug thereof, and / or at least one pharmaceutically acceptable salt thereof, that is effective in "treating" a disease or disorder, as defined herein, in a subject. In the case of a combination therapy, the term "therapeutically effective amount" refers to the total amount of the combined components for effective treatment of a disease, disorder, or condition.
[0244] The term "disease" refers to any disease, ailment, disorder, symptom or indication, and may be used interchangeably with the term "disorder" or "condition."
[0245] Throughout this specification and the claims that follow, unless the context otherwise requires, the word "comprise," as well as variations such as "comprises" and "comprising," are intended to specify the presence of the subsequent feature but do not exclude the presence or addition of one or more other features. As used herein, the word "comprising" can be replaced with the words "containing," "including," or, in some cases, "having."
[0246] Throughout this specification and the claims that follow, "C n-m " or "C n -Cm The term "" denotes a range inclusive of the endpoints, where n and m are integers and indicate the number of carbons. Examples include C 1-8 , C 1-6 , C1-C8, C1-C6, etc.
[0247] Unless otherwise specified, percentages, ratios, proportions or parts used in this application are by weight or volume. Quantities used in this application are amounts by weight or volume, which can be easily determined by one skilled in the art.
[0248] Hereinafter, the present application will illustrate the beneficial effects of the present invention through examples. Those skilled in the art will recognize that these examples are illustrative and not limiting. These examples do not limit the scope of the present application in any way. The experimental methods described in the following examples are conventional methods unless otherwise specified; reagents and materials are commercially available unless otherwise specified.
[0249] Unless otherwise defined elsewhere herein, all other technical and scientific terms used herein have the meaning commonly understood by one of ordinary skill in the art to which this invention belongs. [Example]
[0250] The following examples are intended to be merely illustrative and should not be construed as limiting in any way. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should be accounted for. Temperatures are in degrees Celsius unless otherwise indicated. Reagents were purchased from commercial suppliers: Sigma-Aldrich, Alfa Aesar, or TCI, and used without further purification unless otherwise indicated. Unless otherwise indicated, reactions described below were carried out in anhydrous solvents under a positive pressure of nitrogen or argon, or using drying tubes; reaction flasks were fitted with rubber septa for introduction of substrates and reagents via syringe; and glassware was oven-dried and / or heat-dried.
[0251] 1 H NMR spectra were recorded on an Agilent instrument operating at 400 MHz. 1 H NMR
[0252] Spectra were obtained using CDCl3, CD2Cl2, CD3OD, DO, d6-DMSO, d6-acetone, or (CD3)2CO as solvents, with tetramethylsilane (0.00 ppm) or residual solvent as the reference standard (CDCl3: 7.25 ppm, CD3OD: 3.31 ppm, DO: 4.79 ppm; d6-DMSO: 2.50 ppm, d6-acetone: 2.05, (CD3)3CO: 2.05). When reporting peak multiplicities, the following abbreviations are used: s (singlet), d (doublet), t (triplet), q (quartet), qn (quintet), sx (sextet), m (multiplet), br (broad), dd (double doublet), and dt (double triplet). Coupling constants, when available, are reported in Hz (Hertz).
[0253] LCMS-1: LC-MS spectrometer (Agilent 1260 Infinity) Detector: MWD (190-400 nm), Mass Detector: 6120 SQ Mobile phase: A: water containing 0.1% formic acid, B: acetonitrile containing 0.1% formic acid Column: Poroshell 120 EC-C18, 4.6 x 50 mm, 2.7 pm Gradient method: Flow rate: 1.8 mL / min Time (min) A (%) B (%) [Table 1]
[0254] LCMS, LCMS-3: LC-MS spectrometer (Agilent 1260 Infinity II) Detector: MWD (190-400 nm), Mass Detector: G6125C SQ Mobile phase: A: water containing 0.1% formic acid, B: acetonitrile containing 0.1% formic acid Column: Poroshell 120 EC-C18, 4.6 x 50 mm, 2.7 pm Gradient method: Flow rate: 1.8 mL / min Time (min) A (%) B (%) [Table 2]
[0255] LCMS-2: LC-MS spectrometer (Agilent 1290 Infinity) Detector: MWD (190-400 nm), Mass Detector: G6125C SQ Mobile phase: A: water containing 0.1% formic acid, B: acetonitrile containing 0.1% formic acid Column: Poroshell 120 EC-C18, 4.6 x 50 mm, 2.7 pm Gradient method: Flow rate: 1.2 mL / min Time (min) A (%) B (%) [Table 3]
[0256] Preparative HPLC was performed on a column (150x21.2mm ID, 5pm, GeminiNXC18) with a flow rate of 20ml / min, injection volume of 2ml, room temperature, and UV detection at 214nm and 254nm.
[0257] In the examples below, the following abbreviations are used: [Table 4-1] [Table 4-2] [Table 4-3] [Table 4-4]
[0258] Example 5: (R)-3-(2,6-difluoro-4-((R)-3-(4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacyloundecaphane-5 6 -yl)methyl)piperazine-1-carbonyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione
[0259] Step 1: Methyl (R)-1-(4-bromo-3,5-difluorophenyl)pyrrolidine-3-carboxylate [ka]
[0260] To a 250 mL DMSO solution containing 2-bromo-1,3-difluoro-5-iodobenzene (15 g, 47 mmol), methyl (R)-pyrrolidine-3-carboxylate hydrochloride (8.56 g, 51.7 mmol), and KPO (20 g, 94 mmol), CuI (893 mg, 4.7 mmol) and L-proline (1 g, 9.4 mmol) were added. The mixture was stirred at 80 °C for 16 h. After LCMS showed the reaction was complete, the mixture was diluted with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The resulting mixture was purified by silica column chromatography (PE:EA = 50:1-30:1) to give the product (4.9 g, 32.5%). [M+H] + = 320.1.
[0261] Step 2: Methyl (R)-1-(4-(2,6-bis(benzyloxy)pyridin-3-yl)-3,5-difluorophenyl)pyrrolidine-3-carboxylate [ka]
[0262] To a solution of methyl (R)-1-(4-bromo-3,5-difluorophenyl)pyrrolidine-3-carboxylate (4.9 g, 15.3 mmol), 2,6-bis(benzyloxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (6.7 g, 16 mmol), and CsF (4.6 g, 30.6 mmol) in 150 mL of L DMF and 15 mL of water was added Pd(dtbpf)Cl (498 mg, 0.8 mmol). The mixture was stirred at 80 °C for 4 h. After LCMS showed the reaction was complete, the mixture was diluted with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The resulting mixture was purified by Combi-Flash (EA: PE = 0-12%) to give the product (7.9 g, 97.4%). [M+H] + = 531.30.
[0263] Step 3: (R)-1-(4-(2,6-bis(benzyloxy)pyridin-3-yl)-3,5-difluorophenyl)pyrrolidine-3-carboxylic acid [ka]
[0264] To a solution of methyl (R)-1-(4-(2,6-bis(benzyloxy)pyridin-3-yl)-3,5-difluorophenyl)pyrrolidine-3-carboxylate (7.9 g, 14.9 mmol) in 100 mL of THF and 20 mL of water was added dropwise 10 mL of an aqueous solution of LiOH (394 mg, 16.4 mmol) at room temperature. The mixture was stirred at room temperature for 15 minutes. After TLC showed the reaction was complete, the mixture was concentrated in vacuo at room temperature. The residue was diluted with water and adjusted to pH < 5 with 1N HCl. The liquid was extracted with EtOAc. The organic phase was dried over anhydrous Na2SO4, filtered, and concentrated in vacuo to give the product (7.4 g, 96.0%). [M+H] + = 517.1.
[0265] Step 4: (R)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)pyrrolidine-3-carboxylic acid [ka]
[0266] To a solution of (R)-1-(4-(2,6-bis(benzyloxy)pyridin-3-yl)-3,5-difluorophenyl)pyrrolidine-3-carboxylic acid (7.4 g, 14.3 mmol) in 50 mL of DCM and 250 mL of iPrOH was added Pd / C (7.4 g, 10 wt%, wet). The mixture was stirred under a hydrogen atmosphere (balloon) at 40° C. for 16 hours. After LCMS showed the reaction was complete, the mixture was cooled to room temperature and directly filtered through Celite. The filtrate was concentrated in vacuo to give the crude product, which was purified by SFC (IH (3*25 cm, 5 um), 13% EtOH / 87% CO2, 100 bar, 100 ml / min) to give the title compound, corresponding to Peak A at 0.655 min / 254 nm (1.6 g, 34%). [M+H] + = 339.2.
[0267] Step 5: tert-Butyl(R,E)-4-((1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazine-1-carboxylate [ka]
[0268] In a 250 mL round-bottom flask equipped with a magnetic stir bar, add (R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3-dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 A mixture of 1-carbaldehyde (2.6 g, 5.5 mmol), tert-butyl piperazine-1-carboxylate (8.2 g, 44.0 mmol), NaBH(OAc) (5.8 g, 27.5 mmol), and DCM (100 mL) was added at room temperature. To the stirred reaction mixture was added AcOH (1.9 mL, 33.0 mmol). After stirring at room temperature for 12 h, the reaction mixture was diluted with saturated aqueous NaHCO (150 mL) and the layers were separated. The aqueous layer was extracted with DCM (3 x 70 mL). The combined organic layers were washed with brine (150 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. Purification by flash column chromatography (0-10% MeOH / DCM) afforded the product (3.1 g, 90%). [M+H] + = 629.6.
[0269] Step 6: (R,E)-1 1 ,2 6 ,7-trimethyl-5 6 -(piperazin-1-ylmethyl)-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one [ka]
[0270] In a 100 mL round-bottom flask equipped with a magnetic stir bar, add tert-butyl (R,E)-4-((1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 To the reaction mixture was added (3.1 g, 5.0 mmol), DCM (40 mL), and TFA (10 mL). After stirring at room temperature for 1 hour, the reaction mixture was concentrated under reduced pressure to give the product (6.0 g), which was used without further purification. [M+H] + = 529.4.
[0271] Step 7: (R)-3-(2,6-difluoro-4-((R)-3-(4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazine-1-carbonyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0272] In a 250 mL round-bottom flask equipped with a magnetic stir bar, add (R,E)-1 1 ,2 6 ,7-trimethyl-5 6 -(piperazin-1-ylmethyl)-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (5.0 g), (R)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)pyrrolidine-3-carboxylic acid (1.7 g, 5.0 mmol), and DCM (100 mL) were added. To the reaction mixture were added N,N-diethylpropylethylamine (8.8 mL, 50 mmol) and T3P (50 wt%, 6.4 g, 10 mmol). After stirring at room temperature for 1.5 hours, the reaction mixture was diluted with brine (150 mL), and the layers were separated. The aqueous layer was extracted with DCM (3 x 70 mL). The combined organic layers were washed with brine (150 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. Purification by flash column chromatography (0-6% MeOH / DCM) afforded the title compound (3.3 g, 78%). 1 H NMR (500 MHz, DMSO) δ 12.66 (s, 1H), 10.79 (s, 1H), 8.36 (s, 1H), 7.86 (s, 1H), 7.50 (s, 1H), 7.47 (s, 1H), 7.43 (d, J = 8.0 Hz, 1H), 7.13 (d, J = 8.5 Hz, 1H), 6.15 (d, J = 12.0 Hz, 2H), 4.33 - 4.26 (m, 1H), 4.15 - 4.12 (m, 1H), 4.00 - 3.85 (m, 1H), 3.66 (s, 3H), 3.55 - 3.41 (m, 9H), 3.23 - 3.14 (m, 5H), 2.74 - 2.67 (m, 2H), 2.49 (s, 3H), 2.36 - 2.29 (m, 4H), 2.19 - 2.03 (m, 2H), 2.03 - 1.82 (m, 5H), 1.43 - 1.37 (m, 1H), 0.75 (d, J = 6.5 Hz, 3H);[M+H] + = 849.8.
[0273] Example 6: (R)-3-(2,6-difluoro-4-((R)-3-(4-(1-(((R,E)-1 1,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperidin-4-yl)piperazine-1-carbonyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione
[0274] Step 1: tert-Butyl(R,E)-4-(1-((1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperidin-4-yl)piperazine-1-carboxylate [ka]
[0275] In a 100 mL round-bottom flask equipped with a magnetic stir bar, add (R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6To a mixture of 1,2-dichloro-4-(piperidin-4-yl)piperazine-1-carboxylate (5.4 g, 20.0 mmol), NaBH(OAc) (1.3 g, 12.0 mmol), and DCM (40 mL) were added at room temperature. To the stirred reaction mixture was added AcOH (1.2 mL, 20.0 mmol). After stirring at room temperature for 12 h, the reaction mixture was diluted with saturated aqueous NaHCO (50 mL), and the layers were separated. The aqueous layer was extracted with DCM (3 x 40 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. Purification by flash column chromatography (0-10% MeOH / DCM) afforded the product (780 mg, 55%). [M+H] + = 712.8.
[0276] Step 2: (R,E)-1 1 ,2 6 ,7-trimethyl-5 6 ((4-(piperazin-1-yl)piperidin-1-yl)methyl)-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one [ka]
[0277] In a 100 mL round-bottom flask equipped with a magnetic stir bar, add tert-butyl (R,E)-4-(1-((1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6To the reaction mixture was added (780 mg, 1.1 mmol), DCM (30 mL), and TFA (7 mL). After stirring at room temperature for 1 hour, the reaction mixture was concentrated under reduced pressure to give the product (1.4 g), which was used without further purification. [M+H] + = 612.5.
[0278] Step 3: (R)-3-(2,6-difluoro-4-((R)-3-(4-(1-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperidin-4-yl)piperazine-1-carbonyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0279] In a 40 mL microwave vial equipped with a magnetic stir bar, add (R,E)-1 1 ,2 6 ,7-trimethyl-5 6 -((4-(piperazin-1-yl)piperidin-1-yl)methyl)-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (61.1 mg, 0.1 mmol), (R)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)pyrrolidine-3-carboxylic acid (67.7 mg, 0.2 mmol), and DCM (8 mL) were added to the reaction mixture. N,N-Diethylpropylethylamine (340 mL, 2.0 mmol) and T3P (50 wt%, 380 mg, 0.6 mmol) were added to the reaction mixture.
[0280] After stirring at room temperature for 1.5 hours, the reaction mixture was diluted with brine (30 mL) and the layers were separated. The aqueous layer was extracted with DCM (3 x 15 mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. Purification by flash column chromatography (0-10% MeOH / DCM) followed by preparative HPLC chromatography (gradient elution from 0.1% FA / water:acetonitrile = 90:10 to 50:50) afforded the title compound (52 mg, 56%). 1 H NMR (500 MHz, DMSO) δ 12.74 (s, 1H), 10.84 (s, 1H), 8.43 (s, 1H), 7.93 (s, 1H), 7.57 (s, 1H), 7.55 - 7.50 (m, 2H), 7.23 - 7.18 (m, 1H), 6.21 (d, J = 12.0 Hz, 2H), 4.39 - 4.34 (m, 1H), 4.23 - 4.20 (m, 1H), 4.03 - 4.00 (m, 2H), 3.94 - 3.86 (m, 1H), 3.73 (s, 3H), 3.57 -3.19 (m, 18H), 2.84 - 2.72 (m, 2H), 2.56 (s, 3H), 2.54 - 2.44 (m, 3H), 2.26 - 1.89 (m, 8H), 1.82 - 1.71 (m, 2H), 1.54 - 1.43 (m, 2H), 0.82 (d, J = 6.5 Hz, 3H);[M+H] + = 932.8.
[0281] Example 7: (R)-3-(2,6-difluoro-4-(4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazin-1-yl)piperidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0282] In a 40 mL microwave vial equipped with a magnetic stir bar, add (R,E)-1 1 ,2 6 ,7-trimethyl-5 6 -(piperazin-1-ylmethyl)-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (158.6 mg, 0.3 mmol), (R)-3-(2,6-difluoro-4-(4-oxopiperidin-1-yl)phenyl)piperidine-2,6-dione (compound obtained in a manner similar to that in Example 5) (32.3 mg, 0.1 mmol), and DCE (8 mL) were added. To the reaction mixture were added N,N-diethylpropylethylamine (0.5 mL, 3.0 mmol) and Ti(OiPr) (0.3 mL, 1.0 mmol). After stirring at 70 °C for 12 hours, the reaction mixture was cooled to room temperature, and NaBH(OAc) (84 mg, 0.4 mmol) was added. After stirring at room temperature for 2 hours, the reaction mixture was concentrated under reduced pressure. After purification by flash column chromatography (0-70% MeOH / DCM), the title compound (38 mg, 45%) was obtained by preparative HPLC chromatography (gradient elution with 0.1% FA / water:acetonitrile=90:10-50:50). 1 H NMR (500 MHz, DMSO) δ 12.70 (s, 1H), 10.86 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.49 - 7.47 (m, 2H), 7.17 (d, J = 7.5 Hz, 1H), 6.61 (d, J = 13.0 Hz, 2H), 4.39 - 4.34 (m, 1H), 4.23 - 4.16 (m, 1H), 4.07 - 3.98 (m, 2H), 3.96 - 3.91 (m, 1H), 3.79 - 3.73 (m, 2H), 3.36 - 3.28 (m, 4H), 3.73 (s, 3H), 2.83 - 2.70 (m, 4H), 2.56 (s, 3H), 2.54 - 2.49 (m, 4H), 2.43 - 2.32 (m, 4H), 2.26 - 2.17 (m, 1H), 2.11 - 1.89 (m, 4H), 1.81 - 1.78 (m, 2H), 1.51 - 1.38 (m, 3H), 0.81 (d, J = 6.5 Hz, 3H);[M+H] + = 835.8.
[0283] Example 8: (R)-3-(2,6-difluoro-4-(4-(4-(1-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperidin-4-yl)piperazin-1-yl)piperidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0284] To a 40 mL microwave vial equipped with a magnetic stir bar was added (R,E)-11,26,7-trimethyl-56-((4-(piperazin-1-yl)piperidin-1-yl)methyl)-52,53-dihydro-11H,51H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (183.3 mg, 0.3 mmol), (R)-3-(2,6-difluoro-4-(4-oxopiperidin-1-yl)phenyl)piperidine-2,6-dione (32.3 mg, 0.1 mmol) and DCE (8 mL). To the reaction mixture were added N,N-diethylpropylethylamine (0.5 mL, 3.0 mmol) and Ti(OiPr)4 (0.3 mL, 1.0 mmol). After stirring at 70 °C for 12 h, the reaction mixture was cooled to room temperature, and NaBH(OAc)3 (84 mg, 0.4 mmol) was added. After stirring at room temperature for 2 h, the reaction mixture was concentrated under reduced pressure. Purification by flash column chromatography (0-70% MeOH / DCM) was followed by preparative HPLC chromatography (gradient elution, 0.1% FA / water:acetonitrile = 90:10 to 50:50) afforded the title compound (44 mg, 48%). 1H NMR (500 MHz, DMSO) δ 12.70 (s, 1H), 10.86 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.49 - 7.47 (m, 2H), 7.16 (d, J = 8.5 Hz, 1H), 6.61 (d, J = 13.0 Hz, 2H), 4.40 - 4.32 (m, 1H), 4.23 - 4.16 (m, 1H), 4.08 - 3.97 (m, 2H), 3.97 - 3.90 (m, 1H), 3.81 - 3.73 (m, 2H), 3.73 (s, 3H), 2.92 - 2.60 (m, 8H), 2.56 (s, 3H), 2.54 - 2.45 (m, 5H), 2.38 - 2.29 (m, 2H), 2.25 - 2.05 (m, 4H), 2.05 - 1.89 (m, 6H), 1.84 - 1.69 (m, 4H), 1.48 - 1.37 (m, 6H), 0.81 (d, J = 6.5 Hz, 3H);[M+H] + = 918.8.
[0285] Example 9: (R)-3-(2,6-difluoro-4-((R)-3-(9-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-3,9-diazaspiro[5.5]undecane-3-carbonyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione
[0286] Step 1: Methyl 2-(5-hydroxy-1-methyl-1H-pyrazol-4-yl)-6-methylisonicotinate [ka]
[0287] A solution of the compounds methyl 2-chloro-6-methyl-pyridine-4-carboxylate (200 g, 1.08 mol) and 2-methylpyrazol-3-ol (211.42 g, 2.16 mol) in anisole (3.5 L) was added to the solution of NaCO (285.52 g, 2.69 mol) and Pd(dppf)C l2 CHCl (26.40 g, 32.33 mmol) was added. The mixture was stirred at 130 °C under a N atmosphere for 12 h and turned into a brown suspension. The reaction mixture was then cooled to 20 °C and filtered through a 2 cm pad of Celite. The Celite pad was washed with toluene (2 L). The dark filtrate was treated with MeOH (2 L), followed by the dropwise addition of 4 M HCl (1.2 L) in dioxane. The resulting slurry was stirred at 20 °C for 1 h and filtered. The filter cake was washed with MTBE (2 L) and then dried under vacuum at 50 °C to give a yellow solid. The compound methyl 2-(5-hydroxy-1-methyl-pyrazol-4-yl)-6-methylpyridine-4-carboxylate (334 g, 1.35 mol, 41.79% yield) was obtained. 1 H NMR (400 MHz, chloroform-d) δ 7.72 (d, J 0.6 Hz, 1H), 7.70 (s, 1H), 7.24 (s, 1H), 3.98 (s, 3H), 3.64 (s, 3H), 2.59 (s, 3H).
[0288] Step 2: (R)-5-((5-bromo-2-nitrophenyl)amino)-4-methylpentyl methanesulfonate [ka]
[0289] To a solution of (4R)-5-(5-bromo-2-nitro-anilino)-4-methylpentan-1-ol (200 g, 630.56 mmol) in DCM (1.6 L) was added TEA (95.71 g, 945.84 mmol, 131.65 mL) and MsCl (79.07 g, 690.26 mmol, 53.43 mL) at 0 °C. The mixture was stirred at 15 °C for 12 h. The reaction mixture was then washed with saturated aqueous NaHCO (700 mL*3), and the aqueous layers were combined and extracted with DCM (600 mL*3). The organic layers were combined, dried over NaSO, filtered, and concentrated under reduced pressure to give the product (240 g, 582.29 mmol, 92.34% yield). This product was used in the next step without further purification. [M+H] + = 395.1.
[0290] Step 3: Methyl (R)-2-(5-((5-((5-bromo-2-nitrophenyl)amino)-4-methylpentyl)oxy)-1-methyl-1H-pyrazol-4-yl)-6-methylisonicotinate [ka]
[0291] To a solution of (R)-5-((5-bromo-2-nitrophenyl)amino)-4-methylpentyl methanesulfonate (215.95 g, 546.33 mmol) and methyl 2-(5-hydroxy-1-methyl-pyrazol-4-yl)-6-methylpyridine-4-carboxylate (155 g, 546.33 mmol) in DMF (2 L) was added K2CO3 (151.01 g, 1.09 mol) at 15 °C. The mixture was stirred at 60 °C for 12 h and turned into a yellow suspension. Water (500 mL) was added to the reaction mixture, which was then extracted with EtOAc (300 mL*3). The combined organic layers were washed with brine (500 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 20 / 1 to 0 / 1) to give the product (185 g, 321.64 mmol, yield 58.87%, purity 95%). [M+H] += 546.2.
[0292] Step 4: Methyl (R)-2-(5-((5-((2-amino-5-bromophenyl)amino)-4-methylpentyl)oxy)-1-methyl-1H-pyrazol-4-yl)-6-methylisonicotinate [ka]
[0293] A mixture of methyl (R)-2-(5-((5-((5-bromo-2-nitrophenyl)amino)-4-methylpentyl)oxy)-1-methyl-1H-pyrazol-4-yl)-6-methylisonicotinate (15.0 g, 26.6 mmol) and Pt / C (894 mg, 212 μmol) in MeOH (225 mL) was degassed and purged with H (40 Psi) three times at 20 °C. The mixture was then stirred under an H atmosphere at 30 °C for 24 h, resulting in a black suspension. The mixture was filtered and concentrated under reduced pressure. The product (14.0 g, 24.9 mmol, 93.6% yield) was used in the next step without purification. [M+H] + = 516.1.
[0294] Step 5: Methyl (R)-2-(5-((5-(2-amino-6-bromo-1H-benzo[d]imidazol-1-yl)-4-methylpentyl)oxy)-1-methyl-1H-pyrazol-4-yl)-6-methylisonicotinate [ka]
[0295] To a solution of the compound methyl (R)-2-(5-((5-((2-amino-5-bromophenyl)amino)-4-methylpentyl)oxy)-1-methyl-1H-pyrazol-4-yl)-6-methylisonicotinate (14.0 g, 24.9 mmol) in DCM (112 mL) and t-BuOH (23.8 mL) at 15 °C, CNBr (5.89 g, 55.6 mmol, 4.09 mL) was added. The mixture was stirred at 15 °C for 24 h. The reaction mixture was then quenched with aqueous NaHCO (60 mL) for 10 min. The layers were separated, and the organic layer was washed with saturated aqueous NaHCO (60 mL * 2). The organic layer was dried over NaSO, filtered, and concentrated under reduced pressure to give the product (14.0 g, 24.4 mmol, 97.7% yield), which was used in the next step without further purification. [M+H] + = 541.3.
[0296] Step 6: (R)-2-(5-((5-(2-amino-6-bromo-1H-benzo[d]imidazol-1-yl)-4-methylpentyl)oxy)-1-methyl-1H-pyrazol-4-yl)-6-methylisonicotinic acid [ka]
[0297] To a solution of methyl (R)-2-(5-((5-(2-amino-6-bromo-1H-benzo[d]imidazol-1-yl)-4-methylpentyl)oxy)-1-methyl-1H-pyrazol-4-yl)-6-methylisonicotinate (14.0 g, 25.8 mmol) in THF (112 mL) was added NaOH (4.14 g, 103 mmol) in HO (112 mL) at 15° C. The mixture was stirred at 15° C. for 1 hour. The reaction mixture was then concentrated under reduced pressure to remove the solvent. The residue was acidified with 4 M aqueous HCl to pH=5, resulting in the formation of a slurry. The solid was filtered, washed with water (30 mL), and dried under reduced pressure to give the product. The product (14.0 g, crude) was used in the next step without purification. [MH] - = 525.2.
[0298] Step 7: (R,E)-5 6 -Bromo-1 1 ,2 6 ,7-trimethyl-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one [ka]
[0299] To a solution of (R)-2-(5-((5-(2-amino-6-bromo-1H-benzo[d]imidazol-1-yl)-4-methylpentyl)oxy)-1-methyl-1H-pyrazol-4-yl)-6-methylisonicotinic acid (13.0 g, 24.6 mmol) in DCM (210 mL) was added TBTU (9.50 g, 29.5 mmol) and TEA (3.74 g, 36.9 mmol, 5.15 mL) at 20 °C. The mixture was stirred at 20 °C for 1 h, resulting in a black solution. The reaction mixture was washed with saturated NaHCO solution (100 mL*3), dried over NaSO, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO, dichloromethane:methanol = 100 / 1 to 10 / 1) to give the product (10.3 g, 82.0% yield). 1H NMR (400 MHz, DMSO): δ 12.79 (br s, 1 H), 8.36 (s, 1 H), 7.83 - 7.92 (m, 2 H), 7.51 (s, 1 H), 7.39 - 7.46 (m, 1 H), 7.30 - 7.38 (m, 1 H), 4.22 - 4.37 (m, 1 H), 4.10 (dd, J = 13.59, 2.85 Hz, 1 H), 3.89 - 3.98 (m, 2 H), 3.68 (s, 3 H), 2.68 - 2.82 (m, 1 H), 2.51 (s, 3 H), 2.09 - 2.23 (m, 1 H), 1.78 - 1.98 (m, 2 H), 1.33 - 1.45 (m, 1 H), 0.76 (d, J = 6.58 Hz, 3 H).
[0300] Step 8: (R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carbaldehyde [ka]
[0301] (R,E)-5 6 -Bromo-1 1 ,2 6 ,7-trimethyl-5 2 ,5 3 -dihydro-1 1 H,5 1To a solution of H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (10.3 g, 20.2 mmol) in dioxane (16 mL) at 20 °C, Pd(OAc) (453 mg, 2.02 mmol), bis(1-adamantyl)-butyl-phosphane (2.17 g, 6.07 mmol), and TMEDA (4.70 g, 40.4 mmol, 6.10 mL) were added. The suspension was degassed under vacuum and purged with CO / H several times. The mixture was stirred at 100 °C for 48 h. The reaction mixture was then filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 10 / 1 to 0 / 1) to give the product (4.50 g, yield 48.5%).
[0302] 1 H NMR: (400 MHz, CDCl3): δ 10.04 (s, 1 H), 8.46 (s, 1 H), 8.16 (s, 1 H), 7.82 (s, 1 H), 7.76 (br d, J = 6.91 Hz, 1 H), 7.65 (s, 1 H), 7.47 (br d, J = 7.75 Hz, 1 H), 4.30 - 4.52 (m, 2 H), 3.86 - 3.97 (m, 1 H), 3.80 (s, 3 H), 2.86 (br s, 1 H), 2.60 (s, 3 H), 2.21 - 2.35 (m, 1 H), 2.14 (ddd, J = 13.83, 9.18, 4.53 Hz, 1 H), 1.95 (br s, 2 H), 1.45 - 1.73 (m, 2 H), 0.93 (d, J = 6.56 Hz, 3 H). [M+H] + = 459.3.
[0303] Step 9: tert-Butyl(R,E)-9-((1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-3,9-diazaspiro[5.5]undecane-3-carboxylate [ka]
[0304] In a 100 mL round-bottom flask equipped with a magnetic stir bar, add (R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 A mixture of 1,9-di-carbaldehyde (458 mg, 1.0 mmol), tert-butyl 3,9-diazaspiro[5.5]undecane-3-carboxylate (1.01 g, 4.0 mmol), NaBH(OAc) (636 mg, 3.0 mmol), and DCM (30 mL) was added at room temperature. To the stirred reaction mixture was added AcOH (457 mL, 8.0 mmol). After stirring at room temperature for 12 h, the reaction mixture was diluted with saturated aqueous NaHCO (30 mL) and the layers were separated. The aqueous layer was extracted with DCM (3 x 30 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. Purification by flash column chromatography (0-10% MeOH / DCM) afforded the product (368 mg, 53%). [M+H] + = 697.7.
[0305] Step 10: (R,E)-5 6 -((3,9-diazaspiro[5.5]undecan-3-yl)methyl)-1 1 ,2 6 ,7-trimethyl-5 2 ,5 3 -dihydro-1 1H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one [ka]
[0306] In a 100 mL round-bottom flask equipped with a magnetic stir bar, add tert-butyl (R,E)-9-((1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 To the reaction mixture was added (368 mg, 0.53 mmol), DCM (20 mL), and TFA (5 mL). After stirring at room temperature for 1 hour, the reaction mixture was concentrated under reduced pressure to give the product as the TFA salt (720 mg), which was used without further purification. [M+H] + = 597.5.
[0307] Step 11: (R)-3-(2,6-difluoro-4-((R)-3-(9-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-3,9-diazaspiro[5.5]undecane-3-carbonyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0308] In a 40 mL microwave vial equipped with a magnetic stir bar, add (R,E)-5 6 -((3,9-diazaspiro[5.5]undecan-3-yl)methyl)-1 1 ,2 6 ,7-trimethyl-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (90.0 mg, 0.15 mmol), (R)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)pyrrolidine-3-carboxylic acid (60.8 mg, 0.18 mmol), and DCM (8 mL) were added. To the reaction mixture were added N,N-diethylpropylethylamine (260 mL, 1.5 mmol) and T3P (50 wt%, 286 mg, 0.45 mmol). After stirring at room temperature for 1.5 h, the reaction mixture was diluted with brine (30 mL), and the layers were separated. The aqueous layer was extracted with DCM (3 × 15 mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. Purification by flash column chromatography (0-10% MeOH / DCM) and preparative HPLC chromatography (gradient elution: 0.1% FA / water:acetonitrile = 90:10 to 50:50) afforded the title compound (42 mg, 31%). 1H NMR (500 MHz, DMSO) δ 12.72 (s, 1H), 10.88 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.50 (s, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.17 (d, J = 8.0 Hz, 1H), 6.16 (d, J = 11.0 Hz, 2H), 4.40 - 4.36 (m, 1H), 4.23 - 4.17 (m, 1H), 4.06 - 3.96 (m, 6H), 3.82 - 3.77 (m, 3H), 3.73 (s, 3H), 3.58 -3.42 (m, 6H), 2.83 - 2.72 (m, 5H), 2.56 (s, 3H), 2.41 - 2.31 (m, 2H), 2.11 - 1.89 (m, 5H), 1.52 - 1.35 (m, 10H), 0.81 (d, J = 6.5 Hz, 3H);[M+H] + = 917.8.
[0309] Example 10: (R)-3-(2,6-difluoro-4-(3-(4-(1-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperidin-4-yl)piperazine-1-carbonyl)azetidin-1-yl)phenyl)piperidine-2,6-dione
[0310] Step 1: Methyl 1-(4-(2,6-bis(benzyloxy)pyridin-3-yl)-3,5-difluorophenyl)azetidine-3-carboxylate [ka]
[0311] A mixture of 2,6-bis(benzyloxy)-3-(4-bromo-2,6-difluorophenyl)pyridine (3.00 g, 6.22 mmol), methyl azetidine-3-carboxylate hydrochloride (1.41 g, 9.33 mmol), CsCO (6.06 g, 18.66 mmol), and RuPhosPdG (520.7 mg, 0.622 mmol) in toluene (50 mL) was stirred overnight at 100 °C under a nitrogen atmosphere. The resulting mixture was extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (2:1) to give the product (1.7 g, 53%). [M+1] + = 517.1.
[0312] Step 2: 1-(4-(2,6-bis(benzyloxy)pyridin-3-yl)-3,5-difluorophenyl)azetidine-3-carboxylic acid [ka]
[0313] To a stirred mixture of methyl 1-(4-(2,6-bis(benzyloxy)pyridin-3-yl)-3,5-difluorophenyl)azetidine-3-carboxylate (1.7 g, 3.29 mmol) in THF (20 mL) was added LiOH HO (168 mg, 4 mmol in 10 mL water) dropwise at room temperature. The mixture was then stirred for 2 hours. The resulting mixture was concentrated in vacuo. The aqueous layer was adjusted to pH < 5 with 1N HCl and then extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure to give the product (1.4 g, 85%). [M+1] + = 503.2.
[0314] Step 3: (R)-1-(4-(2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)azetidine-3-carboxylic acid [ka]
[0315] To a solution of 1-(4-(2,6-bis(benzyloxy)pyridin-3-yl)-3,5-difluorophenyl)azetidine-3-carboxylic acid (1.40 g, 2.79 mmol) in iPrOH (20 mL) and DCM (20 mL) was added Pd / C (1.0 g, 10% wt), and the mixture was stirred under a hydrogen atmosphere at room temperature for 48 hours. The resulting mixture was filtered, and the filter cake was washed with DCM (20 mL). The filtrate was concentrated under reduced pressure to give the crude product. The residue was purified by SFC (IH (3*25 cm, 5 um), 13% EtOH / 87% CO2, 100 bar, 100 ml / min), and the title compound (190 mg, 21%) corresponded to Peak A at 1.853 min / 254 nm. [M+1] + =325.3.
[0316] Step 4: (R)-3-(2,6-difluoro-4-(3-(4-(1-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperidin-4-yl)piperazine-1-carbonyl)azetidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0317] In a 40 mL microwave vial equipped with a magnetic stir bar, add (R,E)-1 1 ,2 6 ,7-trimethyl-5 6 -((4-(piperazin-1-yl)piperidin-1-yl)methyl)-5 2 ,5 3 -Dihydro- 11H,5 1 H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (92.0 mg, 0.15 mmol), (R)-1-(4-(2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)azetidine-3-carboxylic acid (compound obtained in a similar manner to Example 5) (97.3 mg, 0.30 mmol), and DCM (8 mL) were added. To the reaction mixture were added N,N-diethylpropylethylamine (520 mL, 3.0 mmol) and T3P (50% by weight, 570 mg, 0.90 mmol). After stirring at room temperature for 1.5 hours, the reaction mixture was diluted with brine (30 mL), and the layers were separated. The aqueous layer was extracted with DCM (3 × 15 mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. Purification by flash column chromatography (0-10% MeOH / DCM) followed by preparative HPLC chromatography (gradient elution: 0.1% FA / water:acetonitrile = 90:10 to 50:50) afforded the title compound (102 mg, 74%). 1H NMR (500 MHz, DMSO) δ 12.71 (s, 1H), 10.88 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.49 (s, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.16 (d, J = 8.0 Hz, 1H), 6.16 (d, J = 11.0 Hz, 2H), 4.39 - 4.34 (m, 1H), 4.23 - 4.15 (m, 1H), 4.05 - 3.89 (m, 8H), 3.82 - 3.77 (m, 2H), 3.73 (s, 3H), 3.59 -3.42 (m, 3H), 2.91 - 2.70 (m, 5H), 2.56 (s, 3H), 2.50 - 2.40 (m, 5H), 2.27 - 2.16 (m, 2H), 2.08 - 1.86 (m, 6H), 1.71 - 1.69 (m, 2H), 1.51 - 1.35 (m, 3H), 0.80 (d, J = 6.5 Hz, 3H);[M+H] + = 918.4.
[0318] Example 12: (R)-3-(2,6-difluoro-4-(3-(9-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-3,9-diazaspiro[5.5]undecane-3-carbonyl)azetidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0319] In a 40 mL microwave vial equipped with a magnetic stir bar, add (R,E)-5 6-((3,9-diazaspiro[5.5]undecan-3-yl)methyl)-1 1 ,2 6 ,7-trimethyl-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (90.0 mg, 0.15 mmol), (R)-1-(4-(2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)azetidine-3-carboxylic acid (58.3 mg, 0.18 mmol), and DCM (8 mL) were added. To the reaction mixture were added N,N-diethylpropylethylamine (260 mL, 1.5 mmol) and T3P (50 wt%, 286 mg, 0.45 mmol). After stirring at room temperature for 1.5 hours, the reaction mixture was diluted with brine (30 mL), and the layers were separated. The aqueous layer was extracted with DCM (3 × 15 mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. Purification by flash column chromatography (0-10% MeOH / DCM) and preparative HPLC chromatography (gradient elution: 0.1% FA / water:acetonitrile = 90:10 to 50:50) afforded the title compound (51 mg, 38%). 1H NMR (500 MHz, DMSO) δ 12.73 (s, 1H), 10.88 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.50 (s, 1H), 7.47 (d, J = 8.5 Hz, 1H), 7.17 (d, J = 8.0 Hz, 1H), 6.16 (d, J = 11.0 Hz, 2H), 4.39 - 4.34 (m, 1H), 4.22 - 4.17 (m, 1H), 4.06 - 3.96 (m, 4H), 3.95 - 3.85 (m, 4H), 3.82 - 3.77 (m, 1H), 3.73 (s, 3H), 3.61 - 3.54 (m, 2H), 3.48 - 3.42 (m, 4H), 2.83 - 2.72 (m, 5H), 2.56 (s, 3H), 2.41 - 2.31 (m, 2H), 2.24 - 2.17 (m, 1H), 2.11 - 1.89 (m, 4H), 1.52 - 1.35 (m, 10H), 0.81 (d, J = 6.5 Hz, 3H);[M+H] + = 903.3.
[0320] Example 14: (R)-3-(2,6-difluoro-4-(2-(4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazin-1-yl)ethyl)phenyl)piperidine-2,6-dione
[0321] Step 1: Ethyl 4-(4-bromo-2,6-difluorophenyl)-4-cyanobutanoate [ka]
[0322] To a solution of 2-(4-bromo-2,6-difluorophenyl)acetonitrile (10 g, 43.1 mmol) in THF (150 mL) was added LDA (2 M in THF, 24 mL, 48 mmol) dropwise over 20 minutes at -65 °C. The reaction solution was stirred at this temperature for 1 hour, and then a solution of ethyl 3-bromopropanoate (9.4 g, 51.7 mmol) in THF (30 mL) was added dropwise over 10 minutes. The resulting solution was stirred at -65 °C for 30 minutes and then allowed to warm to room temperature. The reaction was quenched by adding saturated aqueous NH4Cl (50 mL) and extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to give the product (13.8 g, 96.5%). [M+H] + = 332.0.
[0323] Step 2: 4-(4-bromo-2,6-difluorophenyl)-4-cyanobutanoic acid [ka]
[0324] LiOH (2.9 g, 0.122 mol) was added to a solution of ethyl 4-(4-bromo-2,6-difluorophenyl)-4-cyanobutanoate (13.5 g, 40.7 mmol) in THF / HO (90 mL / 30 mL). The reaction mixture was stirred for 12 hours at room temperature. The resulting mixture was diluted with water and extracted with EtOAc (50 mL x 2). The pH of the aqueous phase was adjusted to 4-5 with 1N HCl (10 mL) and extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (50 mL x 3) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure to give the product (10.2 g, 82.5%). [M+H] + = 304.2.
[0325] Step 3: 3-(4-bromo-2,6-difluorophenyl)piperidine-2,6-dione [ka]
[0326] To a stirred solution of 4-(4-bromo-2,6-difluorophenyl)-4-cyanobutanoic acid (10.2 g, 33.5 mmol) in toluene (100 mL) was added concentrated H2SO4 (2 mL, 36.9 mmol). The resulting solution was stirred at 100 °C for 3 h. The reaction mixture was concentrated in vacuo, and then the mixture was poured into water. The pH value was adjusted to 7-8 with saturated aqueous NaHCO3 (40 mL), and the resulting solution was extracted with EtOAc (50 mL x 3). The combined organic layers were washed with water and brine, dried over anhydrous Na2SO4, filtered, and concentrated to give the product (8.2 g, 80.4%). [M+H] + = 304.3.
[0327] Step 4: (R,E)-3-(4-(2-ethoxyvinyl)-2,6-difluorophenyl)piperidine-2,6-dione [ka]
[0328] To a stirred solution of 3-(4-bromo-2,6-difluorophenyl)piperidine-2,6-dione (8.2 g, 27.0 mmol) and (E)-2-(2-ethoxyvinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (6.4 g, 32.4 mmol) in DMF / HO (100 mL / 20 mL) was added Pd(dtbpf)Cl (883 mg, 1.35 mmol) and CsF (8.2 g, 54.0 mmol). The resulting mixture was stirred at 80 °C under a nitrogen atmosphere for 2 hours. The reaction solution was diluted with water and extracted with EtOAc (100 mL x 2). The combined organic layers were washed with water and brine, dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified by SFC (IH (3*25 cm, 5 μm), 13% EtOH / 87% CO2, 100 bar, 100 ml / min) to give the title compound (3.1 g, 39.0%) corresponding to peak A at 1.679 min / 254 nm. [M+H] + = 296.1.
[0329] Step 5: (R)-2-(4-(2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)acetaldehyde [ka]
[0330] (R,E)-3-(4-(2-ethoxyvinyl)-2,6-difluorophenyl)piperidine-2,6-dione (3.1 g, 10.4 mmol) was dissolved in FA (50 mL). The resulting solution was stirred at room temperature for 2 hours. The reaction solution was evaporated to dryness to give the product (2.6 g, 91.8%). [M+H] + 268.1.
[0331] Step 6: (R)-3-(2,6-difluoro-4-(2-(4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazin-1-yl)ethyl)phenyl)piperidine-2,6-dione [ka]
[0332] In a 40 mL microwave vial equipped with a magnetic stir bar, add (R,E)-1 1 ,2 6 ,7-trimethyl-5 6 -(piperazin-1-ylmethyl)-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (52.9 mg, 0.1 mmol), (R)-2-(4-(2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)acetaldehyde (54.0 mg, 0.2 mmol), NaBH(OAc) (63.6 mg, 0.3 mmol), and DCM (8 mL) were added. After stirring at 40 °C for 12 h, the reaction mixture was concentrated under reduced pressure. Purification by flash column chromatography (0-70% MeOH / DCM) followed by preparative HPLC chromatography (gradient elution: 0.1% FA / water:acetonitrile = 90:10 to 50:50) afforded the title compound (43 mg, 55%). 1 H NMR (500 MHz, DMSO) δ 12.65 (s, 1H), 10.90 (s, 1H), 8.36 (s, 1H), 7.86 (s, 1H), 7.50 (s, 1H), 7.44 (s, 1H), 7.41 (d, J = 8.0 Hz, 1H), 7.11 (d, J = 8.0 Hz, 1H), 6.95 (d, J = 10.5 Hz, 2H), 4.31- 4.25 (m, 1H), 4.20 - 4.09 (m, 3H), 3.97 - 3.84 (m, 2H), 3.67 (s, 3H), 3.54 - 3.43 (m, 2H), 2.80 - 2.64 (m, 6H), 2.49 (s, 3H), 2.49 - 2.44 (m, 5H), 2.19 - 1.99 (m, 4H), 1.98 - 1.79 (m, 4H), 1.44 - 1.35 (m, 1H), 0.74 (d, J = 6.0 Hz, 3H);[M+H] + = 780.7.
[0333] Example 1: 3-(4-(2-(4-((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)piperidin-1-yl)ethyl)phenyl)piperidine-2,6-dione
[0334] Step 1: 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethan-1-ol [ka]
[0335] 2-(4-Bromophenyl)ethan-1-ol (20 g, 100 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-1,3,2-dioxaborolane (38.1 g, 150 mmol), Pd(dppf)Cl2 (7.3 g, 10 mmol), and KOAc (19.6 g, 200 mmol) were added to dioxane (400 mL). The resulting mixture was heated to reflux for 2 hours. The mixture was cooled to room temperature, and the solid was filtered off and concentrated to give the crude product (28 g, crude), which was used directly without further purification. [M+H] + =249.2.
[0336] Step 2: 2-(4-(2,6-bis(benzyloxy)pyridin-3-yl)phenyl)ethan-1-ol [ka]
[0337] 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethan-1-ol (28 g, crude product), Pd(dppf)Cl (7.3 g, 10 mmol), 2,6-bis(benzyloxy)-3-bromopyridine (36.9 g, 100 mmol), and CsCO (65.2 g, 200 mmol) were added to dioxane / water (300 mL, 10:1). The mixture was stirred at 100 °C overnight. The reaction was cooled to room temperature, the solids were filtered off, and the filtrate was concentrated and purified on a SiO gel column (eluted with 1:2 EtOAc / hexane) to give the crude product, which was used directly in the next step. [M+H] + =412.2.
[0338] Step 3: 3-(4-(2-hydroxyethyl)phenyl)piperidine-2,6-dione [ka]
[0339] 2-(4-(2,6-bis(benzyloxy)pyridin-3-yl)phenyl)ethan-1-ol (crude product from the last step) was dissolved in MeOH (500 mL) and Pd / C (10 wt%, 5 g) was added to the solution in one portion. The resulting mixture was stirred overnight under H atmosphere (1 atm). The solid was filtered off and the filtrate was concentrated to give the crude product. The crude product was triturated with MTBE (50 mL) to give the desired product (13.5 g, 57.9% for three steps). [M+H] + =234.1.
[0340] Step 4: 2-(4-(2,6-dioxopiperidin-3-yl)phenyl)acetaldehyde [ka]
[0341] A mixture of 3-(4-(2-hydroxyethyl)phenyl)piperidine-2,6-dione (100 mg, 0.43 mmol) and IBX (132 mg, 0.47 mmol) in DMSO (10 mL) was stirred in a flask at room temperature overnight. The reaction was quenched with water, and the mixture was extracted with EtOAc and washed three times with saturated aqueous NaCl and twice with saturated aqueous NaHCO. The organic layer was dried over anhydrous NaSO and evaporated in vacuo to give the product (70 mg, 70%). [M+H]=232.19.
[0342] Step 5: tert-Butyl(R,E)-4-(1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)-3,6-dihydropyridine-1(2H)-carboxylate [ka]
[0343] (R,E)-5 6 -Bromo- 1 1, 2 6 , 7-trimethyl-5 2 , 5 3 -Dihydro- 1 1H, 5 1A mixture of H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (200 mg, 0.39 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (157 mg, 0.51 mmol), Pd(dppf)Cl (29 mg, 0.04 mmol), and NaCO (83 mg, 0.78 mmol) in dioxane (10 mL) and HO (2 mL) was stirred at 90 °C under N for 18 h. After cooling to room temperature, the reaction mixture was extracted with DCM (20 mL x 3). The combined organic phase was washed with brine (20 mL), dried over NaSO, filtered, and concentrated in vacuo. The residue was purified by silica gel column (DCM:CHOH=0-6:1) to give tert-butyl (R,E)-4-(1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,51H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)-3,6-dihydropyridine-1(2H)-carboxylate (150 mg, 62.7%) was obtained. [M+H] + = 612.6.
[0344] Step 6: tert-Butyl(R,E)-4-(1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)piperidine-1-carboxylate [ka]
[0345] tert-Butyl (R,E)-4-(1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 To a solution of tert-butyl (R,E)-4-(1H-yl)-3,6-dihydropyridine-1(2H)-carboxylate (150 mg, 0.25 mmol) in THF (8 mL) was added Pd / C (90 mg, 10%). The reaction mixture was stirred under a H balloon at room temperature for 4 h. The catalyst was filtered off, and the filtrate was concentrated in vacuo to give tert-butyl (R,E)-4-(1H-yl)-3,6-dihydropyridine-1(2H)-carboxylate. 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)piperidine-1-carboxylate (140 mg, 93%) was obtained. [M+H] + = 614.6.
[0346] Step 7: (R,E)-1 1 ,2 6 ,7-trimethyl-5 6 -(piperidin-4-yl)-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one [ka]
[0347] tert-Butyl (R,E)-4-(1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 To a solution of (R,E)-1-ylpiperidine-1-carboxylate (140 mg, 0.23 mmol) in DCM (8 mL) was added TFA (2 mL). The reaction solution was stirred at room temperature for 1 hour and then concentrated in vacuo. The residue was dissolved in DCM, washed with saturated NaHCO3 solution (5 mL) and brine (5 mL), dried over Na2SO4, filtered, and concentrated in vacuo to give (R,E)-1 1 ,2 6 ,7-trimethyl-5 6 -(piperidin-4-yl)-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (80 mg, 68%) was obtained. [M+H] + =514.6.
[0348] Step 8: 3-(4-(2-(4-((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)piperidin-1-yl)ethyl)phenyl)piperidine-2,6-dione [ka]
[0349] The title compound (12 mg, 27%) was obtained by the same procedure as in Step 6 of Example 14, (R,E)-1 1 ,2 6 ,7-trimethyl-5 6 -(piperidin-4-yl)-5 2 ,5 3 -dihydro-1 1 H,5 1 It was prepared from H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one and 2-(4-(2,6-dioxopiperidin-3-yl)phenyl)acetaldehyde. 1 H NMR (500 MHz, DMSO) δ 12.75 - 12.50 (m, 1H), 10.89 (s, 1H), 8.48 - 8.38 (m, 1H), 8.01 - 7.85 (m, 1H), 7.55 (d, J = 10.1 Hz, 2H), 7.47 - 7.39 (m, 1H), 7.23 - 7.18 (m, 2H), 7.17 - 7.03 (m, 3H), 4.38 - 4.34 (m, 1H), 4.17 (d, J = 11.2 Hz, 1H), 4.02 - 3.98 (m, 2H), 3.88 - 3.78 (m, 1H), 3.73 (s, 3H), 3.12 (d, J = 10.3 Hz, 2H), 2.85 - 2.73 (m, 3H), 2.71 - 2.59 (m, 4H), 2.55 (d, J = 6.5 Hz, 3H), 2.25 - 2.18 (m, 5H), 2.06 - 1.89 (m, 3H), 1.77 (d, J = 27.3 Hz, 4H), 1.45 (d, J = 6.2 Hz, 1H), 0.82 (d, J = 6.4 Hz, 3H). [M+H] + = 729.6.
[0350] Example 2: 3-(2-fluoro-4-(4-(2-(4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazin-1-yl)ethyl)piperidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0351] The title compound was prepared in a similar manner to Example 14.
[0352] 1 H NMR (500 MHz, DMSO) δ 12.71 (s, 1H), 10.80 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.55 - 7.39 (m, 2H), 7.17 (d, J = 8.1 Hz, 1H), 7.05 (t, J = 8.7 Hz, 1H), 6.82 - 6.51 (m, 2H), 4.36 (s, 1H), 4.20 (d, J = 12.0 Hz, 1H), 3.96 - 3.85 (m, 3H), 3.73 (s, 3H), 3.68 (d, J = 12.3 Hz, 2H), 3.57 (s, 2H), 2.79 (s, 1H), 2.72 - 2.59 (m, 4H), 2.55 (d, J = 7.8 Hz, 4H), 2.43 - 2.36 (m, 8H), 2.21 (s, 1H), 2.15 - 2.05 (m, 1H), 2.03 - 1.86 (m, 4H), 1.72 (d, J = 12.1 Hz, 2H), 1.54 - 1.34 (m, 4H), 1.27 - 1.14 (m, 2H), 0.81 (d, J = 6.3 Hz, 3H). [M+H] + = 845.6.
[0353] Example 3: 3-(2,6-difluoro-4-(4-(2-(4-(1-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperidin-4-yl)piperazin-1-yl)ethyl)piperidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0354] The title compound was prepared in a similar manner to Example 14. 1 H NMR (500 MHz, DMSO) δ 12.69 (s 1H), 10.86 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.51 - 7.40 (m, 2H), 7.15 (d, J = 8.2 Hz, 1H), 6.59 (d, J = 12.8 Hz, 2H), 4.39 - 4.32 (m, 1H), 4.19 (d, J = 11.2 Hz, 1H), 4.10 - 3.86 (m, 3H), 3.73 (s, 3H), 3.71 (s, 2H), 3.53 (s, 2H), 2.85 - 2.73 (m, 4H), 2.72- 2.65 (m, 3H), 2.56 (s, 5H), 2.48 - 2.40 (m, 3H), 2.38 - 2.25 (m, 5H), 2.22 (s, 1H), 2.15 - 2.05 (m, 2H), 1.96-1.90 (m, 5H), 1.74-1.68 (m, 4H), 1.53 - 1.30 (m, 6H), 1.16 (s, 2H), 0.81 (d, J = 6.5 Hz, 3H).[M+H] + = 946.8.
[0355] Example 15: 3-(3-methyl-2-oxo-4-((4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazin-1-yl)piperidin-1-yl)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione [ka]
[0356] In a 40 mL microwave vial equipped with a magnetic stir bar, add (R,E)-1 1 ,2 6 ,7-trimethyl-5 6 -(piperazin-1-ylmethyl)-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (238 mg, 0.45 mmol), 3-(3-methyl-2-oxo-4-(4-oxopiperidin-1-yl)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (45.2 mg, 0.15 mmol), and DCE (8 mL) were added to the reaction mixture. N,N-Diethylpropylethylamine (0.5 mL, 3.0 mmol) and Ti(OiPr) (0.3 mL, 1.0 mmol) were added to the reaction mixture. After stirring at 70 °C for 12 h, the reaction mixture was cooled to room temperature and NaBH(OAc) (127 mg, 0.6 mmol) was added. After stirring at 70°C for 2 hours, the reaction mixture was concentrated under reduced pressure and purified by flash column chromatography (0-70% MeOH / DCM) followed by preparative HPLC chromatography (gradient elution: 0.1% FA / water:acetonitrile = 90:10 to 50:50) to give the title compound (38 mg, 45%). 1H NMR (500 MHz, DMSO) δ 12.67 (s, 1H), 11.04 (s, 1H), 8.36 (s, 1H), 7.86 (s, 1H), 7.50 (s, 1H), 7.46 (s, 1H), 7.43 (d, J = 8.0 Hz, 1H), 7.13 (d, J = 8.0 Hz, 1H), 6.90 (t, J = 8.0 Hz, 1H), 6.82 (d, J = 8.0 Hz, 1H), 6.81 (d, J = 8.0 Hz, 1H), 4.28 (dd, J = 12.5, 4.5 Hz, 1H), 4.32 - 4.27 (m, 1H), 4.14 (d, J = 12.5 Hz, 1H), 3.94 - 3.90 (m, 1H), 3.87 (t, J = 12.5 Hz, 1H), 3.67 (s, 3H), 3.55 (s, 3H), 3.12 - 3.05 (m, 2H), 2.86 - 2.70 (m, 3H), 2.65 - 2.53 (m, 7H), 2.49 (s, 3H), 2.45 - 2.30 (m, 7H), 2.21 - 2.10 (m, 1H),1.95 - 1.85 (m, 5H), 1.67 - 1.51 (m, 2H), 1.45 - 1.32 (m, 1H), 0.75 (d, J = 6.5 Hz, 3H);[M+H] + = 869.8.
[0357] Example 16: (R)-3-(2,6-difluoro-4-(1'-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-[1,4'-bipiperidine]-4-yl)phenyl)piperidine-2,6-dione
[0358] Step 1: (R,E)-56 -((1,4-dioxa-8-azaspiro[4.5]decan-8-yl)methyl)-1 1 ,2 6 ,7-trimethyl-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one [ka]
[0359] In a 100 mL round-bottom flask equipped with a magnetic stir bar, add (R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 A mixture of 1,4-dioxa-8-azaspiro[4.5]decane (916 mg, 2.0 mmol), 1,4-dioxa-8-azaspiro[4.5]decane (2.3 g, 16.0 mmol), NaBH(OAc) (2.1 g, 10.0 mmol), and DCM (50 mL) was added at room temperature. To the stirred reaction mixture was added AcOH (0.69 mL, 12.0 mmol). After stirring at room temperature for 12 h, the reaction mixture was diluted with saturated aqueous NaHCO (50 mL) and the layers were separated. The aqueous layer was extracted with DCM (3 x 40 mL). The combined organic layers were washed with brine (100 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. Purification by flash column chromatography (0-10% MeOH / DCM) afforded the product (1.0 g, 85%). [M+H] + = 586.5.
[0360] Step 2: (R,E)-1 1 ,2 6 ,7-trimethyl-5 6-((4-oxopiperidin-1-yl)methyl)-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one [ka]
[0361] In a 100 mL round-bottom flask equipped with a magnetic stir bar, add (R,E)-5 6 -((1,4-dioxa-8-azaspiro[4.5]decan-8-yl)methyl)-1 1 ,2 6 ,7-trimethyl-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (1.0 g, 1.7 mmol) and 6N HCl (40 mL) were added. After stirring at room temperature for 3 hours, the reaction mixture was concentrated under reduced pressure to give the product (670 mg, 70%), which was used without further purification. [M+H2O+H] + = 560.4.
[0362] Step 3: (R)-3-(2,6-difluoro-4-(1'-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-[1,4'-bipiperidine]-4-yl)phenyl)piperidine-2,6-dione [ka]
[0363] In a 40 mL microwave vial equipped with a magnetic stir bar, add (R,E)-1 1 ,2 6 ,7-trimethyl-5 6 -((4-oxopiperidin-1-yl)methyl)-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (167 mg, 0.30 mmol), (R)-3-(2,6-difluoro-4-(piperidin-4-yl)phenyl)piperidine-2,6-dione (compound obtained in a manner similar to that in Example 14) (30.8 mg, 0.10 mmol), and DCE (8 mL) were added. N,N-Diethylpropylethylamine (0.5 mL, 3.0 mmol) and Ti(OiPr) (0.3 mL, 1.0 mmol) were added to the reaction mixture. After stirring at 70 °C for 12 hours, the reaction mixture was cooled to room temperature, and NaBH(OAc) (106 mg, 0.5 mmol) was added. After stirring at 70 °C for 2 hours, the reaction mixture was concentrated under reduced pressure. After purification by flash column chromatography (0-70% MeOH / DCM), the title compound (25 mg, 30%) was obtained by preparative HPLC chromatography (gradient elution with 0.1% FA / water:acetonitrile=90:10-50:50). 1H NMR (500 MHz, DMSO) δ12.74 (s, 1H), 10.98 (s, 1H), 8.44 (s, 1H), 7.93 (s, 1H), 7.63 - 7.49 (m, 3H), 7.23 - 7.13 (m, 1H), 7.02 (d, J = 10.0 Hz, 2H), 4.44 - 4.27 (m, 2H), 4.24 - 4.16 (m, 1H), 4.03 - 3.89 (m, 2H), 3.74 (s, 3H), 3.09 - 2.87 (m, 7H), 2.85 - 2.76 (m, 3H), 2.56 (s, 3H), 2.27 - 2.05 (m, 5H), 2.03 - 1.86 (m, 8H), 1.77 - 1.55 (m, 4H), 0.88 - 0.77 (m, 2H), 0.82 (d, J = 5.0 Hz, 3H);[M+H] + = 834.5.
[0364] Example 17: (R)-3-(2,6-difluoro-4-(3-(9-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-3,9-diazaspiro[5.5]undecan-3-yl)azetidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0365] In a 40 mL microwave vial equipped with a magnetic stir bar, add (R,E)-5 6 -((3,9-diazaspiro[5.5]undecan-3-yl)methyl)-1 1 ,2 6 ,7-trimethyl-5 2 ,53 -dihydro-1 1 H,5 1 H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (143 mg, 0.24 mmol), (R)-3-(2,6-difluoro-4-(3-oxoazetidin-1-yl)phenyl)piperidine-2,6-dione (compound obtained in a manner similar to that in Example 5) (58.8 mg, 0.2 mmol), and DCE (8 mL) were added. To the reaction mixture were added NaBH(OAc) (84.8 mg, 0.4 mmol) and 3 drops of AcOH. After stirring at 70 °C for 4 hours, the reaction mixture was concentrated under reduced pressure. After purification by flash column chromatography (0-70% MeOH / DCM), the title compound (22 mg, 13%) was obtained by preparative HPLC chromatography (gradient elution with 0.1% FA / water:acetonitrile=90:10-50:50). 1 H NMR (500 MHz, DMSO) δ 12.79 (s, 1H), 10.88 (s, 1H), 8.43 (s, 1H), 8.22 (s, 2H), 7.94 (s, 1H), 7.62 - 7.54 (m, 2H), 6.11 (d, J = 11.5 Hz, 2H), 4.44 - 4.32 (m, 2H), 4.26 - 4.18 (m, 1H), 4.06 - 3.97 (m, 2H), 3.94 - 3.84 (m, 3H), 3.74 (s, 3H), 3.64 - 3.53 (m, 3H), 2.98 - 2.86 (m, 5H), 2.84 - 2.73 (m, 2H), 2.56 (s, 3H), 2.34 - 2.17 (m, 5H), 2.11 - 1.89 (m, 6H), 1.53 - 1.35 (m, 8H), 0.84 (d, J = 6.5 Hz, 3H);[M+H] + = 875.5.
[0366] Example 18: (R)-3-(2,6-difluoro-4-(3-(4-(1-(((R,E)-1 1 ,2 6,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperidin-4-yl)piperazin-1-yl)azetidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0367] In a 40 mL microwave vial equipped with a magnetic stir bar, add (R,E)-1 1 ,2 6 ,7-trimethyl-5 6 -((4-(piperazin-1-yl)piperidin-1-yl)methyl)-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (146 mg, 0.24 mmol), (R)-3-(2,6-difluoro-4-(3-oxoazetidin-1-yl)phenyl)piperidine-2,6-dione (58.8 mg, 0.2 mmol), and DCE (8 mL) were added to the reaction mixture. NaBH(OAc) (84.8 mg, 0.4 mmol) and drops of AcOH were added. After stirring at 70 °C for 4 h, the reaction mixture was concentrated under reduced pressure. After purification by flash column chromatography (0-70% MeOH / DCM), the title compound (34 mg, 19%) was obtained by preparative HPLC chromatography (gradient elution with 0.1% FA / water:acetonitrile=90:10-50:50). 1H NMR (500 MHz, DMSO) δ 12.73 (s, 1H), 10.87 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.51 - 7.47 (m, 2H), 7.22 - 7.10 (m, 1H), 6.11 (d, J = 11.0 Hz, 2H), 4.43 - 4.28 (m, 1H), 4.22 - 4.16 (m, 1H), 4.05 - 3.98 (m, 2H), 3.95 - 3.84 (m, 3H), 3.73 (s, 3H), 3.65 - 3.55 (m, 3H), 3.01 - 2.86 (m, 4H), 2.83 - 2.71 (m, 2H), 2.56 (s, 3H), 2.50 - 2.43 (m, 5H), 2.34 - 2.16 (m, 5H), 2.10 - 1.85 (m, 7H), 1.31 - 1.20 (m, 5H), 0.81 (d, J = 6.5 Hz, 3H);[M+H] + = 890.6.
[0368] Example 20: (R)-3-(2,6-difluoro-4-((R)-3-(7-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-2,7-diazaspiro[3.5]nonane-2-carbonyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0369] The title compound was prepared in a similar manner to Example 5. 1H NMR (500 MHz, DMSO) δ 12.74 (s, 1H), 10.86 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.54 - 7.51 (m, 3H), 7.20 (s, 1H), 6.22 (d, J = 12.3 Hz, 2H), 4.36 (d, J = 4.6 Hz, 1H), 4.22 (d, J = 11.9 Hz, 1H), 4.03 - 3.98 (m, 2H), 3.92 (s, 3H), 3.73 (s, 3H), 3.57 (s, 3H), 3.44 - 3.40 (m, 2H), 3.31 - 3.27 (m, 2H), 3.25 - 3.20 (m, 2H), 3.17 - 3.12 (m, 1H), 2.86 - 2.68 (m, 2H), 2.55 (d, J = 8.3 Hz, 3H), 2.50 - 2.46 (m, 3H), 2.22 (s, 2H), 2.17 - 1.97 (m, 5H), 1.96 - 1.85 (m, 2H), 1.74 (s, 3H), 1.46 (s, 1H), 0.82 (d, J = 5.9 Hz, 3H). [M+H] + = 889.6.
[0370] Example 21: 3-(1-oxo-5-(4-((9-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-3,9-diazaspiro[5.5]undecan-3-yl)methyl)piperidin-1-yl)isoindolin-2-yl)piperidine-2,6-dione [ka]
[0371] The title compound was prepared in a similar manner to Example 14. 1 H NMR (500 MHz, DMSO) δ 12.69 (s, 1H), 10.93 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.48 (t, J = 8.9 Hz, 3H), 7.16 (d, J = 8.0 Hz, 1H), 7.02 (d, J = 8.5 Hz, 2H), 5.03 (dd, J = 13.5, 5.1 Hz, 1H), 4.40 - 4.27 (m, 2H), 4.23 - 4.13 (m, 2H), 4.00 (s, 1H), 3.97 - 3.90 (m, 1H), 3.85 (d, J = 11.0 Hz, 2H), 3.73 (s, 3H), 3.55 (s, 2H), 2.96 - 2.85 (m, 1H), 2.80 (t, J = 11.9 Hz, 3H), 2.65 - 2.54 (m, 5H), 2.42 - 2.26 (m, 9H), 2.25 - 2.18 (m, 1H), 2.16 - 2.09 (m, 2H), 2.03 - 1.87 (m, 3H), 1.75 (t, J = 11.6 Hz, 3H), 1.44 - 1.41 (m, 8H), 1.15 (d, J = 11.6 Hz, 2H), 0.81 (d, J = 6.4 Hz, 3H);[M+H] + =936.8.
[0372] Example 22: 3-(4-(methyl (2-(9-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-3,9-diazaspiro[5.5]undecan-3-yl)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione [ka]
[0373] The title compound was prepared in a similar manner to Example 14.
[0374] 1 H NMR (500 MHz, DMSO) δ 12.69 (s, 1H), 10.98 (s, 1H), 8.42 (s, 1H), 7.92 (s, 1H), 7.56 (s, 1H), 7.46 (d, J = 8.5 Hz, 2H), 7.35 (t, J = 7.7 Hz, 1H), 7.14 (t, J = 7.2 Hz, 2H), 6.98 (d, J = 8.0 Hz, 1H), 5.11 (dd, J = 13.3, 5.3 Hz, 1H), 4.50 (d, J = 17.0 Hz, 1H), 4.40 - 4.30 (m, 2H), 4.19 (d, J = 11.0 Hz, 1H), 4.00 (s, 1H), 3.91 (d, J = 12.9 Hz, 1H), 3.73 (s, 3H), 3.55 (s, 2H), 3.49 - 3.36 (m, 4H), 2.92 (s, 4H), 2.78 (s, 1H), 2.65 - 2.60 (m, 1H), 2.59 - 2.54 (m, 4H), 2.44 - 2.39 (m, 2H), 2.37 - 2.29 (m, 7H), 2.24 - 2.16 (m, 1H), 2.03 - 1.87 (m, 3H), 1.52 - 1.43 (m, 1H), 1.36 - 1.32 (m, 7H), 0.80 (d, J = 6.5 Hz, 3H);[M+H] + =896.8.
[0375] Example 23: (R)-3-(2,6-difluoro-4-(2-(7-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)ethyl)phenyl)piperidine-2,6-dione [ka]
[0376] The title compound was prepared in a similar manner to Example 14.
[0377] 1 H NMR (500 MHz, DMSO) δ 12.71 (s, 1H), 10.96 (s, 1H), 8.43 (s, 1H), 7.91 (d, J = 7.2 Hz, 1H), 7.57 (s, 1H), 7.53 - 7.39 (m, 2H), 7.15 (d, J = 13.6 Hz, 1H), 6.98 (d, J = 10.1 Hz, 2H), 4.38 - 4.34 (m, 1H), 4.19 (d, J = 12.6 Hz, 2H), 4.03 - 3.92 (m, 2H), 3.73 (s, 3H), 3.52 (s, 2H), 2.93 (s, 4H), 2.85 - 2.72 (m, 2H), 2.70 - 2.59 (m, 2H), 2.59 - 2.54 (m, 6H), 2.39 - 2.18 (m, 5H), 2.16 - 1.82 (m, 4H), 1.68-1.64 (m, 4H), 1.45 (s, 1H), 0.80 (d, J = 6.4 Hz, 3H). [M+H] + = 820.8.
[0378] Example 24: 2-(2,6-dioxopiperidin-3-yl)-5-(4-((9-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-3,9-diazaspiro[5.5]undecan-3-yl)methyl)piperidin-1-yl)isoindoline-1,3-dione [ka]
[0379] The title compound was prepared in a similar manner to Example 14.
[0380] 1 H NMR (500 MHz, DMSO) δ 12.70 (s, 1H), 11.07 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.64 (d, J = 8.3 Hz, 1H), 7.56 (s, 1H), 7.47 (d, J = 11.8 Hz, 2H), 7.29 (s, 1H), 7.21 (d, J = 8.5 Hz, 1H), 7.16 (d, J = 7.5 Hz, 1H), 5.06 (dd, J = 12.7, 5.4 Hz, 1H), 4.36 (dd, J = 14.9, 6.3 Hz, 1H), 4.20 (d, J = 13.4 Hz, 1H), 4.07 - 3.97 (m, 3H), 3.97 - 3.86 (m, 1H), 3.73 (s, 3H), 3.56 (s, 2H), 2.99 - 2.83 (m, 3H), 2.82 - 2.72 (m, 1H), 2.66 - 2.53 (m, 6H), 2.39 - 2.27 (m, 7H), 2.25 - 2.08 (m, 3H), 2.06 - 1.87 (m, 3H), 1.84 - 1.71 (m, 3H), 1.51 - 1.35 (m, 9H), 1.18 - 1.05 (m, 2H), 0.81 (d, J = 6.3 Hz, 3H);[M+H] + =950.8.
[0381] Example 25: (R)-3-(2,6-difluoro-4-(3-(7-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-2,7-diazaspiro[3.5]nonane-2-carbonyl)azetidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0382] The title compound was prepared in a similar manner to Example 5.
[0383] 1 H NMR (500 MHz, DMSO) δ 12.72 (s, 1H), 10.85 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.50 (s, 2H), 7.19 (s, 1H), 6.14 (d, J = 11.1 Hz, 2H), 4.36 (d, J = 4.2 Hz, 1H), 4.21 (d, J = 12.4 Hz, 1H), 4.09 - 3.88 (m, 5H), 3.83 (t, J = 6.2 Hz, 2H), 3.77 (s, 2H), 3.73 (s, 3H), 3.64 - 3.48 (m, 4H), 3.30 - 3.18 (m, 3H), 2.80 - 2.74 (m, 2H), 2.56 (s, 3H), 2.30 - 2.18 (m, 3H), 2.14 - 1.86 (m, 5H), 1.72 (s, 4H), 1.52 - 1.43 (m, 1H), 0.82 (d, J = 6.3 Hz, 3H). [M+H] + = 875.6.
[0384] Example 26: (R)-3-(4-((R)-3,3-dimethyl-4-(7-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-2,7-diazaspiro[3.5]nonane-2-carbonyl)pyrrolidin-1-yl)-2,6-difluorophenyl)piperidine-2,6-dione [ka]
[0385] The title compound was prepared in a similar manner to Example 5.
[0386] 1H NMR (500 MHz, DMSO) δ 12.70 (s, 1H), 10.83 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.54 - 7.39 (m, 2H), 7.17 (d, J = 8.0 Hz, 1H), 6.14 (d, J = 12.5 Hz, 2H), 4.36 (s, 1H), 4.20 (d, J = 11.9 Hz, 1H), 4.00 (d, J = 7.1 Hz, 2H), 3.96 - 3.88 (m, 2H), 3.83 (d, J = 8.2 Hz, 1H), 3.73 (s, 3H), 3.54 (d, J = 15.6 Hz, 4H), 3.46 - 3.41 (m, 1H), 3.18 - 3.01 (m, 3H), 2.83 - 2.75 (m, 3H), 2.56 (s, 3H), 2.40 - 2.18 (m, 5H), 2.14 - 1.90 (m, 4H), 1.71 (s, 4H), 1.46 (s, 1H), 1.23 (s, 1H), 1.14 (s, 3H), 1.00 (s, 3H), 0.81 (d, J = 6.1 Hz, 3H). [M+H] + = 917.8.
[0387] Example 27: 3-(3-methyl-2-oxo-4-(2-(9-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-3,9-diazaspiro[5.5]undecan-3-yl)ethyl)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione
[0388] Step 1: 7-Bromo-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one [ka]
[0389] 6-Bromo-N 1 To a solution of 4 g (19.9 mmol) of 1,2-dimethylbenzene-1,2-diamine in 50 mL of CH3CN was added CDI (6.4 g, 39.8 mmol). The resulting solution was stirred at 90 °C under a nitrogen atmosphere for 6 hours. The solid was collected by filtration. This afforded 7-bromo-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (4.1 g, 90.7%). [M+H] + = 227.0.
[0390] Step 2: 3-(4-bromo-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)-1-(4-methoxybenzyl)piperidine-2,6-dione [ka]
[0391] To a solution of 7-bromo-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (600 mg, 2.6 mmol) in THF (10 mL) was added t-BuOK (1 M in THF, 3.2 mL, 3.1 mmol) dropwise over 10 min at 0 °C. The reaction solution was stirred at this temperature for 30 min. Then, 1-(4-methoxybenzyl)-2,6-dioxopiperidin-3-yl trifluoromethanesulfonate (1.1 g, 2.9 mmol) in THF (5 mL) was added dropwise over 10 min. The resulting solution was stirred at 0-10 °C for 2 h. The reaction was then quenched by the addition of saturated aqueous NH4Cl and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column and eluted with PE / EtOAc to give the product (910 mg, 75.2%). [M+H] + = 458.1.
[0392] Step 3: 3-(4-bromo-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione [ka]
[0393] 3-(4-Bromo-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)-1-(4-methoxybenzyl)piperidine-2,6-dione (800 mg, 1.75 mmol) was dissolved in MeSO2H / toluene (2 mL / 6 mL). The resulting mixture was stirred at 100°C for 3 hours. The solvent was removed and the residue was poured into ice / water. The solid was collected by filtration. 3-(4-Bromo-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione was obtained (510 mg, 86.4%). [M+H] + = 338.1.
[0394] Step 4: (E)-3-(4-(2-ethoxyvinyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione [ka]
[0395] To a stirred solution of 3-(4-bromo-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (250 mg, 0.74 mmol) and (E)-2-(2-ethoxyvinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (176 mg, 0.89 mmol) in DMF / HO (8 mL / 2 mL) was added Pd(dtbpf)Cl (48 mg, 0.074 mmol) and CsF (225 mg, 1.48 mmol). The resulting mixture was stirred at 80 °C under a nitrogen atmosphere for 2 h. The reaction solution was diluted with water and extracted with EtOAc (10 mL x 3). The organic layer was washed with water and brine, dried over anhydrous NaSO, and evaporated to dryness. The residue was purified by silica gel column elution with PE / EtOAc=1:1 to give the product (180 mg, 73.8%). m / z [M+H] + = 330.2.
[0396] Step 5: 2-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)acetaldehyde [ka]
[0397] (E)-3-(4-(2-ethoxyvinyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (180 mg, 0.55 mmol) was dissolved in HCOOH (2 mL). The resulting solution was stirred at room temperature for 2 hours. The reaction solution was evaporated to dryness to give the product (125 mg, 75.3%), which was used directly in the next step. m / z [M+H] + = 302.1.
[0398] Step 6: 3-(3-methyl-2-oxo-4-(2-(9-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-3,9-diazaspiro[5.5]undecan-3-yl)ethyl)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione [ka]
[0399] In a 40 mL microwave vial equipped with a magnetic stir bar, add (R,E)-5 6 -((3,9-diazaspiro[5.5]undecan-3-yl)methyl)-1 1 ,2 6 ,7-trimethyl-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (59.7 mg, 0.1 mmol), 2-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)acetaldehyde (60.2 mg, 0.2 mmol), NaOAc (32.8 mg, 0.4 mmol), DMSO (2 mL), and DCE (8 mL) were added. To the reaction mixture was added NaBH(OAc) (63.6 mg, 0.3 mmol). After stirring at 70 °C for 4 h, the reaction mixture was diluted with saturated aqueous NaHCO (20 mL), and the layers were separated. The aqueous layer was extracted with DCM (3 × 15 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. Purification by preparative TLC followed by preparative HPLC chromatography (gradient elution: 0.1% FA / water:acetonitrile = 90:10 to 50:50) afforded the title compound (25 mg, 28%). 1H NMR (500 MHz, DMSO) δ 12.64 (s, 1H), 11.02 (s, 1H), 8.36 (s, 1H), 7.86 (s, 1H), 7.50 (s, 1H), 7.44 (s, 1H), 7.42 (d, J = 8.5 Hz, 1H), 7.11 (d, J = 8.0 Hz, 1H), 6.94 - 6.89 (m, 2H), 6.82 (d, J = 8.5 Hz, 1H), 5.29 (dd, J = 12.5, 5.0 Hz, 1H), 4.34 - 4.26 (m, 1H), 4.14 (d, J = 12.5 Hz, 1H), 3.97 - 3.90 (m, 1H), 3.88 - 3.78 (m, 2H), 3.67 (s, 3H), 3.61 - 3.55 (m, 4H), 3.51 (s, 3H), 3.20 - 3.00 (m, 7H), 2.88 - 2.75 (m, 2H), 2.74 - 2.61 (m, 5H), 2.60 - 2.52 (m, 6H), 2.49 (s, 3H), 2.35 - 2.30 (m, 2H), 2.02 - 1.83 (m, 4H), 0.74 (d, J = 6.0 Hz, 3H);[M+H] + = 882.8.
[0400] Example 28: 3-(3-methyl-2-oxo-4-(2-(4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazin-1-yl)ethyl)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione [ka]
[0401] In a 40 mL microwave vial equipped with a magnetic stir bar, add (R,E)-1 1 ,2 6 ,7-trimethyl-5 6 -(piperazin-1-ylmethyl)-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (52.9 mg, 0.1 mmol), 2-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)acetaldehyde (60.2 mg, 0.2 mmol), NaOAc (32.8 mg, 0.4 mmol), DMSO (2 mL), and DCE (8 mL) were added. To the reaction mixture was added NaBH(OAc) (63.6 mg, 0.3 mmol). After stirring at 70 °C for 4 h, the reaction mixture was diluted with saturated aqueous NaHCO (20 mL), and the layers were separated. The aqueous layer was extracted with DCM (3 × 15 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. Purification by preparative TLC followed by preparative HPLC chromatography (gradient elution: 0.1% FA / water:acetonitrile = 90:10 to 50:50) afforded the title compound (34 mg, 42%). 1H NMR (500 MHz, DMSO) δ 12.84 (s, 1H), 11.10 (s, 1H), 8.50 (s, 1H), 8.01 (s, 1H), 7.66 (s, 1H), 7.63 (s, 1H), 7.57 (d, J = 8.0 Hz, 1H), 7.28 (d, J = 8.5 Hz, 1H), 7.04 - 7.02 (m, 2H), 6.93 (d, J = 7.0 Hz, 1H), 5.38 (dd, J = 12.5, 5.0 Hz, 1H), 4.41 - 4.36 (m, 1H), 4.24 (d, J = 11.5 Hz, 1H), 4.07 - 4.03 (m, 2H), 3.93 - 3.88 (m, 2H), 3.75 (s, 3H), 3.59 (s, 3H), 3.45 - 3.35 (m, 9H), 2.93 - 2.85 (m, 2H), 2.84 - 2.77 (m, 1H), 2.76 - 2.67 (m, 2H), 2.66 - 2.63 (m, 2H), 2.61 (s, 3H), 2.28 - 2.19 (m, 1H), 2.05 - 1.87 (m, 3H), 1.51 - 1.44 (m, 1H), 0.84 (d, J = 6.5 Hz, 3H);[M+H] + = 814.8.
[0402] Example 29: (R)-3-(2,6-difluoro-4-(2-(9-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-3,9-diazaspiro[5.5]undecan-3-yl)ethyl)phenyl)piperidine-2,6-dione [ka]
[0403] In a 40 mL microwave vial equipped with a magnetic stir bar, add (R,E)-5 6 -((3,9-diazaspiro[5.5]undecan-3-yl)methyl)-1 1 ,2 6 ,7-trimethyl-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (59.7 mg, 0.10 mmol), (R)-2-(4-(2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)acetaldehyde (58.7 mg, 0.22 mmol), DMSO (2 mL), and DCE (8 mL) were added. To the reaction mixture was added NaBH(OAc) (63.6 mg, 0.3 mmol) and 6 drops of AcOH. After stirring at 70 °C for 4 h, the reaction mixture was diluted with saturated aqueous NaHCO (20 mL), and the layers were separated. The aqueous layer was extracted with DCM (3 × 15 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. Purification by preparative TLC followed by preparative HPLC chromatography (gradient elution: 0.1% FA / water:acetonitrile = 90:10 to 50:50) afforded the title compound (28 mg, 33%). 1H NMR (500 MHz, DMSO) δ 12.70 (s, 1H), 10.94 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.56 (s, 1H), 7.49 (s, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.16 (d, J = 8.0 Hz, 1H), 7.00 (d, J = 10.0 Hz, 2H), 4.40 - 4.31 (m, 1H), 4.23 - 4.15 (m, 2H), 4.03 - 3.95 (m, 1H), 3.94 - 3.89 (m, 1H), 3.73 (s, 3H), 3.60 - 3.55 (m, 3H), 2.85 - 2.71 (m, 4H), 2.56 (s, 3H), 2.56 - 2.53 (m, 3H), 2.45- 2.32 (m, 8H), 2.25 - 2.17 (m, 1H), 2.16 - 2.06 (m, 1H), 2.00 - 1.87 (m, 3H), 1.49 - 1.36 (m, 8H), 0.81 (d, J = 6.5 Hz, 3H);[M+H] + = 848.7.
[0404] Example 30: 3-(3-methyl-2-oxo-4-(2-(7-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)ethyl)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione [ka]
[0405] The title compound was prepared in a similar manner to Example 27.
[0406] 1 H NMR (500 MHz, DMSO) δ 12.70 (s, 1H), 11.08 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.53 - 7.36 (m, 2H), 7.15 (d, J = 8.1 Hz, 1H), 6.98 - 6.90 (m, 2H), 6.87 (d, J = 6.7 Hz, 1H), 5.35 (dd, J = 12.6, 5.3 Hz, 1H), 4.36 (d, J = 4.5 Hz, 1H), 4.20 (d, J = 11.6 Hz, 1H), 4.00 - 3.90 (m, 3H), 3.73 (s, 3H), 3.56 (s, 3H), 3.52 (s, 2H), 2.96 (s, 3H), 2.90 - 2.85 (m, 3H), 2.79 (s, 1H), 2.69 (d, J = 8.0 Hz, 3H), 2.62 (d, J = 18.0 Hz, 2H), 2.56 (s, 3H), 2.28 (s, 4H), 2.06 - 1.84 (m, 3H), 1.66 (s, 4H), 1.46 (s, 1H), 0.81 (d, J = 6.4 Hz, 3H). [M+H] + = 854.6.
[0407] Example 76: (R)-3-(2,6-difluoro-4-(3-(4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazine-1-carbonyl)azetidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0408] In a 40 mL microwave vial equipped with a magnetic stir bar, add (R,E)-1 1 ,2 6 ,7-trimethyl-5 6 -(piperazin-1-ylmethyl)-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (52.9 mg, 0.10 mmol), (R)-1-(4-(2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)azetidine-3-carboxylic acid (32.4 mg, 0.10 mmol), and DCM (8 mL) were added. To the reaction mixture were added N,N-diethylpropylethylamine (174 mL, 1.0 mmol) and T3P (50 wt%, 127 mg, 0.0.2 mmol). After stirring at room temperature for 1.5 h, the reaction mixture was diluted with brine (30 mL), and the layers were separated. The aqueous layer was extracted with DCM (3 × 15 mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. Purification by flash column chromatography (0-10% MeOH / DCM) followed by preparative HPLC chromatography (gradient elution: 0.1% FA / water:acetonitrile = 90:10 to 50:50) afforded the title compound (52 mg, 62%). 1H NMR (500 MHz, DMSO) δ 12.65 (s, 1H), 10.79 (s, 1H), 8.36 (s, 1H), 7.86 (s, 1H), 7.50 (s, 1H), 7.45 (s, 1H), 7.43 (d, J = 8.0 Hz, 1H), 7.12 (d, J = 8.0 Hz, 1H), 6.08 (d, J = 11.0 Hz, 2H), 4.32 - 4.27 (m, 1H), 4.13 (d, J = 11.5 Hz, 1H), 3.98 - 3.93 (m, 4H), 3.89 - 3.78 (m, 3H), 3.78 - 3.72 (m, 1H), 3.66 (s, 3H), 3.54 (s, 2H), 3.43 (s, 2H), 2.74 - 2.67 (m, 2H), 2.49 (s, 3H), 2.44 - 2.41 (m, 3H), 2.36 - 2.25 (m, 4H), 2.20 - 2.10 (m, 1H), 2.06 - 1.80 (m, 4H), 1.45 - 1.35 (m, 1H), 0.75 (d, J = 6.0 Hz, 3H);[M+H] + = 835.5.
[0409] Example 77: (R)-3-(4-((R)-3,3-dimethyl-4-(4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazine-1-carbonyl)pyrrolidin-1-yl)-2,6-difluorophenyl)piperidine-2,6-dione
[0410] Step 1: Methyl (R)-4,4-dimethylpyrrolidine-3-carboxylate [ka]
[0411] To a stirred solution of (R)-4,4-dimethylpyrrolidine-3-carboxylic acid (2 g, 13.96 mmol) in MeOH (30 mL) was added SOCl (1.66 g, 13.96 mmol) dropwise at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred at 60 °C for 2 h. The resulting mixture was concentrated under reduced pressure to give the product (2.1 g, 95.8%), which was used in the next step without further purification. [M+H] + = 158.1
[0412] Step 2: Methyl (R)-1-(4-(2,6-bis(benzyloxy)pyridin-3-yl)-3,5-difluorophenyl)-4,4-dimethylpyrrolidine-3-carboxylate [ka]
[0413] To a stirred solution of 2,6-bis(benzyloxy)-3-(4-bromo-2,6-difluorophenyl)pyridine (9.25 g, 20.25 mmol) and methyl (R)-4,4-dimethylpyrrolidine-3-carboxylate (2.1 g, 13.35 mmol) in dioxane (50 mL) under a nitrogen atmosphere at room temperature was added CsCO (10.95 g, 33.37 mmol), Xantphos (1.54 g, 2.67 mmol), and Pd(dba) (1.22 g, 1.35 mmol). The resulting mixture was stirred at 100 °C under a nitrogen atmosphere for 16 h. The mixture was cooled to room temperature. The resulting mixture was concentrated under reduced pressure. The residue was diluted with EtOAc (500 mL) and washed with water (3 × 200 mL) and brine (200 mL). The organic layer was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with PE / EtOAc (5:1) to give the product (4.5 g, 60.8%). [M+H] + = 559.6
[0414] Step 3: (R)-1-(4-(2,6-bis(benzyloxy)pyridin-3-yl)-3,5-difluorophenyl)-4,4-dimethylpyrrolidine-3-carboxylic acid [ka]
[0415] To a solution of methyl (R)-1-(4-(2,6-bis(benzyloxy)pyridin-3-yl)-3,5-difluorophenyl)-4,4-dimethylpyrrolidine-3-carboxylate (4.5 g, 8.05 mmol) in THF (40 mL) and HO (10 mL) was added lithium hydroxide hydrate (337.9 mg, 8.05 mmol) at 25 °C. The resulting mixture was stirred at 25 °C for 5 h. The reaction was quenched with HCl (1 N) at 0 °C until pH = 6, and the resulting mixture was extracted with EA (2 × 40 mL). The combined organic layers were washed with brine, dried over anhydrous NaSO, filtered, and concentrated in vacuo to give the crude product (4.05 g, 92.46%), which was used in the next step without further purification. [M+H] + =545.6
[0416] Step 4: (R)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)-4,4-dimethylpyrrolidine-3-carboxylic acid [ka]
[0417] (R)-1-(4-(2,6-bis(benzyloxy)pyridin-3-yl)-3,5-difluorophenyl)-4,4-dimethylpyrrolidine-3-carboxylic acid (4.5 g, 8.25 mmol) was dissolved in DCM (30 mL) and iPr—OH (30 mL). Pd / C (1 g, 10 wt%, wet) was added to the solution in one portion. The resulting mixture was stirred overnight at room temperature under a hydrogen atmosphere (1 atm). The solid was filtered off, and the filtrate was concentrated to give the crude product. Trituration of the crude product with MTBE gave the desired product, which was purified by HPLC (IF (2*25 cm, 5 μm), 60% MtBE / 40% MeOH:DCM=1:1, 80 bar, 20 ml / min), corresponding to Peak A at 1.216 min / 254 nm (1.13 g, 25%). [M+H] + = 367.4.
[0418] Step 5: (R)-3-(4-((R)-3,3-dimethyl-4-(4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazine-1-carbonyl)pyrrolidin-1-yl)-2,6-difluorophenyl)piperidine-2,6-dione [ka]
[0419] To a 40 mL microwave vial equipped with a magnetic stir bar was added (R,E)-11,26,7-trimethyl-56-(piperazin-1-ylmethyl)-52,53-dihydro-11H,51H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (52.9 mg, 0.10 mmol), (R)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)-4,4-dimethylpyrrolidine-3-carboxylic acid (36.6 mg, 0.10 mmol) and DCM (8 mL). To the reaction mixture were added N,N-diethylpropylethylamine (174 mL, 1.0 mmol) and T3P (50% wt, 127 mg, 0.0.2 mmol). After stirring at room temperature for 1.5 h, the reaction mixture was diluted with brine (30 mL) and the layers were separated. The aqueous layer was extracted with DCM (3 × 15 mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. Purification by flash column chromatography (0–10% MeOH / DCM) followed by preparative HPLC chromatography (gradient elution, 0.1% FA / water:acetonitrile = 90:10–50:50) afforded the title compound (62 mg, 71%). 1H NMR (500 MHz, DMSO) δ 12.65 (s, 1H), 10.77 (s, 1H), 8.36 (s, 1H), 7.86 (s, 1H), 7.50 (s, 1H), 7.47 (s, 1H), 7.43 (d, J = 8.0 Hz, 1H), 7.13 (d, J = 8.0 Hz, 1H), 6.07 (d, J = 12.5 Hz, 2H), 4.32 - 4.27 (m, 1H), 4.14 (d, J = 11.5 Hz, 1H), 3.95 - 3.85 (m, 3H), 3.66 (s, 3H), 3.58 - 3.42 (m, 6H), 3.38 - 3.29 (m, 4H), 3.00 (dd, J = 19.0, 9.0 Hz, 2H), 2.74 - 2.67 (m, 2H), 2.49 (s, 3H), 2.37 - 2.25 (m, 4H), 2.19 - 2.10 (m, 1H), 2.06 - 1.84 (m, 4H), 1.43 - 1.37 (m, 1H), 1.09 (s, 3H), 0.90 (s, 3H), 0.75 (d, J = 6.5 Hz, 3H);[M+H] + = 877.6.
[0420] Example 78: (R)-3-(2,6-difluoro-4-((R)-3-(6-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-2,6-diazaspiro[3.3]heptane-2-carbonyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione
[0421] Step 1: tert-Butyl (R,E)-6-((1 1 ,2 6 ,7-trimethyl-3-oxo-52 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-2,6-diazaspiro[3.3]heptane-2-carboxylate [ka]
[0422] Place (R,E)-1 in a 40 mL microwave oven equipped with a magnetic stir bar. 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 A mixture of 2,6-dicarbaldehyde (458 mg, 1.0 mmol), tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate (1.0 g, 5.0 mmol), NaBH(OAc) (848 mg, 4.0 mmol), and DCM (20 mL) was added at room temperature. To the stirred reaction mixture was added AcOH (340 mL, 6.0 mmol). After stirring at room temperature for 12 h, the reaction mixture was diluted with saturated aqueous NaHCO (30 mL) and the layers were separated. The aqueous layer was extracted with DCM (3 x 30 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. Purification by flash column chromatography (0-10% MeOH / DCM) afforded the product (351 mg, 55%). [M+H] + = 641.6.
[0423] Step 2: (R,E)-5 6 -((2,6-diazaspiro[3.3]heptan-2-yl)methyl)-1 1 ,2 6,7-trimethyl-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one [ka]
[0424] In a 100 mL round-bottom flask equipped with a magnetic stir bar, add tert-butyl (R,E)-6-((1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 To the reaction mixture was added (351 mg, 0.55 mmol) of (-yl)methyl-2,6-diazaspiro[3.3]heptane-2-carboxylate, DCM (20 mL), and TFA (5 mL). After stirring at room temperature for 1 hour, the reaction mixture was concentrated under reduced pressure to give the product as the TFA salt (468 mg), which was used without further purification. [M+H] + = 541.6.
[0425] Step 3: (R)-3-(2,6-difluoro-4-((R)-3-(6-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-2,6-diazaspiro[3.3]heptane-2-carbonyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0426] To a 40 mL microwave vial equipped with a magnetic stir bar was added (R,E)-56-((2,6-diazaspiro[3.3]heptan-2-yl)methyl)-11,26,7-trimethyl-52,53-dihydro-11H,51H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (54.0 mg, 0.10 mmol), (R)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)pyrrolidine-3-carboxylic acid (33.8 mg, 0.10 mmol) and DCM (8 mL). To the reaction mixture were added N,N-diethylpropylethylamine (174 mL, 1.0 mmol) and T3P (50 wt%, 127 mg, 0.0.2 mmol). After stirring at room temperature for 1.5 h, the reaction mixture was diluted with brine (30 mL) and the layers were separated. The aqueous layer was extracted with DCM (3 × 15 mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. Purification by flash column chromatography (0–10% MeOH / DCM) followed by preparative HPLC chromatography (gradient elution, 0.1% FA / water:acetonitrile = 90:10 to 50:50) afforded the title compound (75 mg, 87%). 1H NMR (500 MHz, DMSO) δ 12.63 (s, 1H), 10.77 (s, 1H), 8.36 (s, 1H), 7.86 (s, 1H), 7.50 (s, 1H), 7.41 (s, 1H), 7.40 (d, J = 8.0 Hz, 1H), 7.06 (d, J = 8.5 Hz, 1H), 6.14 (d, J = 12.5 Hz, 2H), 4.32 - 4.21 (m, 3H), 4.13 (d, J = 12.0 Hz, 1H), 3.96 - 3.93 (m, 2H), 3.90 - 3.85 (m, 3H), 3.66 (s, 3H), 3.58 -3.53 (m, 2H), 3.37 - 3.30 (m, 5H), 3.16 - 3.12 (m, 3H), 3.07 - 3.01 (m, 1H), 2.78 - 2.66 (m, 2H), 2.49 (s, 3H), 2.21 - 2.10 (m, 1H), 2.08 - 1.82 (m, 7H), 1.43 - 1.35 (m, 1H), 0.75 (d, J = 6.5 Hz, 3H);[M+H] + = 861.5.
[0427] Example 79: (R)-3-(2,6-difluoro-4-(3-(6-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-2,6-diazaspiro[3.3]heptane-2-carbonyl)azetidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0428] In a 40 mL microwave vial equipped with a magnetic stir bar, add (R,E)-5 6 -((2,6-diazaspiro[3.3]heptan-2-yl)methyl)-1 1 ,2 6 ,7-trimethyl-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (54.0 mg, 0.10 mmol), (R)-1-(4-(2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)azetidine-3-carboxylic acid (32.4 mg, 0.10 mmol), and DCM (8 mL) were added. To the reaction mixture were added N,N-diethylpropylethylamine (174 mL, 1.0 mmol) and T3P (50 wt%, 127 mg, 0.0.2 mmol). After stirring at room temperature for 1.5 h, the reaction mixture was diluted with brine (30 mL), and the layers were separated. The aqueous layer was extracted with DCM (3 × 15 mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. Purification by flash column chromatography (0-10% MeOH / DCM) and preparative HPLC chromatography (gradient elution: 0.1% FA / water:acetonitrile = 90:10 to 50:50) afforded the title compound (53 mg, 63%). 1H NMR (500 MHz, DMSO) δ 12.70 (s, 1H), 10.85 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.47 (s, 1H), 7.46 (d, J = 8.0 Hz, 1H), 7.12 (d, J = 8.5 Hz, 1H), 6.13 (d, J = 11.5 Hz, 2H), 4.38 - 4.34 (m, 1H), 4.20 4.17 (m, 3H), 4.04 - 3.92 (m, 8H), 3.80 (t,J = 7.0 Hz, 2H), 3.73 (s, 3H), 3.64 - 3.59 (m, 2H), 3.55 - 3.49 (m, 2H), 3.33 - 3.28 (m, 2H), 2.83 - 2.73 (m, 2H), 2.56 (s, 3H), 2.27 - 2.16 (m, 1H), 2.10 - 1.86 (m, 5H), 1.50 - 1.43 (m, 1H), 0.82 (d, J = 6.5 Hz, 3H);[M+H] + = 847.5.
[0429] Example 80: (R)-3-(4-((R)-3,3-dimethyl-4-(6-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-2,6-diazaspiro[3.3]heptane-2-carbonyl)pyrrolidin-1-yl)-2,6-difluorophenyl)piperidine-2,6-dione [ka]
[0430] In a 40 mL microwave vial equipped with a magnetic stir bar, add (R,E)-56 -((2,6-diazaspiro[3.3]heptan-2-yl)methyl)-1 1 ,2 6 ,7-trimethyl-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (54.0 mg, 0.10 mmol), (R)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)-4,4-dimethylpyrrolidine-3-carboxylic acid (36.6 mg, 0.10 mmol), and DCM (8 mL) were added. To the reaction mixture were added N,N-diethylpropylethylamine (174 mL, 1.0 mmol) and T3P (50 wt%, 127 mg, 0.0.2 mmol). After stirring at room temperature for 1.5 h, the reaction mixture was diluted with brine (30 mL), and the layers were separated. The aqueous layer was extracted with DCM (3 × 15 mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. Purification by flash column chromatography (0-10% MeOH / DCM) followed by preparative HPLC chromatography (gradient elution: 0.1% FA / water:acetonitrile = 90:10 to 50:50) afforded the title compound (51 mg, 57%). 1H NMR (500 MHz, DMSO) δ 12.63 (s, 1H), 10.76 (s, 1H), 8.36 (s, 1H), 7.86 (s, 1H), 7.50 (s, 1H), 7.40 - 7.39 (m, 2H), 7.06 (d, J = 8.0 Hz, 1H), 6.07 (d, J = 12.5 Hz, 2H), 4.31 - 4.25 (m, 2H), 4.17 - 4.11 (m, 2H), 3.95 - 3.85 (m, 5H), 3.67 (s, 3H), 3.55 (s, 2H), 3.35 - 3.21 (m, 6H), 3.04 - 2.96 (m, 2H), 2.77 - 2.67 (m, 3H), 2.49 (s, 3H), 2.21 - 2.12 (m, 1H), 2.06 - 1.85 (m, 5H), 1.45 - 1.35 (m, 1H), 1.07 (s, 3H), 0.91 (s, 3H), 0.75 (d, J = 6.5 Hz, 3H);[M+H] + = 889.6.
[0431] Example 81: (R)-3-(2,6-difluoro-4-(2-(6-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-2,6-diazaspiro[3.3]heptan-2-yl)ethyl)phenyl)piperidine-2,6-dione [ka]
[0432] In a 40 mL microwave vial equipped with a magnetic stir bar, add (R,E)-5 6 -((2,6-diazaspiro[3.3]heptan-2-yl)methyl)-11 ,2 6 ,7-trimethyl-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (54.0 mg, 0.10 mmol), (R)-2-(4-(2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)acetaldehyde (58.7 mg, 0.22 mmol), DMSO (2 mL), and DCE (8 mL) were added. To the reaction mixture was added NaBH(OAc) (63.6 mg, 0.3 mmol) and 6 drops of AcOH. After stirring at 70 °C for 4 h, the reaction mixture was diluted with saturated aqueous NaHCO (20 mL), and the layers were separated. The aqueous layer was extracted with DCM (3 × 15 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. Purification by preparative TLC followed by preparative HPLC chromatography (gradient elution: 0.1% FA / water:acetonitrile = 90:10 to 50:50) afforded the title compound (30 mg, 38%). 1H NMR (500 MHz, DMSO) δ 12.69 (s, 1H), 10.94 (s, 1H), 8.42 (s, 1H), 7.92 (s, 1H), 7.56 (s, 1H), 7.46 (s, 1H), 7.45 (d, J = 8.0 Hz, 1H), 7.11 (d, J = 8.5 Hz, 1H), 6.97 (d, J = 10.0 Hz, 2H), 4.42 - 4.32 (m, 1H), 4.22 - 4.13 (m, 2H), 4.02 - 3.90 (m, 3H), 3.73 (s, 3H), 3.61 (s, 2H), 3.25 - 3.18 (m, 8H), 2.85 - 2.75 (m, 3H), 2.56 (s, 3H), 2.56 - 2.53 (m, 3H), 2.26 - 2.16 (m, 1H), 2.07 - 2.03 (m, 1H), 2.02 - 1.89 (m, 3H), 1.51 - 1.42 (m, 1H), 0.81 (d, J = 6.5 Hz, 3H);[M+H] + = 792.6.
[0433] Example 82: (R)-3-(2,6-difluoro-4-((R)-3-((1S,4S)-5-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-2,5-diazabicyclo[2.2.1]heptane-2-carbonyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0434] The title compound was prepared in a similar manner to Example 5. 1H NMR (500 MHz, DMSO) δ H 12.70 (s, 1H), 10.84 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.56 (d, J = 7.2 Hz, 2H), 7.48 (d, J = 8.1 Hz, 1H), 7.23 (d, J = 8.2 Hz, 1H), 6.22 (dd, J = 12.2, 6.4 Hz, 2H), 4.59 (d, J = 28.4 Hz, 1H), 4.36 (s, 1H), 4.25 - 4.15 (m, 1H), 4.05 - 3.91 (m, 3H), 3.82 (d, J = 7.9 Hz, 2H), 3.73 (s, 3H), 3.58 - 3.41 (m, 4H), 3.28 (d, J = 6.1 Hz, 4H), 2.90 - 2.74 (m, 3H), 2.56 (s, 4H), 2.48 (s, 1H), 2.30 - 2.16 (m, 2H), 2.14 - 1.82 (m, 6H), 1.69 (dd, J = 35.7, 8.9 Hz, 1H), 1.47 (s, 1H), 0.82 (d, J = 6.4 Hz, 3H). [M+H] + = 861.7.
[0435] Example 83: (3R)-3-(2,6-difluoro-4-((3R)-3-(3-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0436] The title compound was prepared in a similar manner to Example 5. 1 H NMR (500 MHz, DMSO) δ H 12.71 (s, 1H), 10.84 (d, J = 5.0 Hz, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.53 - 7.47 (m, 2H), 7.19 (t, J = 7.6 Hz, 1H), 6.22 (dd, J = 12.1, 6.9 Hz, 2H), 4.38 (s, 3H), 4.22 (d, J = 12.7 Hz, 1H), 4.05 - 3.97 (m, 2H), 3.92 (s, 1H), 3.73 (s, 3H), 3.64 (d, J = 11.4 Hz, 1H), 3.56 (d, J = 11.0 Hz, 1H), 3.46 - 3.40 (m, 2H), 3.25 (d, J = 11.8 Hz, 2H), 2.80 - 2.60 (m, 4H), 2.55 (d, J = 8.0 Hz, 3H), 2.49 - 2.45 (m, 1H), 2.25 - 1.85 (m, 13H), 1.69 (d, J = 5.2 Hz, 1H), 1.46 (s, 1H), 0.83 (d, J = 6.4 Hz, 3H). [M+H] + = 875.7.
[0437] Example 84: (R)-3-(2,6-difluoro-4-((R)-3-(2-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-2,7-diazaspiro[3.5]nonane-7-carbonyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0438] The title compound was prepared in a similar manner to Example 5. 1 H NMR (500 MHz, DMSO) δ H 12.70 (s, 1H), 10.84 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.51 - 7.45 (m, 2H), 7.16 (d, J = 8.2 Hz, 1H), 6.20 (d, J = 12.2 Hz, 2H), 4.36 (d, J = 4.6 Hz, 1H), 4.20 (d, J = 11.5 Hz, 1H), 4.05 - 3.89 (m, 3H), 3.72 (d, J = 13.8 Hz, 5H), 3.52 - 3.40 (m, 7H), 3.26 - 3.22 (m, 2H), 3.02 (s, 4H), 2.84 - 2.72 (m, 2H), 2.56 (s, 3H), 2.48 (s, 1H), 2.21 (s, 1H), 2.16 - 1.88 (m, 6H), 1.72 (d, J = 5.1 Hz, 2H), 1.62 (s, 2H), 1.47 (d, J = 6.2 Hz, 1H), 0.82 (d, J = 6.4 Hz, 3H). [M+H] + = 889.7.
[0439] Example 85: 2-(2,6-dioxopiperidin-3-yl)-5-((S)-3-((4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazin-1-yl)methyl)pyrrolidin-1-yl)isoindoline-1,3-dione [ka]
[0440] The title compound was prepared in a similar manner to Example 14.
[0441] 1 H NMR (500 MHz, DMSO) δ 12.70 (s, 1H), 11.06 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.63 (d,J = 8.4 Hz, 1H), 7.57 (s, 1H), 7.52 - 7.45 (m, 2H), 7.17 (d, J = 8.3 Hz, 1H), 6.88 (s, 1H), 6.80 (d, J = 8.2 Hz, 1H), 5.05 (dd, J = 12.9, 5.0 Hz, 1H), 4.36 (s, 1H), 4.22 - 4.18 (m, 1H), 4.00 (s, 1H), 3.96 - 3.89 (m, 1H), 3.73 (s, 3H), 3.62 - 3.45 (m, 4H), 3.41 - 3.36 (m, 1H), 3.16 - 3.08 (m, 1H), 2.94 - 2.75 (m, 2H), 2.65 - 2.53 (m, 7H), 2.48 - 2.31 (m, 9H), 2.26 - 2.17 (m, 1H), 2.15 - 2.06 (m, 1H), 2.05 - 1.87 (m, 3H), 1.78 - 1.68 (m, 1H), 1.52 - 1.40 (m, 1H), 0.81 (d, J = 6.3 Hz, 3H) ;[M+H] + =868.60.
[0442] Example 86: 2-(2,6-dioxopiperidin-3-yl)-5-((R)-3-((4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazin-1-yl)methyl)pyrrolidin-1-yl)isoindoline-1,3-dione [ka]
[0443] The title compound was prepared in a similar manner to Example 14.
[0444] 1 H NMR (500 MHz, DMSO) δ 12.70 (s, 1H), 11.06 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.63 (d, J = 8.4 Hz, 1H), 7.57 (s, 1H), 7.52 - 7.45 (m, 2H), 7.17 (d, J = 8.3 Hz, 1H), 6.88 (s, 1H), 6.80 (d, J = 8.2 Hz, 1H), 5.05 (dd, J = 12.9, 5.0 Hz, 1H), 4.36 (s, 1H), 4.22 - 4.18 (m, 1H), 4.00 (s, 1H), 3.96 - 3.89 (m, 1H), 3.73 (s, 3H), 3.62 - 3.45 (m, 4H), 3.41 - 3.36 (m, 1H), 3.16 - 3.08 (m, 1H), 2.94 - 2.75 (m, 2H), 2.65 - 2.53 (m, 7H), 2.48 - 2.31 (m, 9H), 2.26 - 2.17 (m, 1H), 2.15 - 2.06 (m, 1H), 2.05 - 1.87 (m, 3H), 1.78 - 1.68 (m, 1H), 1.52 - 1.40 (m, 1H), 0.81 (d, J = 6.3 Hz, 3H) ;[M+H] + =868.60.
[0445] Example 88: (R)-3-(2,6-difluoro-4-((R)-3-((4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazin-1-yl)methyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0446] The title compound was prepared in a similar manner to Example 14.
[0447] 1H NMR (500 MHz, DMSO) δ 12.70 (s, 1H), 10.83 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.56 (s, 1H), 7.52 - 7.45 (m, 2H), 7.17 (d, J = 8.1 Hz, 1H), 6.17 (d, J = 9.6 Hz, 2H), 4.40 - 4.32 (m, 1H), 4.20 (d, J = 11.8 Hz, 1H), 4.00 (dd, J = 11.1, 4.6 Hz, 2H), 3.96 - 3.90 (m, 1H), 3.73 (s, 3H), 3.57 (s, 2H), 3.30 - 3.23 (m, 1H), 3.22 - 3.13 (m, 1H), 2.97 - 2.89 (m, 1H), 2.84 - 2.71 (m, 2H), 2.61 - 2.52 (m, 5H), 2.48 - 2.34 (m, 9H), 2.30 (d, J = 7.4 Hz, 2H), 2.27 - 2.16 (m, 1H), 2.12 - 1.88 (m, 5H), 1.73 - 1.62 (m, 1H), 1.52 - 1.42 (m, 1H), 0.81 (d, J = 6.3 Hz, 3H) ;[M+H] + =835.60.
[0448] Example 90: (R)-3-(2,6-difluoro-4-((R)-3-((4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazin-1-yl)methyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0449] The title compound was prepared in a similar manner to Example 14.
[0450] 1 H NMR (500 MHz, DMSO) δ 12.70 (s, 1H), 10.83 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.56 (s, 1H), 7.52 - 7.45 (m, 2H), 7.17 (d, J = 8.1 Hz, 1H), 6.17 (d, J = 9.6 Hz, 2H), 4.40 - 4.32 (m, 1H), 4.20 (d, J = 11.8 Hz, 1H), 4.00 (dd, J = 11.1, 4.6 Hz, 2H), 3.96 - 3.90 (m, 1H), 3.73 (s, 3H), 3.57 (s, 2H), 3.30 - 3.23 (m, 1H), 3.22 - 3.13 (m, 1H), 2.97 - 2.89 (m, 1H), 2.84 - 2.71 (m, 2H), 2.61 - 2.52 (m, 5H), 2.48 - 2.34 (m, 9H), 2.30 (d, J = 7.4 Hz, 2H), 2.27 - 2.16 (m, 1H), 2.12 - 1.88 (m, 5H), 1.73 - 1.62 (m, 1H), 1.52 - 1.42 (m, 1H), 0.81 (d, J = 6.3 Hz, 3H) ;[M+H] + =835.60.
[0451] Example 91: (R)-3-(2,6-difluoro-4-(2-((1S,4S)-5-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6-yl)methyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)ethyl)phenyl)piperidine-2,6-dione [ka]
[0452] The title compound was prepared in a similar manner to Example 14. 1 H NMR (500 MHz, DMSO) δ H 12.68 (s, 1H), 10.95 (s, 1H), 8.42 (s, 1H), 7.92 (s, 1H), 7.55 (d, J = 10.9 Hz, 2H), 7.47 (d, J = 8.1 Hz, 1H), 7.21 (d, J = 8.1 Hz, 1H), 7.03 (d, J = 10.2 Hz, 2H), 4.36 (d, J = 4.4 Hz, 1H), 4.24 - 4.14 (m, 2H), 4.00 (s, 1H), 3.97 - 3.89 (m, 1H), 3.81 (d, J = 13.4 Hz, 1H), 3.72 (d, J = 10.1 Hz, 4H), 3.65 - 3.61 (m, 1H), 3.29 (s, 4H), 2.80 (t, J = 13.9 Hz, 4H), 2.70 - 2.65 (m, 4H), 2.56 (s, 3H), 2.22 - 2.08 (m, 2H), 2.03 - 1.88 (m, 3H), 1.64 (dd, J = 34.3, 8.8 Hz, 2H), 1.46 (s, 1H), 0.81 (d, J = 6.3 Hz, 3H). [M+H] + = 792.7.
[0453] Example 92: (3R)-3-(2,6-difluoro-4-(2-(3-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-3,8-diazabicyclo[3.2.1]octan-8-yl)ethyl)phenyl)piperidine-2,6-dione [ka]
[0454] The title compound was prepared in a similar manner to Example 14. 1 H NMR (500 MHz, DMSO) δ H 12.70 (s, 1H), 10.94 (s, 1H), 8.42 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.48 (d, J = 8.3 Hz, 2H), 7.16 (d, J = 8.1 Hz, 1H), 7.03 (d, J = 10.2 Hz, 2H), 4.36 (d, J = 4.5 Hz, 1H), 4.20 (d, J = 3.0 Hz, 2H), 4.00 (s, 1H), 3.93 - 3.86 (m, 1H), 3.73 (s, 3H), 3.59 (s, 1H), 3.51 (s, 1H), 3.27 - 3.22 (m, 2H), 2.85 - 2.69 (m, 4H), 2.60 - 2.53 (m, 7H), 2.30 (d, J = 9.7 Hz, 1H), 2.22 (s, 2H), 2.16 - 2.07 (m, 1H), 2.00 - 1.72 (m, 8H), 1.46 (s, 1H), 0.82 (d, J = 6.4 Hz, 3H). [M+H] + = 806.7.
[0455] Example 93: (R)-3-(2,6-difluoro-4-(2-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-2,7-diazaspiro[3.5]nonane-7-yl)ethyl)phenyl)piperidine-2,6-dione [ka]
[0456] The title compound was prepared in a similar manner to Example 14. 1 H NMR (500 MHz, DMSO) δ H 12.68 (s, 1H), 10.94 (s, 1H), 8.42 (s, 1H), 7.92 (s, 1H), 7.56 (s, 1H), 7.47 (d, J = 11.2 Hz, 2H), 7.14 (d, J = 8.0 Hz, 1H), 6.99 (d, J = 10.2 Hz, 2H), 4.36 (d, J = 4.2 Hz, 1H), 4.18 (dd, J = 11.6, 6.5 Hz, 2H), 4.02 - 3.90 (m, 2H), 3.73 (s, 3H), 3.67 (s, 2H), 2.95 (s, 4H), 2.83 - 2.70 (m, 4H), 2.58 - 2.53 (m, 4H), 2.48 - 2.44 (m, 2H), 2.38 - 2.20 (m, 5H), 2.11 (d, J = 10.3 Hz, 1H), 2.03 - 1.87 (m, 3H), 1.66 (s, 4H), 1.46 (s, 1H), 0.81 (d, J = 6.3 Hz, 3H). [M+H] + = 820.7.
[0457] Example 94: 3-(7-fluoro-3-methyl-2-oxo-4-(3-(4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazine-1-carbonyl)azetidin-1-yl)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione
[0458] Step 1: 2-((2,6-bis(benzyloxy)pyridin-3-yl)amino)-6-bromo-3-fluorobenzoic acid [ka]
[0459] To a solution of 2,6-bis(benzyloxy)pyridin-3-amine (15 g, 49.0 mmol) in THF (300 mL) was added LiHMDS (1 M in THF, 80 mL) dropwise over 30 min at 0 °C. The reaction solution was stirred at this temperature for 60 min. Then, a solution of 6-bromo-2,3-difluorobenzoic acid (10 g, 42.4 mmol) in THF (50 mL) was added dropwise over 20 min. The resulting solution was stirred at 10–20 °C for 12 h. The reaction was stopped by the addition of saturated aqueous sodium chloride. The reaction was quenched by the addition of saturated aqueous NH4Cl and concentrated. The residue was purified on a silica gel column eluted with DCM / MeOH to give the product (20 g, 90.4%). [M+H] + = 523.1.
[0460] Step 2: 1-(2,6-bis(benzyloxy)pyridin-3-yl)-4-bromo-7-fluoro-1,3-dihydro-2H-benzo[d]imidazol-2-one [ka]
[0461] To a solution of 2-((2,6-bis(benzyloxy)pyridin-3-yl)amino)-6-bromo-3-fluorobenzoic acid (20 g, 38.3 mmol) in DMA (400 mL) was added TEA (11.6 g, 114.8 mmol) and DPPA (15.8 g, 57.4 mmol). The mixture was stirred at 80° C. under a nitrogen atmosphere for 12 hours. The mixture was quenched with water at 30° C. and extracted with EtOAc. The combined organic phases were concentrated under reduced pressure. The residue was purified by silica gel column eluting with DCM / EtOAc to give the product (18 g, 90.9%). [M+H] + = 520.2.
[0462] Step 3: 1-(2,6-bis(benzyloxy)pyridin-3-yl)-4-bromo-7-fluoro-3-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one [ka]
[0463] To a solution of 1-(2,6-bis(benzyloxy)pyridin-3-yl)-4-bromo-7-fluoro-1,3-dihydro-2H-benzo[d]imidazol-2-one (10 g, 19.2 mmol) in DMF (100 mL) was added CsCO (18.7 g, 57.5 mmol) at 0 °C for 10 min. CHCl (8.2 g, 57.7 mmol) was then added. The resulting solution was stirred at 10–20 °C for 12 h. The mixture was quenched with water at 30 °C and extracted with EtOAc. The combined organic phase was concentrated under reduced pressure. The residue was purified by silica gel column eluting with DCM / EtOAc to give the product (8 g, 77.9%). [M+H] + =534.3.
[0464] Step 4: Benzyl 1-(1-(2,6-bis(benzyloxy)pyridin-3-yl)-7-fluoro-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)azetidine-3-carboxylate [ka]
[0465] To a solution of 1-(2,6-bis(benzyloxy)pyridin-3-yl)-4-bromo-7-fluoro-3-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (4 g, 7.4 mmol) in dioxane (40 mL) was added benzylazetidine-3-carboxylate TFA salt (3.0 g, 10.4 mmol), Ruphos (0.6 g, 1.2 mmol), Pd(dba) (0.6 g, 0.6 mmol), and CsCO (9.6 g, 29.6 mmol). The resulting solution was stirred at 90 °C under a nitrogen atmosphere for 3 hours. The resulting mixture was concentrated under reduced pressure. The residue was purified on a silica gel column eluted with DCM / EtOAc to give the product (2.36 g, 49.5%). [M+H] + = 645.2.
[0466] Step 5: 1-(1-(2,6-dioxopiperidin-3-yl)-7-fluoro-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)azetidine-3-carboxylic acid [ka]
[0467] To a solution of benzyl 1-(1-(2,6-bis(benzyloxy)pyridin-3-yl)-7-fluoro-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)azetidine-3-carboxylate (1.4 g, 2.2 mmol) in THF (30 mL) was added Pd / C (1.4 g, 10% wt) and CHCOOH (0.3 mL). The resulting solution was stirred under a H atmosphere at 30 °C for 8 hours. After filtration, the filtrate was concentrated under reduced pressure to give 1-(1-(2,6-dioxopiperidin-3-yl)-7-fluoro-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)azetidine-3-carboxylic acid (0.5 g, 65.6%). 1H NMR (300 MHz, DMSO-d6) δ 12.48 (s, 1H), 11.10 (d, J = 8.4 Hz, 1H), 7.30 - 7.05 (m, 1H), 6.98 - 6.79 (m, 1H), 5.49 (s, 1H), 4.08 - 3.91 (m, 1H), 3.85 (td, J = 6.6, 2.7 Hz, 1H), 3.53 (s, 2H), 3.50 - 3.35 (m, 3H), 2.97 (d, J = 14.8 Hz, 1H), 2.61 (d, J = 18.1 Hz, 1H), 2.38 - 2.02 (m, 2H), 1.95 (d, J = 23.9 Hz, 1H). [M+H] + = 377.1.
[0468] Step 6: 3-(7-fluoro-3-methyl-2-oxo-4-(3-(4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazine-1-carbonyl)azetidin-1-yl)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione [ka]
[0469] In a 40 mL microwave vial equipped with a magnetic stir bar, add (R,E)-1 1 ,2 6 ,7-trimethyl-5 6 -(piperazin-1-ylmethyl)-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (52.9 mg, 0.10 mmol), 1-(1-(2,6-dioxopiperidin-3-yl)-7-fluoro-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)azetidine-3-carboxylic acid (37.6 mg, 0.10 mmol), and DCM (8 mL) were added. To the reaction mixture were added N,N-diethylpropylethylamine (174 mL, 1.0 mmol) and T3P (50 wt%, 127 mg, 0.0.2 mmol). After stirring at room temperature for 1.5 hours, the reaction mixture was diluted with brine (30 mL), and the layers were separated. The aqueous layer was extracted with DCM (3 × 15 mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. Purification by flash column chromatography (0–10% MeOH / DCM) followed by preparative HPLC chromatography (gradient elution: 0.1% FA / water:acetonitrile = 90:10–50:50) afforded the title compound (58 mg, 65%). 1H NMR (500 MHz, DMSO) δ 12.71 (s, 1H), 11.89 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.52 (s, 1H), 7.49 (d, J = 8.0 Hz, 1H), 7.19 (d, J = 8.0 Hz, 1H), 6.87 (t, J = 9.5 Hz, 1H), 6.77 (dd, J = 8.5, 4.0 Hz, 1H), 5.51 - 5.46 (m, 1H), 4.38 - 4.34 (m, 1H), 4.20 (d, J = 12.0 Hz, 1H), 4.02 - 3.91 (m, 5H), 3.88 - 3.86 (m, 3H), 3.73 (s, 3H), 3.65 - 3.61 (m, 5H), 3.47 (s, 3H), 3.05 - 2.92 (m, 1H), 2.56 (s, 3H), 2.42 - 2.34 (m, 4H), 2.28 - 2.16 (m, 2H), 2.06 - 1.80 (m, 4H), 1.52 - 1.41 (m, 2H), 0.81 (d, J = 6.5 Hz, 3H);[M+H] + = 887.5.
[0470] Example 96: (R)-3-(2,6-difluoro-4-((R)-3-(4-((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -carbonyl)piperazine-1-carbonyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione
[0471] Step 1: ((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3-dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -carboxylic acid [ka]
[0472] Place (R,E)-1 in a 40 mL microwave oven equipped with a magnetic stir bar. 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 To the mixture was added 1H-carbaldehyde (458 mg, 1.0 mmol), NaClO (362 mg, 4.0 mmol), NaHPO (960 mg, 8.0 mmol), and THF / tBuOH / H O (4:4:1, 18 mL) at room temperature. After stirring at room temperature for 3 hours, the reaction mixture was filtered through Celite and the solid was washed with MeOH (40 mL). The resulting solution was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to give the desired product (307 mg, 65%), which was used without further purification. [M+H] + = 475.3.
[0473] Step 2: tert-Butyl(R,E)-4-(1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 (-carbonyl)piperazine-1-carboxylate [ka]
[0474] Place (R,E)-1 in a 40 mL microwave oven equipped with a magnetic stir bar. 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 To the reaction mixture was added N,N-diethylpropylethylamine (906 mL, 5.2 mmol), tert-butyl piperazine-1-carboxylate (241 mg, 1.3 mmol), and DCM (10 mL) at room temperature. After stirring for 2 hours at room temperature, the reaction mixture was diluted with brine (30 mL), and the layers were separated. The aqueous layer was extracted with DCM (3 x 30 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. Purification by flash column chromatography (0-10% MeOH / DCM) afforded the product (353 mg, 85%). [M+H] + = 643.4.
[0475] Step 3: (R,E)-1 1 ,2 6 ,7-trimethyl-5 6 -(piperazine-1-carbonyl)-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one [ka]
[0476] In a 100 mL round-bottom flask equipped with a magnetic stir bar, add tert-butyl (R,E)-4-(1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 To the reaction mixture was added (353 mg, 0.53 mmol)-carbonylpiperazine-1-carboxylate, DCM (10 mL), and TFA (2 mL). After stirring at room temperature for 1 hour, the reaction mixture was concentrated under reduced pressure. To the residue was added DCM (30 mL) and saturated aqueous NaHCO3 (20 mL), and the layers were separated. The aqueous layer was extracted with DCM (3 x 30 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give the product (242 mg, 85%), which was used without further purification. [M+H] + = 543.6.
[0477] Step 4: (R)-3-(2,6-difluoro-4-((R)-3-(4-((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -carbonyl)piperazine-1-carbonyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0478] In a 40 mL microwave vial equipped with a magnetic stir bar, add (R,E)-1 1 ,26 ,7-trimethyl-5 6 -(piperazine-1-carbonyl)-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (54.3 mg, 0.10 mmol), (R)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)pyrrolidine-3-carboxylic acid (40.6 mg, 0.12 mmol), and DCM (8 mL) were added. To the reaction mixture were added N,N-diethylpropylethylamine (87 mL, 0.5 mmol) and T3P (50 wt%, 127 mg, 0.2 mmol). After stirring at room temperature for 1.5 h, the reaction mixture was diluted with brine (20 mL), and the layers were separated. The aqueous layer was extracted with DCM (3 × 15 mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. Purification by flash column chromatography (0-10% MeOH / DCM) and preparative HPLC chromatography (gradient elution: 0.1% FA / water:acetonitrile = 90:10 to 50:50) afforded the title compound (62 mg, 72%). 1H NMR (500 MHz, DMSO) δ 12.88 (s, 1H), 10.84 (s, 1H), 8.43 (s, 1H), 7.93 (s, 1H), 7.72 (s, 1H), 7.60 (d, J = 8.0 Hz, 1H), 7.58 (s, 1H), 7.31 (d, J = 8.5 Hz, 1H), 6.23 (d, J = 12.0 Hz, 2H), 4.41 - 4.33 (m, 1H), 4.21 (d, J = 12.5 Hz, 1H), 4.04 - 4.00 (m, 3H), 3.73 (s, 3H), 3.67 - 3.50 (m, 8H), 3.48 - 3.41 (m, 3H), 3.28 -3.21 (m, 3H), 2.83 - 2.74 (m, 2H), 2.56 (s, 3H), 2.25 - 2.17 (m, 2H), 2.15 - 2.04 (m, 2H), 2.02 - 1.89 (m, 3H), 1.51 - 1.42 (m, 1H), 0.83 (d, J = 6.5 Hz, 3H);[M+H] + = 863.7.
[0479] Example 97: (R)-3-(2,6-difluoro-4-(2-(4-((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -carbonyl)piperazin-1-yl)ethyl)phenyl)piperidine-2,6-dione [ka]
[0480] In a 40 mL microwave vial equipped with a magnetic stir bar, add (R,E)-1 1 ,2 6 ,7-trimethyl-56 -(piperazine-1-carbonyl)-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (108.5 mg, 0.20 mmol), (R)-2-(4-(2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)acetaldehyde (106.8 mg, 0.40 mmol), and DCM (8 mL) were added. To the reaction mixture was added one drop of Ti(OiPr). After stirring at 40 °C for 1 h, NaBH(OAc) (127 mg, 0.6 mmol) was added. After stirring at 40 °C for an additional 2 h, the reaction mixture was diluted with saturated aqueous NaHCO (20 mL), and the layers were separated. The aqueous layer was extracted with DCM (3 × 15 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. Purification by preparative TLC followed by preparative HPLC chromatography (gradient elution: 0.1% FA / water:acetonitrile = 90:10 to 50:50) afforded the title compound (128 mg, 81%). 1H NMR (500 MHz, DMSO) δ 12.86 (s, 1H), 10.95 (s, 1H), 8.42 (s, 1H), 7.93 (s, 1H), 7.68 (s, 1H), 7.62 - 7.57 (m, 2H), 7.26 (d, J = 7.5 Hz, 1H), 7.04 (d, J = 10.0 Hz, 2H), 4.40 - 4.31 (m, 1H), 4.21 - 4.18 (m, 2H), 4.04 - 3.99 (m, 2H), 3.73 (s, 3H), 3.64 - 3.39 (m, 5H), 2.84 - 2.73 (m, 5H), 2.61 - 2.59 (m, 3H), 2.56 (s, 3H), 2.49 - 2.42 (m, 2H), 2.26 - 2.06 (m, 2H), 2.00 - 1.91 (m, 3H), 1.52 - 1.40 (m, 1H), 0.81 (d, J = 5.5 Hz, 3H);[M+H] + = 794.6.
[0481] Example 98: (3R)-3-(2,6-difluoro-4-((3R)-3-(6-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-3,6-diazabicyclo[3.1.1]heptane-3-carbonyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0482] The title compound was prepared in a similar manner to Example 5.
[0483] 1H NMR (500 MHz, DMSO) δ 12.68 (s, 1H), 10.85 (d, J = 5.3 Hz, 1H), 8.42 (s, 1H), 7.92 (s, 1H), 7.57 (d, J = 9.7 Hz, 2H), 7.48 (d, J = 8.0 Hz, 1H), 7.25 (dd, J = 14.8, 8.4 Hz, 1H), 6.27 (t, J = 13.0 Hz, 2H), 4.34 (dd, J = 8.2, 5.6 Hz, 1H), 4.24 - 4.14 (m, 1H), 4.07 - 3.87 (m, 4H), 3.73 (s, 3H), 3.68 (s, 3H), 3.62-3.52 (m, 5H), 3.47-3.33 (m, 6H), 2.86 - 2.73 (m, 2H), 2.55 (s, 3H), 2.33 - 2.05 (m, 4H), 2.02 - 1.82 (m, 3H), 1.53 - 1.40 (m, 2H), 0.81 (t, J = 7.0 Hz, 3H);[M+H] + =861.7.
[0484] Example 99: (R)-3-(2,6-difluoro-4-((R)-3-((S)-3-methyl-4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazine-1-carbonyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0485] The title compound was prepared in a similar manner to Example 5.
[0486] 1 H NMR (500 MHz, DMSO) δ 12.70 (s, 1H), 10.84 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.53 (d, J = 6.1 Hz, 1H), 7.49 (d, J = 8.0 Hz, 1H), 7.20 (t, J = 6.8 Hz, 1H), 6.22 (s, 1H), 6.20 (s, 1H), 4.41 - 4.33 (m, 1H), 4.21 (d, J = 11.7 Hz, 1H), 4.06 - 3.92 (m, 6H), 3.86 - 3.66 (m, 5H), 3.51 (dd, J = 15.7, 7.5 Hz, 1H), 3.46 - 3.38 (m, 3H), 3.27 - 2.92 (m, 4H), 2.85 - 2.73 (m, 2H), 2.69 - 2.60 (m, 1H), 2.56 (s, 3H), 2.22-1.90 (m, 8H), 1.54 - 1.42 (m, 1H), 1.15-1.09 (m, 3H), 0.82 (d, J = 6.3 Hz, 3H);[M+H] + =863.7.
[0487] Example 100: (R)-3-(2,6-difluoro-4-((R)-3-((R)-3-methyl-4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazine-1-carbonyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0488] The title compound was prepared in a similar manner to Example 5.
[0489] 1 H NMR (500 MHz, DMSO) δ 12.70 (s, 1H), 10.84 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.53 (s, 1H), 7.49 (d, J = 8.2 Hz, 1H), 7.21 (d, J = 8.2 Hz, 1H), 6.22 (s, 1H), 6.20 (s, 1H), 4.42 - 4.32 (m, 1H), 4.21 (d, J = 13.2 Hz, 1H), 4.07 - 3.91 (m, 4H), 3.87 - 3.69 (m, 5H), 3.62 - 3.33 (m, 6H), 3.28 - 2.89 (m, 4H), 2.84 - 2.72 (m, 2H), 2.72 - 2.62 (m, 1H), 2.56 (s, 3H), 2.23 - 1.92 (m, 8H), 1.52 - 1.42 (m, 1H), 1.16-1.10 (m, 3H), 0.81 (d, J = 5.3 Hz, 3H);[M+H] + =863.7.
[0490] Example 101: (3R)-3-(2,6-difluoro-4-(2-(6-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)ethyl)phenyl)piperidine-2,6-dione [ka]
[0491] The title compound was prepared in a similar manner to Example 14. 1 H NMR (500 MHz, DMSO) δ 12.68 (s, 1H), 10.95 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.56 (s, 1H), 7.53 (s, 1H), 7.46 (d, J = 7.9 Hz, 1H), 7.22 (d, J = 7.2 Hz, 1H), 7.09 (s, 1H), 7.07 (s, 1H), 4.36 (s, 1H), 4.20 (d, J = 13.3 Hz, 2H), 4.00 (s, 1H), 3.98 - 3.89 (m, 1H), 3.73 (s, 3H), 3.67 (s, 2H), 3.48 (s, 2H), 3.25 - 3.19 (m, 1H), 3.02 (s, 2H), 2.95 - 2.77 (m, 8H), 2.55 (s, 3H), 2.34 - 2.08 (m, 3H), 2.01-1.93 (m, 3H), 1.80 (s, 1H), 1.47 (s, 1H), 0.81 (d, J = 6.5 Hz, 3H);[M+H] + =792.7.
[0492] Example 102: (3R)-3-(2,6-difluoro-4-(2-(3-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-6-yl)ethyl)phenyl)piperidine-2,6-dione [ka]
[0493] The title compound was prepared in a similar manner to Example 14.
[0494] 1 H NMR (500 MHz, DMSO) δ 12.67 (s, 1H), 10.93 (s, 1H), 8.42 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.54 (s, 1H), 7.48 (d, J = 8.1 Hz, 1H), 7.20 (d, J = 8.0 Hz, 1H), 6.91 (s, 1H), 6.89 (s, 1H), 4.38 - 4.30 (m, 1H), 4.21-4.13 (m, 2H), 4.02 - 3.81 (m, 4H), 3.73 (s, 3H), 3.49 (s, 2H), 3.28 - 3.15 (m, 2H), 3.00 (dd, J = 10.8, 5.3 Hz, 2H), 2.81 - 2.67 (m, 4H), 2.56 (s, 3H), 2.47 - 2.35 (m, 3H), 2.22 (s, 2H), 2.11-2.06 (m, 1H), 2.01 - 1.84 (m, 4H), 1.44 (td, J = 11.5, 4.2 Hz, 1H), 0.76 (d, J = 6.4 Hz, 3H);[M+H] + =792.7.
[0495] Example 103: (3R)-3-(2,6-difluoro-4-(2-(5-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-2,5-diazabicyclo[2.2.2]octan-2-yl)ethyl)phenyl)piperidine-2,6-dione [ka]
[0496] The title compound was prepared in a similar manner to Example 14.
[0497] 1 H NMR (500 MHz, DMSO) δ 12.69 (s, 1H), 10.95 (s, 1H), 8.42 (s, 1H), 7.92 (s, 1H), 7.56 (s, 1H), 7.53 (s, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.21 (dd, J = 7.8, 4.3 Hz, 1H), 7.06 (s, 1H), 7.04 (s, 1H), 4.39 - 4.32 (m, 1H), 4.20 (d, J = 12.5 Hz, 2H), 4.00 (s, 1H), 3.96 - 3.87 (m, 1H), 3.80 (d, J = 17.8 Hz, 2H), 3.73 (s, 3H), 3.25 - 3.20 (m, 1H), 3.05 (d, J = 8.9 Hz, 1H), 2.92 (d, J = 9.0 Hz, 1H), 2.86 - 2.60 (m, 10H), 2.56 (s, 3H), 2.27 - 2.07 (m, 2H), 2.04 - 1.80 (m, 5H), 1.65 - 1.40 (m, 3H), 0.80 (t, J = 5.5 Hz, 3H);[M+H] + =806.7.
[0498] Example 104: (R)-3-(2,6-difluoro-4-(2-((S)-3-methyl-4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazin-1-yl)ethyl)phenyl)piperidine-2,6-dione [ka]
[0499] The title compound was prepared in a similar manner to Example 14.
[0500] 1 H NMR (500 MHz, DMSO) δ 12.70 (s, 1H), 10.94 (s, 1H), 8.43 (s, 1H), 7.93 (d, J = 9.7 Hz, 1H), 7.58 (d, J = 9.4 Hz, 1H), 7.49 (s, 1H), 7.47 (s, 1H), 7.17 (d, J = 8.1 Hz, 1H), 7.02 (s, 1H), 7.00 (s, 1H), 4.36 (d, J = 4.9 Hz, 1H), 4.19 (dd, J = 13.7, 8.8 Hz, 2H), 4.02 (dd, J = 16.1, 9.6 Hz, 2H), 3.96 - 3.88 (m, 1H), 3.73 (s, 3H), 3.27 (s, 2H), 2.86 - 2.69 (m, 5H), 2.65 - 2.52 (m, 8H), 2.28 - 2.06 (m, 4H), 2.05 - 1.84 (m, 4H), 1.53 - 1.42 (m, 1H), 1.11 (d, J = 6.0 Hz, 3H), 0.81 (d, J = 6.4 Hz, 3H);[M+H] + =794.7.
[0501] Example 105: (R)-3-(2,6-difluoro-4-(2-((R)-3-methyl-4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazin-1-yl)ethyl)phenyl)piperidine-2,6-dione [ka]
[0502] The title compound was prepared in a similar manner to Example 14.
[0503] 1 H NMR (500 MHz, DMSO) δ 12.69 (s, 1H), 10.94 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.50 (s, 1H), 7.48 (d, J = 8.3 Hz, 1H), 7.18 (d, J = 8.1 Hz, 1H), 7.02 (s, 1H), 7.00 (s, 1H), 4.40 - 4.31 (m, 1H), 4.25 - 4.15 (m, 2H), 4.08 (d, J = 12.4 Hz, 1H), 4.00 (s, 1H), 3.96 - 3.89 (m, 1H), 3.73 (s, 3H), 3.31 - 3.14 (m, 3H), 2.84-2.64 (m, 5H), 2.68 - 2.52 (m, 7H), 2.26 - 1.88 (m, 8H), 1.51 - 1.42 (m, 1H), 1.11 (d, J = 5.7 Hz, 3H), 0.80 (d, J = 6.2 Hz, 3H);[M+H] + =794.7.
[0504] Example 106: (R)-3-(2,6-difluoro-4-((R)-3-((R)-2-methyl-4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazine-1-carbonyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0505] The title compound was prepared in a similar manner to Example 5.
[0506] 1 H NMR (500 MHz, DMSO) δ 12.65 (s, 1H), 10.77 (s, 1H), 8.36 (s, 1H), 7.86 (s, 1H), 7.49 (d, J = 6.8 Hz, 2H), 7.43 (d, 1H), 7.13 (s, 1H), 6.15 (d, J = 7.2 Hz, 2H), 4.28 (s, 1H),4.14 (d, J = 6.1 Hz, 3H), 3.93 (s, 3H), 3.86 (s, 2H), 3.78 (d, J = 6.3 Hz, 2H), 3.66 (s, 3H), 2.82 (s, 2H), 2.70 (m, 3H), 2.58 - 2.51 (m, 2H), 2.49 (m, 3H), 2.14 (s, 3H), 1.93 (m, 8H), 1.40 (s, 1H), 1.24 (d, J = 5.5 Hz, 1H), 1.08 (d, J = 6.4 Hz, 2H), 0.75 (d, J = 6.1 Hz, 3H). [M+H] + =863.4
[0507] Example 107: (R)-3-(2,6-difluoro-4-(2-((R)-2-methyl-4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazin-1-yl)ethyl)phenyl)piperidine-2,6-dione [ka]
[0508] The title compound was prepared in a similar manner to Example 14.
[0509] 1 H NMR (500 MHz, DMSO) δ 12.70 (s, 1H), 10.94 (s, 1H), 8.42 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.48 (d, J = 7.1 Hz, 2H), 7.17 (d, J = 6.1 Hz, 1H), 7.01 (d, J = 6.8 Hz, 2H), 4.36 (s, 1H), 4.19 (d, J = 6.4 Hz, 2H), 4.00 (s, 1H), 3.96 - 3.89 (m, 1H), 3.73 (s, 3H), 3.53 (m, 4H), 2.85 - 2.77 (m, 4H), 2.71 (d, J = 7.0 Hz, 2H), 2.61 (m, 2H), 2.56 (s, 3H), 2.37 (d, J = 6.7 Hz,1H), 2.27 - 2.06 (m, 4H), 1.98 (d, J = 6.2 Hz, 2H), 1.91 (s, 2H), 1.47 (s, 1H), 0.95 (d, J = 6.9 Hz, 3H), 0.81 (d, J = 6.3 Hz, 3H). [M+H] + =794.4
[0510] Example 108: (R)-3-(2,6-difluoro-4-((R)-3-(8-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6-yl)methyl)-2-oxa-5,8-diazaspiro[3.5]nonane-5-carbonyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0511] The title compound was prepared in a similar manner to Example 5.
[0512] 1 H NMR (500 MHz, DMSO) δ 12.83 - 12.49 (m, 1H), 10.84 (s, 1H), 8.43 (s, 1H), 8.32 (s, 1H), 7.92 (s, 1H), 7.74 (d, J = 7.9 Hz, 1H), 7.55 (d, J = 6.9 Hz, 1H), 7.29 (d, J = 6.2 Hz, 1H), 6.22 (d, J = 12.7 Hz, 2H), 4.60 (s, 2H), 4.36 (s, 1H), 4.23 (d, J = 8.9 Hz, 3H), 4.00 (s, 3H), 3.73 (s, 5H), 3.67 - 3.53 (m, 4H), 2.74 (m, 4H), 2.55 (d, J = 6.1 Hz, 5H), 2.36 (s, 4H), 2.16 (s, 2H), 2.08 (d, J = 6.8 Hz, 3H), 1.95 (s, 2H), 1.46 (s, 1H), 0.86 - 0.64 (m, 3H). [M+H]+ =891.4.
[0513] Example 59: (R)-3-(2,6-difluoro-4-((R)-3-(4-(((R,E)-5 7 -Fluoro-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazine-1-carbonyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0514] The title compound was prepared in a similar manner to Example 5. 1 H NMR (500 MHz, DMSO) δ 12.94 (s, 1H), 10.84 (s, 1H), 8.40 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.38 (d, J = 8.0 Hz, 1H), 7.26 (s, 1H), 6.21 (d, J = 12.0 Hz, 2H), 4.39 - 4.28 (m, 2H), 4.07 - 3.90 (m, 3H), 3.73 (s, 3H), 3.63 - 3.17 (m, 11H), 2.85 - 2.72 (m, 2H), 2.56 (s, 3H), 2.31 - 1.81 (m, 8H), 1.69 - 1.37 (m, 3H), 1.02 - 0.80 (m, 5H);[M+H] + =867.8.
[0515] Example 64: (R)-3-(4-(3-(4-(((R,E)-1 3 -(difluoromethyl)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazine-1-carbonyl)azetidin-1-yl)-2,6-difluorophenyl)piperidine-2,6-dione [ka]
[0516] The title compound was prepared in a similar manner to Example 5. 1 H NMR (500 MHz, DMSO) δ 12.74 (s, 1H), 10.85 (s, 1H), 8.51 (s, 1H), 7.80 (t, J = 54.5 Hz, 1H), 7.63 (s, 1H), 7.53 (s, 1H), 7.50 (d, J = 8.0 Hz, 1H), 7.20 (d,J = 8.0 Hz, 1H), 6.15 (d, J = 11.5 Hz, 2H), 4.45 - 4.36 (m, 1H), 4.21 (d, J = 12.6 Hz, 1H), 4.10 - 3.79 (m, 13H), 3.61 (s, 2H), 3.50 (s, 2H), 2.90 - 2.72 (m, 3H), 2.58 (s, 3H), 2.43 - 2.33 (m, 3H), 2.28 - 2.18 (m, 1H), 2.14 - 1.88 (m, 5H), 1.52 - 1.42 (m, 1H), 0.82 (d, J = 6.0 Hz, 3H).[M+H] + = 885.70.
[0517] Example 144: (R,E)-3-(4-(2-(4-((1 1 ,2 6 -dimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazin-1-yl)ethyl)-2,6-difluorophenyl)piperidine-2,6-dione [ka]
[0518] The title compound was prepared in a similar manner to Example 14. 1 H NMR (500 MHz, DMSO) δ 12.65 (s, 1H), 10.94 (s, 1H), 8.41 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.52 - 7.45 (m, 2H), 7.18 (d, J = 8.1 Hz, 1H), 7.01 (d, J = 10.2 Hz, 2H), 4.21 (s, 5H), 3.73 (s, 3H), 3.55 (s, 2H), 2.77 (dt, J = 14.4, 10.1 Hz, 3H), 2.55 (d, J = 12.4 Hz, 7H), 2.36 (s, 7H), 2.07 (m, 6H), 1.80 (s, 2H). [M+H] + = 766.7.
[0519] Example 147: (R)-3-(2,6-difluoro-4-(3-((4-(((R,E)-1 1 ,2 6 ,5 5 ,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazin-1-yl)methyl)azetidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0520] The title compound was prepared in a similar manner to Example 14. 1H NMR (500 MHz, DMSO) δ 12.61 (s, 1H), 10.84 (s, 1H), 8.42 (s, 1H), 7.92 (s, 1H), 7.56 (s, 1H), 7.43 (s, 1H), 7.33 (s, 1H), 6.09 (d, J = 11.3 Hz, 2H), 4.35 (s, 1H), 4.20 (d, J = 12.3 Hz, 1H), 4.04 - 3.98 (m, 2H), 3.91 (t, J = 6.9 Hz, 3H), 3.73 (s, 3H), 3.53 (d, J = 13.1 Hz, 1H), 3.48 - 3.46 (m, 3H), 2.90 (s, 1H), 2.76 (d, J = 11.8 Hz, 2H), 2.55 (s, 4H), 2.54 (s, 1H), 2.49 - 2.45 (m, 4H), 2.39 (s, 6H), 2.37 - 2.34 (m, [M+H] + =835.7.
[0521] Example 148: (R)-3-(2,6-difluoro-4-(3-((4-(((R,E)-1 1 ,2 6 ,5 7 ,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazin-1-yl)methyl)azetidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0522] The title compound was prepared in a similar manner to Example 14. 1 H NMR (500 MHz, DMSO) δ 12.77 (s, 1H), 10.85 (s, 1H), 8.38 (s, 1H), 7.93 (s, 1H), 7.57 (s, 1H), 7.38 (d, J = 7.7 Hz, 1H), 7.11 (d, J = 7.4 Hz, 1H), 6.09 (d, J = 11.3 Hz, 2H), 4.36-4.27 (m, 3H), 4.07 - 3.96 (m, 2H), 3.92 (s, 2H), 3.73 (s, 3H), 3.64 - 3.53 (m, 1H), 3.47 (s, 3H), 3.30 - 3.24 (m, 2H), 2.90 (s, 2H), 2.83 - 2.71 (m, 2H), 2.67 (s, 3H), 2.55 - 2.51 (m, 6H), 2.36 (s, 5H), 2.22 (s, 1H), 2.11 - 2.03 (m, 2H), 1.98 - 1.90 (m, 1H), 1.84 (s, 1H), 1.51 (s, 1H), 0.89 (d, J = 6.5 Hz, 3H). [M+H] + = 835.6
[0523] Example 150: (R)-3-(2,6-difluoro-4-(3-((4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazin-1-yl)methyl)azetidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0524] The title compound was prepared in a similar manner to Example 14. 1 H NMR (500 MHz, DMSO) δ 12.63 (s, 1H), 10.78 (s, 1H), 8.36 (s, 1H), 7.85 (s, 1H), 7.50 (s, 1H), 7.42 (s, 1H), 7.41 (d, J = 8.5 Hz, 1H), 7.10 (d, J = 8.0 Hz, 1H), 6.02 (d, J = 12.0 Hz, 2H), 4.33 - 4.25 (m, 1H), 4.16 - 4.09 (m, 1H), 3.94 (dd, J = 12.0, 4.0 Hz, 2H), 3.88 - 3.82 (m, 3H), 3.66 (s, 3H), 3.49 (s, 2H), 3.38 - 3.35 (m, 4H), 2.86 - 2.79 (m, 1H), 2.74 - 2.67 (m, 2H), 2.44 - 2.39 (m, 7H), 2.38 - 2.24 (m, 5H), 2.20 - 2.10 (m, 1H), 2.03 - 1.81 (m, 4H), 1.45 - 1.34 (m, 1H), 0.74 (d, J = 5.5 Hz, 3H);[M+H] + = 821.8.
[0525] Example 154: (R)-3-(2, 6 -difluoro-4-(3-(4-(((S,E)-1 1 ,2 6 ,5 4 ,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazine-1-carbonyl)azetidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0526] The title compound was prepared in a similar manner to Example 5. 1 H NMR (500 MHz, DMSO) δ 12.17 (s, 1H), 10.86 (s, 1H), 8.42 (s, 1H), 7.92 (s, 1H), 7.55 (s, 1H), 7.37 (s, 1H), 7.03 (s, 1H), 6.15 (d, J = 11.2 Hz, 2H), 4.35 (d, J = 4.5 Hz, 1H), 4.20 (d, J = 12.5 Hz, 1H), 4.03 (d, J = 9.8 Hz, 4H), 3.96 - 3.86 (m, 3H), 3.82 (d, J = 6.5 Hz, 1H), 3.73 (s, 3H), 3.58 (s, 2H), 3.50 (s, 2H), 3.32 (s, 3H), 2.85 - 2.71 (m, 2H), 2.54 (d, J = 12.4 Hz, 6H), 2.37 (s, 4H), 2.21 (s, 1H), 1.98 - 1.96 (m, 4H), 1.46 (s, 1H), 0.82 (d, J = 6.3 Hz, 3H);[M+H] + =849.7.
[0527] Example 156: (R)-3-(2,6-difluoro-4-(3-(4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)oxy)piperidine-1-carbonyl)azetidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0528] The title compound was prepared in a similar manner to Example 5. 1 H NMR (500 MHz, DMSO) δ12.62 (s, 1H), 10.86 (s, 1H), 8.43 (s, 1H), 7.93 (s, 1H), 7.56 (s, 1H), 7.43 (d, J = 8.5 Hz, 1H), 7.33 (s, 1H), 6.89 (d, J = 8.1 Hz, 1H), 6.17 (d, J = 11.2 Hz, 2H), 4.68 (s, 1H), 4.37 (s, 1H), 4.17 (d, J = 13.1 Hz, 1H), 4.08 - 3.85 (m, 10H), 3.73 (s, 3H), 3.55 (s, 1H), 2.87 - 2.72 (m, 2H), 2.56 (s, 4H), 2.22 (s, 1H), 2.10 - 1.90 (m, 7H), 1.68 - 1.55 (m, 2H), 1.45 (s, 1H), 0.82 (d, J = 6.1 Hz, 3H). [M+H] + = 836.7.
[0529] Example 159: (R)-3-(2,6-difluoro-4-(3-(4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperidine-1-carbonyl)azetidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0530] The title compound was prepared in a similar manner to Example 5. 1H NMR (500 MHz, DMSO) δ12.71 (s, 1H), 10.86 (s, 1H), 8.50 (s, 1H), 8.02 (s, 1H), 7.66 (s, 1H), 7.50 - 7.39 (m, 2H), 7.06 (d, J = 8.1 Hz, 1H), 6.16 (d, J = 11.2 Hz, 2H), 4.36 (d, J = 8.9 Hz, 2H), 4.20 (d, J = 12.8 Hz, 1H), 4.07 - 3.85 (m, 7H), 3.80 (s, 1H), 3.75 (s, 3H), 3.59 (d, J = 11.9 Hz, 1H), 2.93 (t, J = 12.6 Hz, 1H), 2.77 (t, J = 12.4 Hz, 2H), 2.68 - 2.53 (m, 6H), 2.22 (s, 1H), 2.13 - 1.76 (m, 6H), 1.60 (d, J = 13.8 Hz, 2H), 1.46 (s, 1H), 1.16 - 1.00 (m, 2H), 0.82 (d, J = 5.4 Hz, 3H). [M+H] + = 834.7.
[0531] Example 158: (R)-3-(2,6-difluoro-4-(3-(4-((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)piperidine-1-carbonyl)azetidin-1-yl)phenyl)piperidine-2,6-dione
[0532] Step 1: tert-Butyl(R,E)-4-(1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,51 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)-3,6-dihydropyridine-1(2H)-carboxylate [ka]
[0533] tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (455.25 mg, 1.47 mmol) and (R,E)-5 6 -Bromo-1 1 ,2 6 ,7-trimethyl-5 2 ,5 3 -dihydro-1 1 H,5 1 To a suspension of H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (500 mg, 0.981 mmol) in dioxane (10 mL) and water (2 mL) was added K2CO3 (406.7 mg, 2.943 mmol) and Pd(dppf)Cl2 (142.37 mg, 0.196 mmol) under N2. The mixture was warmed to 100 °C and stirred for 16 h. The reaction mixture was cooled to room temperature and filtered. The filtrate was concentrated in vacuo. The residue was purified by Combi-Flash (silica column, 40 g, DCM:MeOH = 15:1) to give the product (270.2 mg, 45%). [M+H] + = 612.3.
[0534] Step 2: tert-Butyl(R,E)-4-(1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)piperidine-1-carboxylate [ka]
[0535] tert-Butyl (R,E)-4-(1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 A mixture of (2H-yl)-3,6-dihydropyridine-1(2H)-carboxylate (270 mg, 0.441 mmol) and PtO (10 wt%, 27 mg) in THF (10 mL) was stirred at 40 °C under a hydrogen atmosphere for 5 h. The mixture was cooled to room temperature. The resulting mixture was filtered, and the solid was washed with THF. The filtrate was concentrated under reduced pressure to give the product (216.71 mg, 80%), which was used without further purification. [M+H] + = 614.6.
[0536] Step 3: (R,E)-1 1 ,2 6 ,7-trimethyl-5 6 -(piperidin-4-yl)-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one hydrochloride [ka]
[0537] tert-Butyl (R,E)-4-(1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 To a stirred solution of (-yl)piperidine-1-carboxylate (200 mg, 0.326 mmol) in DCM (6 mL) was added 4 M HCl in dioxane (2 mL). The reaction mixture was stirred at room temperature for 2 hours and concentrated in vacuo to give the product (170.29 mg, 95%). [M+H] + = 514.6.
[0538] Step 4: (R)-3-(2,6-difluoro-4-(3-(4-((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)piperidine-1-carbonyl)azetidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0539] (R,E)-1 1 ,2 6 ,7-trimethyl-5 6 -(piperidin-4-yl)-5 2 ,5 3 -dihydro-1 1 H,5 1To a solution of H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one hydrochloride (50 mg, 0.0908 mmol), (R)-1-(4-(2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)azetidine-3-carboxylic acid (33.37 mg, 0.109 mmol), and DIEA (35.24 mg, 0.272 mmol) in DCM (3 mL) was added T3P (72.30 mg, 0.227 mmol) dropwise at room temperature. The resulting mixture was stirred at room temperature for 1 h. The reaction was quenched with water (20 mL) and extracted with DCM (2 x 10 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered, and evaporated in vacuo. The crude residue was purified by silica gel column chromatography (DCM:MeOH = 100:0 to 10:1 gradient elution) to give an impure product, which was further purified by preparative HPLC (C-18 column chromatography (0.1% FA aqueous solution:acetonitrile = 90:10 to 60:40 gradient elution)) to give the desired product (37.6 mg, 50.5%).
[0540] 1H NMR (500 MHz, DMSO) δ 12.65 (s, 1H), 10.85 (s, 1H), 8.45 (s, 1H), 7.94 (s, 1H), 7.65 - 7.53 (m, 2H), 7.45 (d, J = 7.7 Hz, 1H), 7.14 (d, J = 8.0 Hz, 1H), 6.18 (dd, J = 11.0, 6.4 Hz, 2H), 4.57 (s, 1H), 4.36 (s, 1H), 4.18 (d, J = 12.3 Hz, 1H), 4.06 (s, 3H), 4.01 (d, J = 5.8 Hz, 3H), 3.97 (s, 1H), 3.88 (s, 1H), 3.74 (s, 4H), 3.14 (s, 1H), 2.90 (s, 2H), 2.80 (d, J = 13.2 Hz, 2H), 2.74 - 2.66 (m, 2H), 2.57 (s, 3H), 2.22 (s, 1H), 2.08 (d, J = 12.8 Hz, 1H), 1.97 (s, 2H), 1.84 (s, 2H), 1.64 (d, J = 11.7 Hz, 2H), 1.46 (s, 1H), 0.82 (s, 3H). [M+H] + = 820.5.
[0541] Example 162: (R)-3-(2,6-difluoro-4-(4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,51H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazine-1-carbonyl)piperidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0542] The title compound was prepared in a similar manner to Example 5. 1 H NMR (500 MHz, DMSO) δ 12.72 (s, 1H), 10.86 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.60 - 7.45 (m, 3H), 7.19 (d, J = 8.3 Hz, 1H), 6.62 (d, J = 12.9 Hz, 2H), 4.41 - 4.32 (m, 1H), 4.25 - 4.16 (m, 1H), 4.08 - 3.90 (m, 3H), 3.81 - 3.70 (m, 5H), 3.64 - 3.44 (m, 6H), 2.88 - 2.73 (m, 4H), 2.60 - 2.53 (m, 6H), 2.44 - 2.30 (m, 3H), 2.27 - 2.17 (m, 1H), 2.12 - 2.05 (m, 1H), 2.04 - 1.88 (m, 3H), 1.68 - 1.54 (m, 3H), 1.53 - 1.42 (m, 1H), 0.88 - 0.77 (m, 4H);[M+H] + =863.5.
[0543] Example 163: (3R)-3-(2,6-difluoro-4-((3R)-3-(3-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-3,6-diazabicyclo[3.1.1]heptane-6-carbonyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0544] The title compound was prepared in a similar manner to Example 5. 1H NMR (500 MHz, DMSO) δ 12.70 (s, 1H), 10.84 (s, 1H), 8.42 (d, J = 7.4 Hz, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.49 (d, J = 8.8 Hz, 2H), 7.18 (t, J = 6.9 Hz, 1H), 6.21 (t, J = 11.5 Hz, 2H), 4.52 (s, 1H), 4.35 (s, 1H), 4.21 (d, J = 13.1 Hz, 2H), 4.01 (d, J = 12.0 Hz, 2H), 3.95 - 3.88 (m, 1H), 3.88 - 3.76 (m, 2H), 3.73 (s, 3H), 3.47 (t, J = 8.9 Hz, 1H), 3.36 (s, 2H), 3.22 (d, J = 8.1 Hz, 1H), 3.14 (dd, J = 14.4, 7.1 Hz, 1H), 3.08 - 2.89 (m, 3H), 2.82 - 2.62 (m, 3H), 2.56 (s, 3H), 2.48 - 2.42 (m, 2H), 2.22 - 1.84 (m, 7H), 1.78 (d, J = 7.6 Hz, 1H), 1.44 (s, 1H), 0.80 (dd, J = 16.5, 6.5 Hz, 3H) ;[M+H] + =861.7.
[0545] Example 164: (3R)-3-(2,6-difluoro-4-((3R)-3-(5-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-2,5-diazabicyclo[2.2.2]octane-2-carbonyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0546] The title compound was prepared in a similar manner to Example 5. 1 H NMR (500 MHz, DMSO) δ 12.70 (s, 1H), 10.84 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.57 (s, 2H), 7.48 (d, J = 8.1 Hz, 1H), 7.23 (d, J = 8.1 Hz, 1H), 6.23 (t, J = 12.9 Hz, 2H), 4.35 (s, 1H), 4.20 (d, J = 12.1 Hz, 1H), 4.10 - 3.90 (m, 4H), 3.89-3.74 (m, 2H), 3.73 (s, 3H), 3.66 (d, J = 11.5 Hz, 1H), 3.56-3.48 (m, 1H), 3.46 - 3.35 (m, 2H), 3.26 (d, J = 13.2 Hz, 2H), 2.89-2.72 (m, 5H), 2.56 (s, 3H), 2.50 - 2.41 (m, 2H), 2.27 - 1.69 (m, 10H), 1.58 (s, 1H), 1.46 (s, 1H), 0.81 (d, J = 6.1 Hz, 3H);[M+H] + =875.7.
[0547] Example 165: (R)-3-(4-((R)-4-(4-(((R,E)-1 1 -cyclopropyl-2 6 ,7-Dimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazine-1-carbonyl)-3,3-dimethylpyrrolidin-1-yl)-2,6-difluorophenyl)piperidine-2,6-dione [ka]
[0548] The title compound was prepared in the same manner as in Example 5. 1 H NMR (500 MHz, DMSO) δ 12.72 (s, 1H), 10.84 (d, J = 9.4 Hz, 1H), 8.48 (d, J = 10.3 Hz, 1H), 7.89 (d, J = 11.1 Hz, 1H), 7.55 (d, J = 14.0 Hz, 2H), 7.50 (d, J = 8.1 Hz, 1H), 7.20 (d, J = 8.3 Hz, 1H), 6.14 (d, J = 12.4 Hz, 2H), 4.41 (s, 1H), 4.21 (d, J = 12.8 Hz, 1H), 4.12 (s, 1H), 4.06 - 3.90 (m, 2H), 3.77 - 3.59 (m, 5H), 3.53 (d, J = 15.5 Hz, 2H), 3.43 (d, J = 5.9 Hz, 5H), 3.07 (q, J = 9.1 Hz, 2H), 2.90 - 2.74 (m, 2H), 2.57 (d, J = 11.6 Hz, 5H), 2.39 (s, 3H), 2.26 (s, 1H), 2.16 - 1.99 (m, 2H), 1.95 (s, 2H), 1.49 (s, 1H), 1.17 (d, J = 10.2 Hz, 4H), 1.11 - 1.02 (m, 3H), 0.97 (s, 2H), 0.82 (d, J = 6.6 Hz, 2H). [M+H] + =903.4.
[0549] Example 172: (R)-3-(2,6-ジフルオロ-4-((R)-3-(4-(メチル((R,E)-1) 1 ,2 6 ,7-トリメチル-3-オキソ-5 2 ,5 3 -ジヒドロ-1 1 H,5 1H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)amino)piperidine-1-carbonyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0550] The title compound was prepared in a similar manner to Example 5. 1 H NMR (500 MHz, DMSO) δ 12.46 (s, 1H), 10.84 (s, 1H), 8.43 (s, 1H), 7.92 (d, J = 3.5 Hz, 1H), 7.56 (s, 1H), 7.37 (d, J = 8.8 Hz, 1H), 7.00 (s, 1H), 6.86 (s, 1H), 6.23 (t, J = 10.8 Hz, 2H), 4.55 (d, J = 13.9 Hz, 1H), 4.37 (s, 1H), 4.16 (d, J = 13.4 Hz, 2H), 3.99 (d, J = 10.2 Hz, 5H), 3.73 (s, 3H), 3.57 (s, 1H), 3.01 (s, 1H), 2.75 (s, 8H), 2.55 (s, 6H), 2.19 (s, 3H), 1.95 (s, 3H), 1.73 (s, 3H), 1.47 (s, 2H), 0.83 (d, J = 6.1Hz, 3H). [M+H] + = 863.8.
[0551] Example 185: (R)-3-(4-((R)-3,3-dimethyl-4-((1S,4S)-5-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-2,5-diazabicyclo[2.2.1]heptane-2-carbonyl)pyrrolidin-1-yl)-2,6-difluorophenyl)piperidine-2,6-dione [ka]
[0552] The title compound was prepared in a similar manner to Example 5. 1 H NMR (500 MHz, DMSO) δ 12.70 (s, 1H), 10.84 (s, 1H), 8.42 (s, 1H), 7.92 (s, 1H), 7.58 - 7.46 (m, 3H), 7.20 (dd, J = 21.6, 8.2 Hz, 1H), 6.15 (d, J = 12.4 Hz, 2H), 4.62 (s, 1H), 4.36 (s, 1H), 4.20 (t, J = 13.0 Hz, 1H), 4.05 - 3.78 (m, 6H), 3.73 (s, 3H), 3.70 - 3.44 (m, 5H), 3.16 (d, J = 8.4 Hz, 3H), 2.95 - 2.73 (m, 4H), 2.56 (s, 3H), 2.22 (s, 1H), 2.10 - 1.82 (m, 5H), 1.74 - 1.60 (m, 1H), 1.47 (s, 1H), 1.26 - 0.97 (m, 6H), 0.81 (s, 3H). [M+H] + = 889.7.
[0553] Example 187: (3R)-3-(2,6-difluoro-4-((3R)-3-(8-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-3,8-diazabicyclo[3.2.1]octane-3-carbonyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0554] The title compound was prepared in a similar manner to Example 5. 1 H NMR (500 MHz, DMSO) δ 12.70 (s, 1H), 10.84 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.62 (s, 1H), 7.57 (s, 1H), 7.50 (d, J = 8.0 Hz, 1H), 7.26 (d, J = 7.3 Hz, 1H), 6.22 (dd, J = 12.3, 7.0 Hz, 2H), 4.36 (s, 1H), 4.21 (d, J = 12.6 Hz, 1H), 4.05 - 3.90 (m, 4H), 3.73 (s, 3H), 3.69-3.61 (m, 3H), 3.53-3.41 (m, 4H), 3.28 - 3.13 (m, 6H), 2.86-2.74 (m, 3H), 2.56 (s, 3H), 2.29 - 1.87 (m, 8H), 1.69 - 1.55 (m, 1H), 1.46 (d, J = 6.8 Hz, 2H), 0.82 (d, J = 4.5 Hz, 3H).;[M+H] + =875.7.
[0555] Example 190: (R)-3-(4-((R)-2,2-dimethyl-3-((S)-3-methyl-4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazine-1-carbonyl)pyrrolidin-1-yl)-2,6-difluorophenyl)piperidine-2,6-dione [ka]
[0556] The title compound was prepared in a similar manner to Example 5. 1 H NMR (500 MHz, DMSO) δ 12.71 (s, 1H), 10.83 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.53 (s, 1H), 7.49 (d, J = 8.2 Hz, 1H), 7.20 (d, J = 7.8 Hz, 1H), 6.14 (d, J = 13.2 Hz, 2H), 4.37 (s, 1H), 4.21 (d, J = 12.1 Hz, 1H), 4.03-3.95 (m, 5H), 3.81 (d, J = 13.6 Hz, 2H), 3.73 (s, 3H), 3.42 (d, J = 14.1 Hz, 6H), 3.08 (dd, J = 12.3, 7.1 Hz, 2H), 2.81 - 2.73 (m, 2H), 2.63 (s, 1H), 2.56 (s, 3H), 2.21 (s, 1H), 2.08 (d, J = [M+H] + =891.7.
[0557] Example 194: (R)-3-(2,6-difluoro-4-((R)-3-((R)-3-(methoxymethyl)-4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-52 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazine-1-carbonyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0558] The title compound was prepared in a similar manner to Example 5. 1 H NMR (500 MHz, DMSO) δ 12.71 (s, 1H), 10.84 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.56 (d, J = 9.9 Hz, 2H), 7.49 (d, J = 8.1 Hz, 1H), 7.22 (d, J = 8.2 Hz, 1H), 6.22 (d, J = 12.3 Hz, 2H), 4.36 (d, J = 4.8 Hz, 1H), 4.22 (d, J = 11.9 Hz, 1H), 4.00 (s, 3H), 3.91 (dd, J = 21.9, 9.8 Hz, 2H), 3.73 (s, 3H), 3.72 - 3.70 (m, 1H), 3.65 (d, J = 5.5 Hz, 1H), 3.63 - 3.55 (m, 2H), 3.51 (s, 2H), 3.44 (dd, J = 16.0, 8.6 Hz, 2H), 3.34 (s, 2H), 3.26 (d, J = 19.6 Hz, 5H), 3.20 - 3.08 (m, 1H), 2.84 - 2.74 (m, 2H), 2.71 (d, J = 16.9 Hz, 1H), 2.56 (s, 3H), 2.21 (s, 2H), 2.13 (s, 1H), 2.10 - 2.01 (m, 2H), 2.01 - 1.86 (m, 3H), 1.47 (s, 1H), 0.82 (d, J = 6.2 Hz, 3H). [M+H]+ = 893.4.
[0559] Example 195: (R)-3-(2,6-difluoro-4-((R)-3-((R)-3-(hydroxymethyl)-4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazine-1-carbonyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0560] The title compound was prepared in a similar manner to Example 5. 1 H NMR (500 MHz, DMSO) δ 12.70 (s, 1H), 10.84 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.56 (d, J = 8.0 Hz, 1H), 7.49 (d, J = 8.0 Hz, 1H), 7.22 (d, J = 7.5 Hz, 1H), 6.21 (d, J = 13.0 Hz, 2H), 4.76 - 4.63 (m, 1H), 4.42 - 4.31 (m, 1H), 4.23 - 3.89 (m, 8H), 3.73 (s, 3H), 3.57 - 3.42 (m, 8H), 3.07 - 2.98 (m, 1H), 2.84 - 2.66 (m, 5H), 2.56 (s, 3H), 2.26 - 1.89 (m, 7H), 1.53 - 1.40 (m, 1H), 0.82 (d, J = 5.0 Hz, 3H);[M+H] + = 879.7.
[0561] Example 196: (R)-3-(2,6-difluoro-4-((R)-3-((S)-3-(hydroxymethyl)-4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazine-1-carbonyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0562] The title compound was prepared in a similar manner to Example 5. 1 H NMR (500 MHz, DMSO) δ 12.70 (s, 1H), 10.84 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.56 (d, J = 8.0 Hz, 1H), 7.49 (d, J = 8.0 Hz, 1H), 7.22 (d, J = 7.5 Hz, 1H), 6.21 (d, J = 13.0 Hz, 2H), 4.76 - 4.63 (m, 1H), 4.42 - 4.31 (m, 1H), 4.23 - 3.89 (m, 8H), 3.73 (s, 3H), 3.57 - 3.42 (m, 8H), 3.07 - 2.98 (m, 1H), 2.84 - 2.66 (m, 5H), 2.56 (s, 3H), 2.26 - 1.89 (m, 7H), 1.53 - 1.40 (m, 1H), 0.82 (d, J = 5.0 Hz, 3H);[M+H] + = 879.7.
[0563] Example 199: (R)-3-(2,6-difluoro-4-((R)-3-(5-(((R,E)-1 1 ,26 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)-2-oxa-5,8-diazaspiro[3.5]nonane-8-carbonyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0564] The title compound was prepared in a similar manner to Example 5. 1 H NMR (500 MHz, DMSO) δ 12.72 (s, 1H), 10.84 (d, J = 2.8 Hz, 1H), 8.44 (s, 1H), 8.00 - 7.90 (m, 1H), 7.63 - 7.56 (m, 2H), 7.54 - 7.46 (m, 1H), 7.27 (d, J = 8.4 Hz, 1H), 6.23 (d, J = 12.7 Hz, 2H), 4.72 (d, J = 9.6 Hz, 2H), 4.37 (s, 3H), 4.22 (d, J = 15.2 Hz, 3H), 4.01 (s, 5H), 3.95 (s, 2H), 3.86 (d, J = 17.0 Hz, 1H), 3.77 - 3.70 (m, 4H), 3.53 (s, 3H), 2.80 (d, J = 14.4 Hz, 4H), 2.37 (s, 1H), 2.23 (s, 2H), 2.07 (s, 3H), 1.98 (d, J = 30.2 Hz, 4H), 1.48 (s, 1H), 0.83 (d, J = 6.4 Hz, 4H). [M+H] + =891.4
[0565] Example 200: (R)-3-(2,6-difluoro-4-((R)-3-(3-oxo-4-(((R,E)-1 1,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazine-1-carbonyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0566] The title compound was prepared in a similar manner to Example 5. 1 H NMR (500 MHz, DMSO) δ 12.74 (s, 1H), 10.84 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.52 (d, J = 8.0 Hz, 1H), 7.48 (s, 1H), 7.47 (s, 1H), 7.16 (d, J = 8.0 Hz, 1H), 6.26 - 6.12 (m, 2H), 4.80 - 4.56 (m, 2H), 4.39 - 4.34 (m, 2H), 4.23 - 3.81 (m, 6H), 3.73 (s, 3H), 3.71 - 3.21 (m, 9H), 2.82 - 2.73 (m, 2H), 2.56 (s, 3H), 2.26 - 1.87 (m, 7H), 1.50 - 1.43 (m, 1H), 0.82 (s, 1H), 0.80 (s, 1H);[M+H] + = 863.7.
[0567] Example 202: (R)-3-(2,6-difluoro-4-((R)-3-((S)-2-(methoxymethyl)-4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,51 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazine-1-carbonyl)pyrrolidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0568] The title compound was prepared in a similar manner to Example 5. 1 H NMR (500 MHz, DMSO) δ 12.73 (s, 1H), 10.83 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.54 - 7.47 (m, 2H), 7.21 - 7.15 (m, 1H), 6.26 - 6.14 (m, 2H), 4.40 - 4.32 (m, 1H), 4.30 - 4.16 (m, 2H), 4.05 - 3.91 (m, 3H), 3.90 - 3.80 (m, 1H), 3.74 - 3.67 (m, 4H), 3.58 - 3.48 (m, 2H), 3.44 - 3.34 (m, 3H), 3.30 - 3.19 (m, 6H), 2.96 - 2.69 (m, 5H), 2.56 (s, 3H), 2.27 - 1.86 (m, 10H), 1.46 (s, 1H), 0.84 (t, J = 7.2 Hz, 3H);[M+H] + =893.7.
[0569] Example 256: (R,E)—N-((3R,4S)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)-3-methylpiperidin-4-yl)-N,1 1 ,2 6 ,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0570] The title compound was prepared in a similar manner to Example 260.
[0571] 1 H NMR (500 MHz, DMSO) δ 12.83 (s, 1H), 10.93 (s, 1H), 8.43 (s, 1H), 7.93 (s, 1H), 7.67 (s, 1H), 7.57 (s, 2H), 7.22 (d, J = 8.2 Hz, 1H), 7.01 (d, J = 10.0 Hz, 2H), 4.36 (d, J = 4.3 Hz, 1H), 4.20 (d, J = 10.7 Hz, 2H), 4.06-4.00 (m, 2H), 3.73 (s, 3H), 2.98 (s, 1H), 2.89 (s, 3H), 2.82-2.77 (m, 3H), 2.70 (s, 3H), 2.56 (s, 4H), 2.52 (s, 2H), 2.36 (s, 2H), 2.21 (s, 1H), 2.15 - 2.04 (m, 3H), 2.03 - 1.87 (m, 3H), 1.60 (d, J = 9.3 Hz, 1H), 1.45 (s, 1H), 1.06 (d, J = 6.7 Hz, 3H), 0.82 (d, J = 6.2 Hz, 3H);[M+H] + =836.6.
[0572] Example 211: 3-(7-fluoro-3-methyl-2-oxo-4-((R)-3-(4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazine-1-carbonyl)pyrrolidin-1-yl)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione [ka]
[0573] The title compound was prepared in a similar manner to Example 5. 1 H NMR (500 MHz, DMSO) δ = 12.71 (s, 1H), 11.10 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.53 (s, 1H), 7.49 (d, J=8.1, 1H), 7.19 (d, J=7.8, 1H), 7.00 (m, 1H), 6.88 (t, J=10.0, 1H), 5.50 (d, J=8.3, 1H), 4.36 (m, 1H), 4.20 (d, J=12.4, 1H), 4.00 (s, 1H), 3.98 - 3.89 (m, 1H), 3.73 (s, 3H), 3.62 (d, J=12.7, 5H), 3.52 (s, 4H), 3.44 (m, 1H), 3.18 (d, J=6.0, 2H), 3.03 (m, 3H), 2.81 (s, 1H), 2.63 (d, J=20, 2H), 2.38 (m, 6H), 2.25 - 1.87 (m, 7H), 1.46 (s, 1H), 0.81 (d, J=6.2, 3H);[M+H] + =901.8.
[0574] Example 214: (R)-3-(2,6-difluoro-4-(4-methyl ((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)amino)-[1,4'-bipiperidine]-1'-yl)phenyl)piperidine-2,6-dione [ka]
[0575] The title compound was prepared in a similar manner to Example 14. 1 H NMR (500 MHz, DMSO) δ 12.44 (s, 1H), 10.86 (s, 1H), 8.42 (s, 1H), 8.24 (s, 1H), 7.92 (d, J = 5.3 Hz, 1H), 7.55 (s, 1H), 6.93 (s, 1H), 6.78 (d, J = 8.3 Hz, 1H), 6.63 (d, J = 12.7 Hz, 2H), 4.37 (s, 1H), 4.15 (d, J = 15.2 Hz, 1H), 4.00 (m, 4H), 3.81 (d, J = 12.9 Hz, 3H), 3.73 (s, 3H), 3.60 (s, 1H), 2.95 (s, 2H), 2.75 (s, 4H), 2.55 (s, 6H), 2.29 (s, 3H), 2.07 (s, 1H), 1.97 (s, 2H), 1.80 (d, J = 10.8 Hz, 2H), 1.65 (s, 5H), 1.49 (s, 3H), 0.82 (d, J = 6.1 Hz, 3H). [M+H] + = 849.7.
[0576] Example 216: 2-(2,6-dioxopiperidin-3-yl)-5-((R)-3-(4-(((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -yl)methyl)piperazine-1-carbonyl)pyrrolidin-1-yl)isoindoline-1,3-dione [ka]
[0577] The title compound was prepared in a similar manner to Example 5. 1 H NMR (500 MHz, DMSO) δ 12.73 (s, 1H), 11.06 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.57 (s, 1H), 7.50 (s, 2H), 7.19 (s, 1H), 6.92 (s, 1H), 6.83 (d, J = 8.6 Hz, 1H), 5.05 (dd, J = 12.9, 5.4 Hz, 1H), 4.36 (d, J = 5.1 Hz, 1H), 4.21 (d, J = 12.2 Hz, 1H), 4.00 (s, 1H), 3.94 (d, J = 11.3 Hz, 1H), 3.73 (s, 3H), 3.65-3.53 (m, 5H), 3.51-3.43 (m, 5H), 2.96-2.84 (m, 2H), 2.83-2.81 (m, 2H), 2.67-2.53 (m, 6H), 2.49-2.42 (m, 2H), 2.22 (d, J = 6.3 Hz, 3H), 2.12 (d, J = 7.4 Hz, 1H), 2.04-1.84 (m, 4H), 1.75 (s, 2H), 1.46 (s, 3H), 0.82 (d, J = 6.4 Hz, 3H), 0.82 (d, J = 6.4 Hz, 3H). [M+H] + = 965.6
[0578] Example 221: (R)-3-(2,6-difluoro-4-(3-(7-((R,E)-1 1 ,2 6,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -carbonyl)-2,7-diazaspiro[3.5]nonane-2-carbonyl)azetidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0579] The title compound was prepared in a similar manner to Example 96. 1 H NMR (500 MHz, DMSO) δ 12.86 (s, 1H), 10.86 (s, 1H), 8.43 (s, 1H), 7.93 (s, 1H), 7.67 (s, 1H), 7.58 - 7.56 (m, 2H), 7.25 (d, J = 8.0 Hz, 1H), 6.14 (d, J = 11.5 Hz, 2H), 4.38 - 4.34 (m, 1H), 4.21 - 4.17 (m, 1H), 4.05 - 3.97 (m, 5H), 3.85 - 3.83 (m, 4H), 3.73 (s, 3H), 3.66 (s, 2H), 3.59 - 3.53 (m, 2H), 2.88 - 2.70 (m, 2H), 2.56 (s, 3H), 2.50 - 2.44 (m, 4H), 2.28 - 2.18 (m, 1H), 2.10 - 1.89 (m, 4H), 1.82 - 1.68 (m, 4H), 1.53 - 1.39 (m, 1H), 0.82 (d, J = 6.5 Hz, 3H);[M+H] + = 889.8.
[0580] Example 229: (R)-3-(2,6-difluoro-4-(3-(6-((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -carbonyl)-2,6-diazaspiro[3.3]heptane-2-carbonyl)azetidin-1-yl)phenyl)piperidine-2,6-dione [ka]
[0581] The title compound was prepared in a similar manner to Example 96. 1 H NMR (500 MHz, DMSO) δ 12.91 (s, 1H), 10.85 (s, 1H), 8.44 (s, 1H), 7.93 (s, 1H), 7.82 (s, 1H), 7.58 - 7.57 (m, 2H), 7.52 (d, J = 8.0 Hz, 1H), 6.14 (d, J = 16.0 Hz, 2H), 4.56 - 4.50 (m, 2H), 4.40 - 4.33 (m, 1H), 4.28 - 4.19 (m, 5H), 4.08 - 3.97 (m, 7H), 3.86 - 3.79 (m, 2H), 3.73 (s, 3H), 3.57 - 3.50 (m, 1H), 2.85 - 2.72 (m, 2H), 2.57 (s, 3H), 2.27 - 2.17 (m, 1H), 2.12 - 1.89 (m, 5H), 1.53 - 1.39 (m, 1H), 0.83 (d, J = 6.5 Hz, 3H);[M+H] + = 861.7.
[0582] Example 232: (R,E)—N-(1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)piperidin-4-yl)-5 5 -Fluoro-N,1 1 ,2 6 ,7-Tetramethyl-3-oxo-5 2 ,53 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0583] The title compound was prepared in a similar manner to Example 260.
[0584] 1 H NMR (500 MHz, DMSO) δ 12.90 (s, 1H), 10.93 (d, J = 12.3 Hz, 1H), 8.42 (s, 1H), 7.92 (s, 1H), 7.68 (d, J = 5.5 Hz, 1H), 7.57 (s, 1H), 7.42 - 7.32 (m, 1H), 7.04 (d, J = 9.9 Hz, 1H), 6.95 (s, 1H), 4.34 - 4.32 (m,1H), 4.24 - 4.11 (m, 2H), 4.05 - 3.94 (m, 2H), 3.73 (s, 3H), 3.29 (s, 1H), 3.11 - 3.02 (m, 1H), 2.92 (s, 2H), 2.79 - 2.77 (m,3H), 2.69 (s, 2H), 2.65 - 2.63 (m,1H), 2.61 - 2.52 (m, 5H), 2.45 - 2.34 (m, 2H), 2.27 - 2.16 (m, 1H), 2.15 - 2.04 (m, 2H), 2.03 - 1.87 (m, 3H), 1.87 - 1.73 (m, 2H), 1.69 - 1.60 (m, 1H), 1.59 - 1.51 (m, 1H), 1.44 - 1.42 (m,1H), 0.85 - 0.75 (m, 3H);[M+H] + =840.7.
[0585] Example 233: (R,E)—N-(1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)piperidin-4-yl)-N,1 1 ,1 3 ,2 6 ,7-pentamethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0586] The title compound was prepared in a similar manner to Example 260.
[0587] 1 H NMR (500 MHz, DMSO) δ 12.85 (s, 1H), 10.93 (s, 1H), 8.43 (s, 1H), 7.66 (s, 1H), 7.57 (d, J = 8.1 Hz, 1H), 7.54 (s, 1H), 7.22 (s, 1H), 6.98 (s, 2H), 4.34 (d, J = 2.9 Hz, 1H), 4.23 - 4.13 (m, 2H), 4.05 - 3.94 (m, 2H), 3.66 (s, 3H), 3.28 - 3.21 (m, 2H), 3.09 - 2.62 (m, 10H), 2.56 (s, 3H), 2.53 (d, J = 6.4 Hz, 2H), 2.49 - 2.35 (m, 2H), 2.27 - 2.05 (m, 3H), 2.02 - 1.88 (m, 3H), 1.79 (dd, J = 19.6, 11.0 Hz, 2H), 1.72 - 1.51 (m, 3H), 1.43 (d, J = 6.4 Hz, 1H), 0.82 (d, J = 6.4 Hz, 3H). [M+H] + = 836.7.
[0588] Example 234: (E)-N-(1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)piperidin-4-yl)-N,1 1 ,2 6 -trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-10-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazola-7(1,2)-cyclopropanacyclodecaphane-5 6 -Carboxamide [ka]
[0589] The title compound was prepared in a similar manner to Example 260.
[0590] [M+H] + = 820.7.
[0591] Example 236: (R,E)—N-(1-(4-(2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)piperidin-4-yl)-N,1′,6′-trimethyl-3′-oxospiro[cyclopropane-1,7′-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane]-6′-carboxamide [ka]
[0592] The title compound was prepared in a similar manner to Example 260.
[0593] 1H NMR (500 MHz, DMSO) δ 13.01 (s, 1H), 10.94 (s, 1H), 8.34 (s, 1H), 7.91 (s, 1H), 7.58 (s, 2H), 7.53 (s, 1H), 7.23 (s, 1H), 6.98 (s, 2H),4.29 -4.17 (m, 6H), 3.73 (s, 3H), 3.10 - 2.61 (m, 10H), 2.56 (s, 3H), 2.24 (s, 2H), 2.11 (d, J = 10.7 Hz, 2H), 1.99 (s, 1H), 1.90 - 1.77 (m, 4H), 1.76 - 1.63 (m, 4H), 0.70 (s, 2H), 0.40 (s, 2H);[M+H] + =834.4.
[0594] Example 238: (R,E)—N-(1-(4-(2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)piperidin-4-yl)-N,1 1 ,2 6 -trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0595] The title compound was prepared in a similar manner to Example 260.
[0596] 1H NMR (500 MHz, DMSO) δ 12.80 (s, 1H), 10.94 (s, 1H), 8.41 (s, 1H), 7.92 (s, 1H), 7.67 (s, 1H), 7.60 - 7.49 (m, 2H), 7.24 (d, J = 7.4 Hz, 1H), 7.00 (s, 2H), 4.20 (t, J = 11.0 Hz, 5H), 3.73 (s, 3H), 3.11 - 2.61 (m, 9H), 2.55 (d, J = 13.5 Hz, 5H), 2.08 (d, J = 30.9 Hz, 8H), 1.72 (d, J = 65.5 Hz, 7H). [M+H] + = 808.9.
[0597] Example 239: (R,E)-N-cyclopropyl-N-(1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)piperidin-4-yl)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0598] The title compound was prepared in a similar manner to Example 260.
[0599] 1H NMR (500 MHz, DMSO) δ 12.80 (s, 1H), 10.95 (s, 1H), 8.43 (s, 1H), 7.93 (s, 1H), 7.75 (s, 1H), 7.57 (s, 1H), 7.53 (d, J = 8.1 Hz, 1H), 7.34 (d, J = 8.1 Hz, 1H), 7.03 (d, J = 10.1 Hz, 2H), 4.36 (s, 1H), 4.20 (d, J = 12.2 Hz, 2H), 4.04 - 4.01 (m, 3H), 3.73 (s, 3H), 3.04 (s, 2H), 2.78 (d, J = 6.6 Hz, 5H), 2.56 - 2.53 (m, 6H), 2.21 (s, 1H), 2.16 - 1.90 (m, 8H), 1.86 (s, 2H), 1.44 (s, 1H), 0.80 (d, J = 6.2 Hz, 3H), 0.53 - 0.46 (m, 2H), 0.34 - 0.32 (m, 2H);[M+H] + =848.5.
[0600] Example 241: (R,E)—N-(1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)piperidin-4-yl)-N-ethyl-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0601] The title compound was prepared in a similar manner to Example 260.
[0602] 1H NMR (500 MHz, DMSO) δ 12.85 (s, 1H), 10.93 (s, 1H), 8.43 (s, 1H), 7.93 (s, 1H), 7.59 (t, J = 18.7 Hz, 3H), 7.17 (d, J = 7.9 Hz, 1H), 6.97 (s, 2H), 4.37 (s, 1H), 4.19 (d, J = 11.0 Hz, 2H), 4.03 (dd, J = 17.0, 12.4 Hz, 2H), 3.73 (s, 3H), 3.37 (s, 2H), 2.90 (s, 2H), 2.78 (d, J = 12.2 Hz, 2H), 2.66 (s, 2H), 2.56 (s, 3H), 2.53 (s, 2H), 2.42 (s, 3H), 2.21 (s, 1H), 2.10 (d, J = 11.5 Hz, 1H), 2.03 - 1.89 (m, 3H), 1.63 (dd, J = 11.0, 3.0 Hz, 7H), 1.18 (s, 2H), 0.82 (d, J = 6.1 Hz, 3H);[M+H] + =837.0.
[0603] Example 242: (R,E)—N-(1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)piperidin-4-yl)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0604] The title compound was prepared in a similar manner to Example 260. 1H NMR (500 MHz, DMSO) δ 12.89 (s, 1H), 10.95 (s, 1H), 8.43 (s, 1H), 8.26 - 8.15 (m, 1H), 8.06 (s, 1H), 7.93 (s, 1H), 7.78 (d, J = 7.7 Hz, 1H), 7.62 - 7.52 (m, 2H), 7.04 (d, J = 10.1 Hz, 2H), 4.37 (s, 1H), 4.22 (d, J = 11.9 Hz, 2H), 4.03 - 3.92 (m, 2H), 3.83 (s, 2H), 3.74 (s, 3H), 2.98 (d, J = 10.2 Hz, 2H), 2.90 - 2.75 (m, 5H), 2.64 (s, 1H), 2.56 (s, 3H), 2.22 (s, 1H), 2.14 (d, J = 13.5 Hz, 1H), 2.10 - 1.97 (m, 4H), 1.92 (s, 1H), 1.83 (d, J = 11.1 Hz, 2H), 1.60 (s, 2H), 1.49 (s, 1H), 0.83 (d, J = 6.1 Hz, 3H). [M+H] + =808.7
[0605] Example 243: (R,E)-N-((3R,4R)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)-3-hydroxypiperidin-4-yl)-N,1 1 ,2 6 ,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0606] The title compound was prepared in a similar manner to Example 260.
[0607] 1 H NMR (500 MHz, DMSO) δ 12.84 (s, 1H), 10.93 (s, 1H), 8.43 (s, 1H), 7.93 (s, 1H), 7.66 (s, 1H), 7.56 (d, J = 12.2 Hz, 2H), 7.25 (dd, J = 19.2, 8.0 Hz, 1H), 7.00 (dd, J = 18.0, 10.2 Hz, 2H), 5.09 (s, 1H), 4.36 (s, 1H), 4.19 (t, J = 14.6 Hz, 2H), 3.98 (d, J = 17.4 Hz, 2H), 3.73 (s, 3H), 3.18 (d, J = 12.4 Hz, 1H), 2.99 (s, 1H), 2.90 (s, 2H), 2.81 (d, J = 19.0 Hz, 4H), 2.64 (d, J = 17.0 Hz, 2H), 2.55 (d, J = 9.9 Hz, 4H), 2.47 (s, 2H), 2.21 (s, 1H), 2.17 - 1.88 (m, 5H), 1.85 - 1.36 (m, 5H), 0.83 (d, J = 5.5 Hz, 3H);[M+H] + =838.7.
[0608] Example 244: (R,E)—N-((3S,4R)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)-3-methoxypiperidin-4-yl)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0609] The title compound was prepared in a similar manner to Example 260.
[0610] 1 H NMR (500 MHz, DMSO) δ 12.89 (s, 1H), 10.94 (s, 1H), 8.44 (s, 1H), 8.10 (s, 1H), 8.03 (d, J= 7.6 Hz, 1H), 7.93 (s, 1H), 7.81 (d, J = 8.4 Hz, 1H), 7.59 - 7.54 (m, 2H), 7.08 (d, J = 10.2 Hz, 2H), 4.37 (d, J = 4.7 Hz, 1H), 4.21 (t, J = 11.7 Hz, 2H), 4.08 - 3.98 (m, 4H), 3.74 (s, 3H), 3.27 (s, 3H), 3.17 (s, 1H), 2.82 (d, J = 12.4 Hz, 2H), 2.77 (d, J = 7.1 Hz, 2H), 2.60 (d, J = 6.3 Hz, 3H), 2.56 (s, 3H), 2.54 (s, 1H), 2.21 - 2.10 (m, 4H), 2.00 (d, J = 10.8 Hz, 3H), 1.93 (s, 1H), 1.58 - 1.50 (m, 2H), 0.84 (d, J = 6.4 Hz, 3H);[M+H] + =838.6.
[0611] Example 245: (R,E)—N-((3R,4S)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)-3-methoxypiperidin-4-yl)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6-Carboxamide [ka]
[0612] The title compound was prepared in a similar manner to Example 260.
[0613] 1 H NMR (500 MHz, DMSO) δ 12.89 (s, 1H), 10.94 (s, 1H), 8.44 (s, 1H), 8.16 (s, 1H), 8.04 (d,J = 7.4 Hz, 1H), 7.93 (s, 1H), 7.82 (d, J = 8.4 Hz, 1H), 7.60 - 7.52 (m, 2H), 7.08 (d, J = 10.3 Hz, 2H), 4.37 (d, J = 3.9 Hz, 1H), 4.28 - 4.14 (m, 2H), 4.12 - 3.91 (m, 3H), 3.74 (s, 3H), 3.50 (s, 1H), 3.24 - 3.21 (m,3H), 3.19 - 3.15 (m,1H), 2.83 - 2.81 (m,5H), 2.66 - 2.53 (m, 6H), 2.30 - 2.08 (m, 4H), 2.07 - 1.96 (m, 3H), 1.93 - 1.91 (m, 1H), 1.63 - 1.54 (m, 1H), 1.54 - 1.41 (m, 1H), 0.83 (d, J = 6.4 Hz, 3H);[M+H] + =838.5.
[0614] Example 246: (R,E)—N-((3S,4R)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)-3-fluoropiperidin-4-yl)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0615] The title compound was prepared in a similar manner to Example 260.
[0616] 1 H NMR (500 MHz, DMSO) δ 12.91 (s, 1H), 10.95 (s, 1H), 8.44 (s, 1H), 8.36 (d, J = 4.5 Hz, 1H), 8.16 (d, J = 16.2 Hz, 1H), 7.93 (s, 1H), 7.84 (d, J = 4.9 Hz, 1H), 7.61 - 7.45 (m, 2H), 7.06 (d, J = 10.2 Hz, 2H), 4.81 - 4.75 (m, 1H), 4.37 (d, J = 4.3 Hz, 1H), 4.21 - 4.18 (m, 2H), 4.04 - 4.01 (m, 3H), 3.74 (s, 3H), 3.28 (d, J = 13.9 Hz, 1H), 3.02 - 2.98 (m, 1H), 2.86 - 2.83 (m, 1H), 2.83 - 2.73 (m, 3H), 2.61 - 2.58 (m, 2H), 2.55 - 2.52 (m, 4H), 2.21 - 2.16 (m, 4H), 2.07 - 1.97 (m, 3H), 1.96 - 1.87 (m, 1H), 1.74 - 1.62 (m, 1H), 1.54 - 1.42 (m, 1H), 0.90 - 0.78 (m, 3H);[M+H] + =826.7.
[0617] Example 247: (R,E)-N-((3S,4S)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)-3-fluoropiperidin-4-yl)-N,11 ,2 6 ,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0618] The title compound was prepared in a similar manner to Example 251.
[0619] 1 H NMR (500 MHz, DMSO) δ 12.69 (s, 1H), 11.04 - 10.79 (m, 1H), 8.43 (s, 1H), 7.93 (s, 1H), 7.65 (s, 1H), 7.58 (t, J = 3.8 Hz, 2H), 7.20 (s, 1H), 7.10 - 6.90 (m, 2H), 4.82 - 4.44 (m, 1H), 4.36 (d, J = 4.1 Hz, 1H), 4.19 (d, J = 11.8 Hz, 2H), 4.00 (s, 2H), 3.73 (s, 3H), 3.43 (d, J = 21.0 Hz, 2H), 3.26 - 3.19 (m, 1H), 3.00 - 2.61 (m, 9H), 2.56 (s, 3H), 2.54 (s, 1H), 2.26 - 1.69 (m, 9H), 1.44 (s, 1H), 0.83 (d, J = 6.2 Hz, 3H). [M+H] + =840.7.
[0620] Example 250: (R,E)—N—((R)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)-3,3-difluoropiperidin-4-yl)-N,1 1 ,2 6,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0621] The title compound was prepared in a similar manner to Example 251.
[0622] 1 H NMR (500 MHz, DMSO) δ 12.88 (s, 1H), 10.94 (s, 1H), 8.43 (s, 1H), 7.93 (s, 1H), 7.67 (s, 1H), 7.58 (d, J = 7.3 Hz, 2H), 7.23 (s, 1H), 7.02 (s, 2H), 4.36 (d, J = 4.5 Hz, 1H), 4.19 (d, J = 11.2 Hz, 2H), 4.10 - 3.94 (m, 2H), 3.73 (s, 3H), 3.25 - 2.87 (m, 6H), 2.84 - 2.63 (m, 5H), 2.60 - 2.52 (m, 5H), 2.28 - 1.77 (m, 9H), 1.45 (d, J = 6.7 Hz, 1H), 0.81 (d, J = 6.1 Hz, 3H). [M+H] + =858.7.
[0623] Example 251: (R,E)—N—((S)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)-3,3-difluoropiperidin-4-yl)-N,1 1 ,2 6 ,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide
[0624] Step 1: tert-Butyl (S)-4-(((benzyloxy)carbonyl)amino)-3,3-difluoropiperidine-1-carboxylate [ka]
[0625] To a solution of tert-butyl (S)-4-amino-3,3-difluoropiperidine-1-carboxylate (5.3 g, 22.46 mmol) in DCM (80 mL) and DIEA (5.8 g, 44.92 mmol) was added CbzCl (4.96 g, 29.2 mmol) at 5-10 °C. The reaction mixture was stirred at room temperature for 3 h. The reaction was quenched with water (40 mL), and the resulting mixture was extracted with DCM (40 mL x 3). The combined organic phases were washed with brine (20 mL), dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column (PE:EA = 2:1) to give tert-butyl (S)-4-(((benzyloxy)carbonyl)amino)-3,3-difluoropiperidine-1-carboxylate (7.8 g, 93.6%). [M+H] + = 371.2.
[0626] Step 2: tert-Butyl (S)-4-(((benzyloxy)carbonyl)(methyl)amino)-3,3-difluoropiperidine-1-carboxylate [ka]
[0627] To a solution of tert-butyl (S)-4-(((benzyloxy)carbonyl)amino)-3,3-difluoropiperidine-1-carboxylate (7.8 g, 21.02 mmol) and iodomethane (5.9 g, 42.0 mmol) in THF (80 mL) was added NaH (1.26 g, 31.53 mmol, 60%). The reaction was stirred at room temperature overnight. The reaction was quenched with saturated NH4Cl solution (50 mL) at 0-10 °C, and the resulting mixture was extracted with EA (60 mL x 3). The combined organic phase was washed with brine (20 mL), dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column (PE:EA=3:1) to give tert-butyl (S)-4-(((benzyloxy)carbonyl)(methyl)amino)-3,3-difluoropiperidine-1-carboxylate (7.2 g, 89%). [M+H] + = 385.3.
[0628] Step 3: tert-Butyl (S)-3,3-difluoro-4-(methylamino)piperidine-1-carboxylate [ka]
[0629] To a solution of tert-butyl (S)-4-(((benzyloxy)carbonyl)(methyl)amino)-3,3-difluoropiperidine-1-carboxylate (7.2 g, 18.7 mmol) in THF (100 mL) was added Pd / C (2.5 g, 10%). The mixture was stirred under a hydrogen atmosphere at room temperature for 8 hours. The reaction mixture was filtered through Celite, and the filtrate was concentrated in vacuo to give tert-butyl (S)-3,3-difluoro-4-(methylamino)piperidine-1-carboxylate (4.3 g, 91.7%). [M+H] + = 251.1.
[0630] Step 4: tert-Butyl (S)-3,3-difluoro-4-((R,E)-N,1 1 ,2 6 ,7-Tetramethyl-3-oxo-5 2 ,53 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -carboxamido)piperidine-1-carboxylate [ka]
[0631] (R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 To a mixture of 2-(4-methylamino)-3,3-difluoro-4-(methylamino)piperidine-1-carboxylate (1.37 g, 5.49 mmol) in CHCN (30 mL) was added TCFH (1.77 g, 6.33 mmol) and 1-methylimidazole (1.73 g, 21.1 mmol). The reaction was stirred at room temperature for 2 hours. The reaction was quenched with HO (20 mL), and the resulting mixture was extracted with DCM (30 mL x 3). The combined organic phases were washed with brine (30 mL), dried over NaSO, filtered, and concentrated in vacuo. The residue was purified on a silica gel column (DCM:CHOH = 20:1) to give the product (2.7 g, 90.6%). [M+H] + = 707.2.
[0632] Step 5: (R,E)—N-((S)-3,3-difluoropiperidin-4-yl)-N,1 1 ,2 6 ,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0633] tert-Butyl (S)-3,3-difluoro-4-((R,E)-N,1 1 ,2 6 ,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 To a solution of 2.7 g (3.82 mmol) of 1-(2-carboxamido)piperidine-1-carboxylate in 30 mL of DCM was added 6 mL of TFA. The reaction was stirred at room temperature for 2 hours. The reaction was concentrated in vacuo, and the residue was dissolved in 80 mL of DCM, washed with saturated NaHCO3 solution (30 mL) and brine (30 mL), dried over Na2SO4, filtered, and concentrated in vacuo to give the desired product (2.1 g, 90.5%). [M+H] + = 607.2.
[0634] Step 6: (R,E)—N-((S)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)-3,3-difluoropiperidin-4-yl)-N,1 1 ,2 6 ,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka] (R,E)-N-((S)-3,3-difluoropiperidin-4-yl)-N,1 1 ,2 6 ,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 To a mixture of (R)-carboxamide (2.1 g, 3.46 mmol) and (R)-2-(4-(2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)acetaldehyde (1.2 g, 4.5 mmol) in DCE (40 mL) was added STAB (1.83 g, 8.65 mmol). The reaction was stirred at 50 °C for 2 h. After cooling to room temperature, the reaction was quenched with HO (20 mL), and the resulting mixture was extracted with DCM (30 mL x 3). The combined organic phases were washed with brine (30 mL), dried over NaSO, filtered, and concentrated in vacuo. The residue was purified by silica gel column (DCM:CHOH = 20:1) to give the desired product (1.3 g, 43.8%). 1 H NMR (500 MHz, DMSO) δ 12.88 (s, 1H), 10.94 (s, 1H), 8.43 (s, 1H), 7.93 (s, 1H), 7.69 (s, 1H), 7.59 (d, J = 8.6 Hz, 2H), 7.24 (s, 1H), 7.01 (d, J= 13.6 Hz, 2H), 4.36 (d, J = 4.0 Hz, 1H), 4.20 (d, J = 11.3 Hz, 2H), 4.00 (s, 2H), 3.73 (s, 3H), 2.99 (s, 5H), 2.78 (d, J = 11.0 Hz, 5H), 2.56 (s, 4H), 2.53 (s, 2H), 2.30 - 2.06 (m, 4H), 1.97 (d, J = 13.7 Hz, 5H), 1.45 (s, 1H), 0.84 (d, J = 5.2 Hz, 3H). [M+H]+ = 858.6.
[0635] Example 252: (R,E)—N-((3R,4S)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)-3-methoxypiperidin-4-yl)-N,1 1 ,2 6 ,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0636] The title compound was prepared in a similar manner to Example 260.
[0637] 1 H NMR (500 MHz, DMSO) δ 12.86 (s, 1H), 10.94 (s, 1H), 8.43 (s, 1H), 7.93 (s, 1H), 7.68 (s, 1H), 7.57 (d, J = 5.4 Hz, 2H), 7.24 (s, 1H), 7.06 (s, 2H), 4.36 (d, J = 4.6 Hz, 1H), 4.20 (d, J = 11.4 Hz, 2H), 4.01 (s, 2H), 3.73 (s, 3H), 3.30 - 3.28 (m, 4H), 2.99 - 2.96 (m, 4H), 2.82 - 2.79 (m, 4H), 2.57 - 2.55 (m, 7H), 2.27 - 2.07 (m, 4H), 1.97 - 1.94 (m, 4H), 1.54 - 1.49 (m 3H), 0.82 (d, J = 6.1 Hz, 3H);[M+H] + =852.4.
[0638] Example 253: (R,E)—N-((3R,4R)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)-3-methoxypiperidin-4-yl)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0639] The title compound was prepared in a similar manner to Example 260.
[0640] 1 H NMR (500 MHz, DMSO) δ 12.89 (s, 1H), 10.95 (s, 1H), 8.44 (s, 1H), 8.25 (d, J = 8.4 Hz, 1H), 8.05 (s, 1H), 7.92 (d, J = 3.6 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.56 (d, J = 8.3 Hz, 2H), 7.05 (d, J = 10.1 Hz, 2H), 4.34 - 4.32 (m, 1H), 4.24 - 4.21 (m, 2H), 3.98 - 3.95 (m, 2H), 3.80 - 3.77 (m,1H), 3.74 - 3.71 (m, 3H), 2.92 - 2.89 (m,2H), 2.81 - 2.78 (m,5H), 2.69 - 2.60 (m, 4H), 2.58 (s, 5H), 2.26 - 2.07 (m, 2H), 2.07 - 1.96 (m, 3H), 1.91 - 1.87 (m,1H), 1.80 - 1.76 (m,2H), 1.62 - 1.44 (m, 2H), 0.84 - 0.81 (m, 3H);[M+H]+ =838.7.
[0641] Example 254: (R,E)—N-((3R,4R)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)-3-methoxypiperidin-4-yl)-N,1 1 ,2 6 ,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0642] The title compound was prepared in a similar manner to Example 260.
[0643] 1 H NMR (500 MHz, DMSO) δ 12.86 (s, 1H), 10.94 (s, 1H), 8.43 (s, 1H), 7.93 (s, 1H), 7.68 (s, 1H), 7.57 (d, J = 5.4 Hz, 2H), 7.24 (s, 1H), 7.06 (s, 2H), 4.36 (d, J = 4.6 Hz, 1H), 4.20 (d, J = 11.4 Hz, 2H), 4.01 (s, 2H), 3.73 (s, 3H), 3.30 - 3.28 (m, 4H), 2.99 - 2.96 (m, 4H), 2.82 - 2.79 (m, 4H), 2.57 - 2.55 (m, 7H), 2.27 - 2.07 (m, 4H), 1.97 - 1.94 (m,4H), 1.54 - 1.49 (m 3H), 0.82 (d, J = 6.1 Hz, 3H);[M+H] + =852.4.
[0644] Example 255: (R,E)-N-((3S,4R)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)-3-methoxypiperidin-4-yl)-N,1 1 ,2 6 ,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0645] The title compound was prepared in a similar manner to Example 260.
[0646] 1 H NMR (500 MHz, DMSO) δ 12.85 (s, 1H), 10.93 (s, 1H), 8.43 (s, 1H), 7.93 (s, 1H), 7.68 (s, 1H), 7.57 (d, J = 7.7 Hz, 2H), 7.23 (s, 1H), 7.06 (s, 2H), 4.36 (d, J = 4.4 Hz, 2H), 4.19 (d, J = 11.4 Hz, 2H), 4.11 - 3.93 (m, 2H), 3.73 (s, 4H), 3.28 (s, 4H), 2.96 (s, 4H), 2.78 (d, J = 10.6 Hz, 3H), 2.62 (d, J = 18.0 Hz, 1H), 2.55 (d, J = 10.0 Hz, 5H), 2.36 (s, 1H), 2.29 - 1.84 (m, 7H), 1.83 - 1.28 (m, 3H), 0.82 (d, J = 6.4 Hz, 3H);[M+H] + =852.6.
[0647] Example 257: (R,E)—N-((3R,4R)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)-3-methylpiperidin-4-yl)-N,1 1 ,2 6 ,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0648] The title compound was prepared in a similar manner to Example 260. 1 H NMR (500 MHz, DMSO) δ H 12.87 (s, 1H), 10.94 (d, J = 11.4 Hz, 1H), 8.43 (s, 1H), 7.93 (s, 1H), 7.68 - 7.50 (m, 3H), 7.16 (d, J = 7.9 Hz, 1H), 7.08 - 6.93 (m, 2H), 4.36 (s, 1H), 4.22 - 3.96 (m, 5H), 3.73 (s, 3H), 3.15 - 2.65 (m, 11H), 2.55 (d, J = 10.3 Hz, 4H), 2.27 - 1.58 (m, 10H), 1.45 (s, 1H), 0.93 - 0.64 (m, 6H). [M+H] + = 836.6.
[0649] Example 258: (R,E)—N-((2S,4R)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)-2-methylpiperidin-4-yl)-N,1 1 ,2 6 ,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-11 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0650] The title compound was prepared in a similar manner to Example 260.
[0651] 1 H NMR (500 MHz, DMSO) δ 12.85 (s, 1H), 10.93 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.66 (s, 1H), 7.56 (d, J = 9.9 Hz, 2H), 7.21 (s, 1H), 7.00 (s, 2H), 4.36 (d, J = 4.5 Hz, 1H), 4.19 (d, J = 11.3 Hz, 2H), 4.08 - 3.95 (m, 2H), 3.73 (s, 3H), 3.32 (s, 2H), 2.90 - 2.76 (m, 6H), 2.64 (s, 4H), 2.56 (s, 3H), 2.17 - 2.04 (m, 2H), 2.01 - 1.92 (m, 4H), 1.91 (s, 2H), 1.76 (d, J = 8.8 Hz, 2H), 1.50 - 1.47 (m, 4H), 1.06 (s, 1H), 0.82 (d, J = 6.3 Hz, 3H);[M+H] + = 836.4.
[0652] Example 259: (R,E)—N-((2R,4S)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)-2-methylpiperidin-4-yl)-N,1 1 ,2 6 ,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,51 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0653] The title compound was prepared in a similar manner to Example 260.
[0654] 1 H NMR (500 MHz, DMSO) δ 12.87 (s, 1H), 10.94 (s, 1H), 8.43 (s, 1H), 7.93 (s, 1H), 7.68 (s, 1H), 7.57 (s, 2H), 7.23 (s, 1H), 7.11 (s, 1H), 6.99 (s, 1H), 4.36 (d, J = 4.7 Hz, 1H), 4.19 (s, 2H), 4.00 (s, 2H), 3.73 (s, 3H), 3.29 (s, 4H), 2.92 - 2.71 (m, 6H), 2.69 - 2.52 (m, 7H), 2.36 (s, 2H), 2.28 - 2.12 (m, 3H), 2.02 - 1.86 (m, 4H), 1.76 (s, 1H), 1.60 (s, 1H), 1.44 (s, 2H), 0.82 (d, J = 6.3 Hz, 3H). [M+H] + = 836.7.
[0655] Example 260: (R,E)—N—((R)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)-3,3-difluoropiperidin-4-yl)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide
[0656] Step 1: tert-Butyl (R)-3,3-difluoro-4-((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -carboxamido)piperidine-1-carboxylate [ka]
[0657] (R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 A mixture of 1,3-difluoro-3,3-difluoropiperidine-1-carboxylate (800 mg, 1.68 mmol), tert-butyl (R)-4-amino-3,3-difluoropiperidine-1-carboxylate (477 mg, 2.0 mmol), T3P (1.6 g, 2.52 mmol), and DIEA (650 mg, 5.0 mmol) in DCM (20 mL) was stirred in a round-bottom flask at 25 °C for 3 h. The mixture was evaporated under vacuum to give the crude product, which was purified by silica gel column chromatography (gradient elution from PE:EA = 100:0 to 2:1) to give the title product (900 mg, 78%). [M+H] + =693.4.
[0658] Step 2: (R,E)—N-((R)-3,3-difluoropiperidin-4-yl)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0659] tert-Butyl (R)-3,3-difluoro-4-((R,E)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 A solution of (-carboxamido)piperidine-1-carboxylate (695 mg, 1.0 mmol) in 1 / 4 TFA / DCM (5 mL) was stirred in a round-bottom flask at room temperature for 2 hours. The mixture was evaporated in vacuo to give the crude product (590 mg, 99%), which was used in the next step without further purification. [M+H] + = 593.2.
[0660] Step 3: (R,E)—N—((R)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)-3,3-difluoropiperidin-4-yl)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0661] (R,E)-N-((R)-3,3-difluoropiperidin-4-yl)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 A mixture of (R)-2-(4-(2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)acetaldehyde (296 mg, 1.1 mmol) in 1,2-dichloromethane (15 mL) was stirred at room temperature in a round-bottom flask for 1 h. NaBH(OAc)3 (464 mg, 2.2 mmol) was added to the mixture, and the reaction was stirred at room temperature in a round-bottom flask for 2 h. The mixture was then evaporated in vacuo to give the crude product, which was purified by silica gel column chromatography (gradient elution of DCM:MeOH = 100:0 to 80:20) to give the product (420 mg, 50%). 1H NMR (500 MHz, DMSO) δ 12.92 (s, 1H), 10.95 (s, 1H), 8.43 (d, J = 8.2 Hz, 2H), 8.14 (s, 1H), 7.93 (s, 1H), 7.85 (d, J = 8.4 Hz, 1H), 7.57 (d, J = 7.9 Hz, 2H), 7.06 (d, J = 10.1 Hz, 2H), 4.46 (s, 1H), 4.37 (d, J = 4.2 Hz, 1H), 4.27 - 4.15 (m, 2H), 4.05 - 3.93 (m, 2H), 3.74 (s, 3H), 3.27 (s, 1H), 3.01 - 2.97 (m, 1H), 2.86 - 2.84 (m, 1H), 2.80 - 2.75 (m, 3H), 2.73 - 2.65 (m, 2H), 2.60 - 2.54 (m, 4H), 2.49 - 2.42 (m, 1H), 2.38 - 2.06 (m, 3H), 2.06 - 1.97 (m, 2H), 1.92 - 1.89 (m, 2H), 1.85 - 1.78 (m, 1H), 1.54 - 1.43 (m, 1H), 0.84 (d, J = 6.4 Hz, 3H);[M+H] + =844.7.
[0662] Example 261: (R,E)—N-((S)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)-3,3-dimethylpiperidin-4-yl)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0663] The title compound was prepared in a similar manner to Example 260.
[0664] 1 H NMR (500 MHz, DMSO) δ 12.88 (s, 1H), 10.94 (s, 1H), 8.44 (s, 1H), 8.04 (s, 1H), 7.87 (dd, J = 21, 8 Hz, 3H), 7.58 (s, 2H), 7.05 (d, J = 6.2 Hz, 2H), 4.36 (s, 1H), 4.21 (s, 2H), 4.01 (s, 2H), 3.88 - 3.63 (m, 4H), 3.06 - 2.71 (m, 5H), 2.55 - 2.51 (m,7H), 2.33 - 1.75 (m, 8H), 1.65 - 1.41 (m, 2H), 1.09 - 0.93 (m, 3H), 0.92 - 0.75 (m, 6H);[M+H] + =836.7.
[0665] Example 262: (R,E)—N—((R)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)-3,3-dimethylpiperidin-4-yl)-N,1 1 ,2 6 ,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0666] The title compound was prepared in a similar manner to Example 260.
[0667] 1H NMR (500 MHz, DMSO) δ 12.85 (s, 1H), 10.93 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.66 (s, 1H), 7.56 (d, J = 9.9 Hz, 2H), 7.21 (s, 1H), 7.00 (s, 2H), 4.36 (d, J = 4.5 Hz, 1H), 4.19 (d, J = 11.3 Hz, 2H), 4.08 - 3.95 (m, 2H), 3.73 (s, 3H), 3.32 (s, 2H), 2.90 - 2.76 (m, 4H), 2.64 (s, 4H), 2.56 (s, 3H), 2.17 - 2.04 (m, 2H), 2.01 - 1.92 (m, 4H), 1.91 (s, 2H), 1.76 (d, J = 8.8 Hz, 2H), 1.50 - 1.47 (m, 3H), 1.06 (s, 6H), 0.82 (d, J = 6.3 Hz, 3H);[M+H] + =850.6.
[0668] Example 263: (R,E)—N—((R)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)-3,3-dimethylpiperidin-4-yl)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-56-carboxamide [ka]
[0669] The title compound was prepared in a similar manner to Example 260.
[0670] 1H NMR (500 MHz, DMSO) δ 12.88 (s, 1H), 10.95 (s, 1H), 8.44 (s, 1H), 8.05 (s, 1H), 7.93 (s, 1H), 7.87 (d, J = 9.1 Hz, 1H), 7.79 (d, J = 8.4 Hz, 1H), 7.63 - 7.47 (m, 2H), 7.05 (d, J = 10.2 Hz, 2H), 4.37 (d, J = 4.3 Hz, 1H), 4.30 - 4.15 (m, 2H), 4.01 (d, J = 9.2 Hz, 2H), 3.84 (s, 1H), 3.74 (s, 3H), 2.96 (d, J = 9.6 Hz, 1H), 2.87 - 2.69 (m, 4H), 2.62 (d, J = 11.2 Hz, 1H), 2.56 (s, 5H), 2.48 - 2.38 (m, 1H), 2.12 (d, J = 3.3 Hz, [M+H] + =836.9.
[0671] Example 264: (R,E)—N-((1R,3S,5S)-8-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)-8-azabicyclo[3.2.1]octan-3-yl)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0672] The title compound was prepared in a similar manner to Example 260.
[0673] 1 H NMR (500 MHz, DMSO) δ 12.89 (s, 1H), 10.95 (s, 1H), 8.43 (s, 1H), 7.96 (s, 1H), 7.93 (s, 1H), 7.89 (d, J = 4.3 Hz, 1H), 7.68 (d, J = 8.2 Hz, 1H), 7.58 (d, J = 8.0 Hz, 2H), 7.05 (d, J = 10.0 Hz, 2H), 4.36 (d, J = 4.6 Hz, 1H), 4.27 - 4.17 (m, 2H), 4.05 - 3.94 (m, 3H), 3.74 (s, 3H), 3.26 (s, 2H), 2.89 - 2.72 (m, 4H), 2.56 (s, 3H), 2.54 (s, 3H), 2.28 - 1.88 (m, 11H), 1.81 (t, J = 11.8 Hz, 2H), 1.48 (s, 1H), 0.84 (d, J = 6.4 Hz, 3H). [M+H] + = 834.7.
[0674] Example 265: (R,E)—N-((1R,3S,5S)-8-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)-8-azabicyclo[3.2.1]octan-3-yl)-N,1 1 ,2 6 ,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0675] The title compound was prepared in a similar manner to Example 260.
[0676] 1 H NMR (500 MHz, DMSO) δ 12.87 (s, 1H), 10.93 (s, 1H), 8.43 (s, 1H), 7.93 (s, 1H), 7.66 (s, 1H), 7.58 (s, 2H), 7.20 (s, 1H), 7.03 (s, 2H), 4.36 (d, J = 4.3 Hz, 1H), 4.19 (d, J = 12.8 Hz, 2H), 4.10-3.96 (m, 2H), 3.73 (s, 3H), 3.59 (s, 1H), 3.27 - 3.12 (m, 3H), 2.85 - 2.63 (m, 7H), 2.56 (s, 3H), 2.49 - 2.40 (m, 2H), 2.21 (s, 1H), 2.17 - 2.06 (m, 1H), 2.02 - 1.82 (m, 6H), 1.64 (s, 2H), 1.57 - 1.32 (m, 3H), 0.82 (d, J = 6.4 Hz, 3H). [M+H] + =848.7
[0677] Example 266: (7R,E)—N-(9-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)-9-azabicyclo[3.3.1]nonan-3-yl)-N,1 1 ,2 6 ,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0678] The title compound was prepared in a similar manner to Example 260.
[0679] 1 H NMR (500 MHz, DMSO) δ 12.85 (s, 1H), 10.93 (s, 1H), 8.43 (s, 1H), 7.92 (d, J = 3.2 Hz, 1H), 7.67 (s, 1H), 7.57 (s, 2H), 7.22 (s, 1H), 7.04 (s, 2H), 4.39 - 4.34 (m, 1H), 4.27 - 4.12 (m, 2H), 4.00 - 3.98 (, 2H), 3.73 (s, 3H), 3.01 - 2.89 (m, 3H), 2.87 - 2.74 (m, 8H), 2.72 - 2.64 (m, 6H), 2.29 - 2.16 (m, 2H), 2.15 - 2.03 (m, 3H), 2.01 - 1.89 (m, 3H), 1.75 - 1.58 (m, 2H), 1.57 - 1.34 (m, 3H), 1.26 - 1.01 (m, 2H), 0.81 (d, J = 5.4 Hz, 3H);[M+H] + =862.7.
[0680] Example 267: (R,E)—N-((2S,4S)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)-2-methylpiperidin-4-yl)-N,1 1 ,2 6 ,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0681] The title compound was prepared in a similar manner to Example 260. 1H NMR (500 MHz, DMSO) δ 12.86 (s, 1H), 10.93 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.67 (s, 1H), 7.57 (d, J = 7.3 Hz, 2H), 7.23 (s, 1H), 6.95 (s, 2H), 4.36 (d, J = 4.4 Hz, 1H), 4.20 (d, J = 11.8 Hz, 2H), 4.06 - 3.98 (m, 2H), 3.73 (s, 3H), 2.86-2.79 (m, 8H), 2.56 (s, 4H), 2.54 (s, 2H), 2.48 - 2.43 (m, 2H), 2.21 (s, 1H), 2.09 (s, 1H), 2.01 - 1.89 (m, 4H), 1.78 (s, 1H), 1.70 (s, 1H), 1.58 - 1.39 (m, 3H), 1.11-1.01 (m, 3H), 0.83 (d, J = 6.2 Hz, 3H);[M+H] + =836.7.
[0682] Example 268: (R,E)—N-((2R,4R)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)-2-methylpiperidin-4-yl)-N,1 1 ,2 6 ,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0683] The title compound was prepared in a similar manner to Example 260. 1H NMR (500 MHz, DMSO) δ 12.86 (s, 1H), 10.93 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.67 (s, 1H), 7.57 (d, J = 6.7 Hz, 2H), 7.22 (s, 1H), 6.95 (s, 2H), 4.42 - 4.32 (m, 1H), 4.19 (t, J = 9.4 Hz, 2H), 4.08 - 3.97 (m, 2H), 3.73 (s, 3H), 3.00 - 2.70 (m, 8H), 2.66 - 2.53 (m, 6H), 2.49 - 2.40 (m, 2H), 2.27 - 2.17 (m, 1H), 2.16 - 2.05 (m, 1H), 2.03 - 1.87 (m, 4H), 1.78 (d, J = 11.6 Hz, 1H), 1.68 (d, J = 11.3 Hz, 1H), 1.62 - 1.40 (m, 3H), 1.17 - 0.96 (m, 3H), 0.83 (d, J = 6.1 Hz, 3H). [M+H] + =836.7.
[0684] Example 269: (R,E)—N-((2R,4R)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)-2-methylpiperidin-4-yl)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0685] The title compound was prepared in a similar manner to Example 260.
[0686] 1 H NMR (500 MHz, DMSO) δ 12.89 (s, 1H), 10.95 (s, 1H), 8.44 (s, 1H), 8.18 (s, 1H), 8.06 (s, 1H), 7.93 (s, 1H), 7.78 (d, J = 8.9 Hz, 1H), 7.57 (d, J = 6.9 Hz, 1H), 7.54 (s, 1H), 7.04 (d, J = 10.1 Hz, 2H), 4.36 - 4.34 (m, 1H), 4.22 - 4.20 (m, 2H), 3.98 - 3.95 (m, 2H), 3.88 - 3.85 (m, 1H), 3.74 - 3.71 (m, 3H), 3.03 - 3.01 (m, 1H), 2.94 - 2.91 (m,1H), 2.89 - 2.79 (m, 2H), 2.76 - 2.74 (m,2H), 2.55 - 2.53 (m, 5H), 2.42 - 2.29 (m, 2H), 2.22 - 2.20 (m, 1H), 2.13 - 2.11 (m, 1H), 2.01 - 1.98 (m,2H), 1.93 - 1.90 (m, 1H), 1.85 - 1.82 (m, 2H), 1.64 - 1.43 (m, 2H), 1.33 - 1.31(m, 1H), 1.09 (s, 3H), 0.83 (d, J = 6.5 Hz, 3H);[M+H] + =822.7.
[0687] Example 270: (R,E)—N-((2S,4S)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)-2-methylpiperidin-4-yl)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0688] The title compound was prepared in a similar manner to Example 260. 1 H NMR (500 MHz, DMSO) δ 12.88 (s, 1H), 10.95 (s, 1H), 8.44 (s, 1H), 8.19 (d, J = 7.8 Hz, 1H), 8.05 (s, 1H), 7.93 (s, 1H), 7.80 - 7.75 (m, 1H), 7.59 - 7.52 (m, 2H), 7.03 (d, J = 10.0 Hz, 2H), 4.37 (d,J = 4.7 Hz, 1H), 4.23 - 4.18 (m, 2H), 4.03 - 3.93 (m, 2H), 3.89 - 3.83 (m, 1H), 3.74 (s, 3H), 3.04 (d, J = 11.6 Hz, 1H), 2.97 - 2.91 (m, 1H), 2.85 - 2.81 (m, 2H), 2.74 (t, J = 7.4 Hz, 2H), 2.56 (s, 5H), 2.36 (s, 1H), 2.29 (d, J = 11.8 Hz, 1H), 2.22 (s, 1H), 2.16 - 2.10 (m, 1H), 2.04 - 1.98 (m, 2H), 1.93 (d, J = 10.5 Hz, 1H), 1.83 (t, J = 13.9 Hz, 2H), 1.61 - 1.54 (m, 1H), 1.49 (s, 1H), 1.34 - 1.27 (m, 1H), 1.07 (d, J = 5.2 Hz, 3H), 0.84 (d, J = 6.5 Hz, 3H);[M+H] + =822.5.
[0689] Example 271: (R,E)—N—((R)-1-(1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)piperidin-4-yl)ethyl)-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,53 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0690] The title compound was prepared in a similar manner to Example 260. 1 H NMR (500 MHz, DMSO) δ 12.88 (s, 1H), 10.94 (s, 1H), 8.44 (s, 1H), 8.13 (d, J = 8.6 Hz, 1H), 8.06 (s, 1H), 7.93 (s, 1H), 7.78 (d, J = 8.3 Hz, 1H), 7.59 - 7.53 (m, 2H), 7.01 (d,J = 10.0 Hz, 2H), 4.36 (d, J = 4.5 Hz, 1H), 4.25 - 4.16 (m, 2H), 4.04 - 3.95 (m, 2H), 3.91 (dd, J = 15.0, 7.4 Hz, 1H), 3.74 (s, 3H), 2.97 (s, 2H), 2.82 (dd, J = 12.8, 4.8 Hz, 2H), 2.78 - 2.73 (m, 2H), 2.56 (s, 3H), 2.54 (d, J = 7.0 Hz, 3H), 2.23 (s, 1H), 2.15 - 2.08 (m, 1H), 2.04 - 1.88 (m, 5H), 1.72 (d, J = 11.4 Hz, 2H), 1.52 - 1.40 (m, 2H), 1.24 (s, 2H), 1.16 (d, J = 6.7 Hz, 3H), 0.83 (d, J = 6.5 Hz, 3H);[M+H] + =836.6.
[0691] Example 272: (R,E)—N-((S)-1-(1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)piperidin-4-yl)ethyl)-N,1 1 ,2 6 ,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0692] The title compound was prepared in a similar manner to Example 260. 1 H NMR (500 MHz, DMSO) δ 12.84 (d, J = 15.2 Hz, 1H), 10.92 (s, 1H), 8.43 (s, 1H), 7.93 (d, J = 5.4 Hz, 1H), 7.65 (d, J = 15.7 Hz, 1H), 7.58 (s, 2H), 7.22 (s, 1H), 7.04 (s, 1H), 6.95 (s, 1H), 4.44 - 4.38 (m, 1H), 4.18 (s, 2H), 4.00 (s, 2H), 3.73 (s, 3H), 3.32 - 3.25 (m, 2H), 3.10 - 2.71 (m, 7H), 2.57 - 2.46 (m, 8H), 2.31 - 2.09 (m, 8H), 1.73 (s, 1H), 1.45 (s, 1H), 1.20 (m, 1H), 1.12 - 0.91 (m, 4H), 0.83 (s, 3H), 0.60 (s, 1H). [M+H] + =850.7
[0693] Example 273: (R,E)—N-(((S)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)-3,3-difluoropiperidin-4-yl)methyl)-N,1 1 ,2 6 ,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0694] The title compound was prepared in a similar manner to Example 260. 1 H NMR (500 MHz, DMSO) δ 12.86 (s, 1H), 10.93 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.67 (s, 1H), 7.57 - 7.56 (m, 2H), 7.25 (s, 1H), 7.04 - 6.97 (m, 2H), 4.40 - 4.31 (m, 1H), 4.21 - 4.19 (m, 2H), 4.04 - 4.00 (m, 2H), 3.73 (s, 3H), 3.59 - 3.50 (m, 1H), 3.03 - 2.91 (m, 4H), 2.85 - 2.73 (m, 5H), 2.69 - 2.59 (m, 5H), 2.56 (s, 3H), 2.43 - 2.34 (m, 1H), 2.24 - 2.06 (m, 4H), 2.03 - 1.82 (m, 4H), 1.55 - 1.40 (m, 1H), 0.81 (d, J = 5.0 Hz, 3H);[M+H] + = 872.7.
[0695] Example 274: (R,E)—N-(((R)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)-3,3-difluoropiperidin-4-yl)methyl)-N,1 1 ,2 6 ,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0696] The title compound was prepared in a similar manner to Example 260. 1 H NMR (500 MHz, DMSO) δ 12.86 (s, 1H), 10.94 (s, 1H), 8.43 (s, 1H), 7.93 (s, 1H), 7.68 (s, 1H), 7.57 (d, J = 8.0 Hz, 2H), 7.25 (s, 1H), 7.01 - 6.99 (d,2H), 4.36 - 4.33 (m,1H), 4.18 - 4.16 (m,2H), 4.01 - 3.99 (m,2H), 3.73 (s, 4H), 3.53 - 3.50 (m, 1H), 3.20 (s, 1H), 3.05 - 2.90 (m, 4H), 2.87 - 2.72 (m, 4H), 2.65 - 2.63 (m, 2H), 2.55 - 2.53 (m, 4H), 2.43 - 2.30 (m, 1H), 2.29 - 1.79 (m, 8H), 1.54 - 1.40 (m, 2H), 0.81 (d, J = 6.4 Hz, 3H);[M+H] + =872.7.
[0697] Example 275: (R,E)—N-(2-(1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)piperidin-4-yl)-2,2-difluoroethyl)-N,1 1 ,2 6 ,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0698] The title compound was prepared in a similar manner to Example 260. 1 H NMR (500 MHz, DMSO) δ 12.88 (s, 1H), 10.93 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.68 (s, 1H), 7.59 - 7.57 (m, 2H), 7.29 (s, 1H), 7.00 - 6.95 (m, 2H), 4.39 - 4.32 (m, 1H), 4.21 - 4.18 (m, 2H), 4.05 - 4.00 (m, 4H), 3.73 (s, 3H), 3.14 - 3.00 (m, 5H), 2.79 - 2.64 (m, 7H), 2.56 (s, 3H), 2.25 - 2.15 (m, 2H), 2.14 - 2.06 (m, 2H), 1.98 - 1.91 (m, 7H), 1.49 - 1.42 (m, 2H), 0.81 (d, J = 5.5 Hz, 3H);[M+H] + = 886.7.
[0699] Example 276: (R,E)—N-(((S)-1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)piperidin-3-yl)methyl)-N,1 1 ,26 ,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0700] The title compound was prepared in a similar manner to Example 260. 1 H NMR (500 MHz, DMSO) δ 12.83 (s, 1H), 10.94 (s, 1H), 7.92 (s, 1H), 7.68 (s, 1H), 7.57 (s, 1H), 7.55 (s, 1H), 7.24 (s, 1H), 7.01 (s, 2H), 6.53 (s, 1H), 4.35 (s, 1H), 4.19 (d, J = 11.8 Hz, 2H), 4.03 - 4.00 (m, 2H), 3.73 (s, 3H), 2.95 (s, 3H), 2.87 - 2.62 (m, 7H), 2.56 (s, 3H), 2.15 - 2.12 (m, 4H), 2.04 - 1.94 (m, 4H), 1.90 (s, 3H), 1.77 (s, 3H), 1.45 - 1.42 (m, 2H), 1.28 - 1.14 (m, 1H), 0.79 (d, J = 6.4 Hz, 3H);[M+H] + =836.7.
[0701] Example 278: (R,E)—N-(4-((4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenethyl)(methyl)amino)cyclohexyl)-N,1 1 ,2 6 ,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0702] The title compound was prepared in a similar manner to Example 260. 1 H NMR (500 MHz, DMSO) δ 12.84 (s, 1H), 10.93 (s, 1H), 8.43 (s, 1H), 7.93 (s, 1H), 7.63 (s, 1H), 7.57 (d, J = 5.9 Hz, 2H), 7.21 (s, 1H), 7.01 (d, J = 12.0 Hz, 1H), 6.96 (s, 1H), 4.35 (d, J = 4.4 Hz, 1H), 4.19 (d, J = 11.4 Hz, 2H), 4.07 - 3.94 (m, 2H), 3.73 (s, 3H), 2.96 - 2.61 (m, 8H), 2.56 (s, 6H), 2.42 - 2.05 (m, 6H), 2.04 - 1.87 (m, 3H), 1.77 (s, 2H), 1.64 (s, 4H), 1.44 (d, J = 5.2 Hz, 2H), 0.96 (s, 1H), 0.82 (d, J = 5.5Hz, 3H). [M+H] + =850.7
[0703] Example 279: (R,E)—N-(2-(1-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)piperidin-4-yl)ethyl)-N,1 1 ,2 6 ,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-56 -Carboxamide [ka]
[0704] The title compound was prepared in a similar manner to Example 260. 1 H NMR (500 MHz, DMSO) δ 12.86 (s, 1H), 10.85 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.68 (s, 1H), 7.58 - 7.56 (m, 2H), 7.26 (s, 1H), 6.62 - 6.54 (m, 2H), 4.40 - 4.32 (m, 1H), 4.21 - 4.15 (m, 1H), 4.05 - 4.00 (m, 3H), 3.73 (s, 3H), 3.64 - 3.49 (m, 3H), 3.05 - 2.91 (m, 4H), 2.87 - 2.72 (m, 5H), 2.56 (s, 3H), 2.26 - 2.16 (m, 1H), 2.10 - 1.81 (m, 5H), 1.61 - 1.36 (m, 5H), 1.29 - 1.20 (m, 2H), 0.82 (d, J = 6.0 Hz, 3H);[M+H] + = 822.8.
[0705] Example 280: (R,E)—N-(2-(4-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)piperazin-1-yl)ethyl)-N,1 1 ,2 6 ,7-Tetramethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0706] The title compound was prepared in a similar manner to Example 260. 1 H NMR (500 MHz, DMSO) δ 12.85 (s, 1H), 10.86 (s, 1H), 8.42 (s, 1H), 7.92 (s, 1H), 7.67 (s, 1H), 7.57 (s, 1H), 7.56 (d, J = 8.0 Hz, 1H), 7.27 (d, J = 8.0 Hz, 1H), 6.63 (d, J = 11.5 Hz, 2H), 4.39 - 4.31 (m, 1H), 4.21 - 4.15 (m, 1H), 4.05 - 3.95 (m, 3H), 3.73 (s, 3H), 3.24 - 3.15 (m, 2H), 3.12 - 3.07 (m, 2H), 3.05 - 3.03 (m, 3H), 2.85 - 2.71 (m, 3H), 2.67 - 2.56 (m, 4H), 2.34 - 2.17 (m, 3H), 2.13 - 1.89 (m, 5H), 1.49 - 1.39 (m, 1H), 1.28 - 1.23 (m, 4H), 0.80 (d, J = 5.0 Hz, 3H);[M+H] + = 823.7.
[0707] Example 281: (R,E)—N-(2-(4-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)piperazin-1-yl)ethyl)-N-ethyl-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0708] The title compound was prepared in a similar manner to Example 260. 1 H NMR (500 MHz, DMSO) δ 12.85 (s, 1H), 10.86 (s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.65 (s, 1H), 7.58 (s, 1H), 7.57 (d, J = 8.0 Hz, 1H), 7.23 (d, J = 8.0 Hz, 1H), 6.63 (s, 2H), 4.39 - 4.32 (m, 1H), 4.20 - 4.17 (m, 1H), 4.06 - 3.95 (m, 3H), 3.73 (s, 3H), 3.58 - 3.44 (m, 4H), 3.24 - 3.03 (m, 6H), 2.84 - 2.72 (m, 3H), 2.56 (s, 3H), 2.32 - 2.18 (m, 3H), 2.14 - 2.03 (m, 1H), 1.99 - 1.88 (m, 3H), 1.48 - 1.39 (m, 1H), 1.23 - 1.04 (m, 5H), 0.81 (d, J = 5.5 Hz, 3H);[M+H] + = 837.9.
[0709] Example 282: (R,E)—N-(2-(4-(4-((R)-2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)piperazin-1-yl)ethyl)-N-isopropyl-1 1 ,2 6 ,7-trimethyl-3-oxo-5 2 ,5 3 -dihydro-1 1 H,5 1 H-11-Oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-5 6 -Carboxamide [ka]
[0710] The title compound was prepared in a similar manner to Example 260.1 H ...
Claims
1. A compound of formula (I), 【Chemistry 1】 or an N-oxide thereof, or a pharma- ceutically acceptable salt thereof, or a stereoisomer thereof, or a deuterated analogue thereof, or a prodrug thereof; During the ceremony, R 3 and R 4 are each independently absent, hydrogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl or -C 3-8 is cycloalkyl; 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl or -C 3-8 Each cycloalkyl is selected from hydrogen, halogen, -C 1-8 Alkoxy, -C 3-8 optionally substituted with at least one substituent selected from cycloalkyl or -CN; R 1a , R 1b , R 1c , R 1d , R 5a , R 5b , R 6a , R 6b , R 7a , R 7b , R 2 , R 8 , R 9 and R 10 are each independently absent, hydrogen, halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 Alkoxy, -C 3-8 cycloalkyl or -CN, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 Alkoxy, or -C 3-8 Each cycloalkyl is selected from hydrogen, halogen, -C 1-8 Alkoxy, -C 3-8 optionally substituted with at least one substituent selected from cycloalkyl or -CN; 【Chemistry 2】 is optionally O or NR a may be substituted with; R 1a , R 1b , R 1c , R 1d , R 5a , R 5b , R 6a , R 6b , R 7a and R 7b two pairs or adjacent substituents from are taken together with the carbon atoms to which they are attached to form a 3-12 membered ring, said ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring containing at least one substituent, halogen, hydroxy, or -C 1 ~C 8 optionally substituted with alkyl; R 11a , R 11b , R 11c , R 11d , R 12a , R 12b , R 12c and R 12d are each independently absent, oxo, hydrogen, halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 Alkoxy or -C 3-8 cycloalkyl; 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 Alkoxy or -C 3-8 Each cycloalkyl is selected from hydrogen, halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 optionally substituted with at least one substituent selected from alkoxy or -CN; or R 11a and R 12a form a 3- to 12-membered ring together with the carbon atom to which they are attached, said ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; said ring is free of hydrogen, halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 optionally substituted with at least one substituent selected from alkoxy or -CN; R 11b and R 12b form a 3- to 12-membered ring together with the carbon atom to which they are attached, said ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; said ring is free of hydrogen, halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 optionally substituted with at least one substituent selected from alkoxy or -CN; R 11c and R 12c form a 3- to 12-membered ring together with the carbon atom to which they are attached, said ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; said ring is free of hydrogen, halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 optionally substituted with at least one substituent selected from alkoxy or -CN; R 11d and R 12d form a 3- to 12-membered ring together with the carbon atom to which they are attached, said ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; said ring is free of hydrogen, halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 optionally substituted with at least one substituent selected from alkoxy or -CN; L 1 は、-O-、-NR a -、-C(O)-、* L1 -C(O)NR a -** L1 、* L1 -C(O)O-** L1 、* L1 -NR a C(O)-** L1 、* L1 -OC (O) -** L1、 【Chemistry 3】 are independently selected from 【Chemistry 4】 Each of the groups is selected from at least one R L1c and optionally replaced by: In the formula, * L1 The part 【Chemistry 5】 and ** L1 The part 【Chemistry 6】 refers to the position where the L 2 は、-O-、-NR a -、-C(O)-、* L2 -C(O)NR a -** L2 、* L2 -C(O)O-** L2 、* L2 -NR a C(O)-** L2 、* L2 -OC (O) -** L2 、 【Chemistry 7】 are independently selected from 【Chemistry 8】 Each of the groups is selected from at least one R L2c and optionally replaced by: During the ceremony, * L2 The part 【Chemistry 9】 and ** L2 The part 【Chemistry 10】 refers to the position where the L 3 は、-O-、-NR a -、-C(O)-、* L3 -C(O)NR a -** L3 、* L3 -C(O)O-** L3 、* L3 -NR a C(O)-** L3 、* L3 -OC (O) -** L3 、 【Chemistry 11】 are independently selected from 【Chemistry 12】 Each of the groups is selected from at least one R L3c and optionally replaced by: During the ceremony, * L3 The part 【Chemistry 13】 ** L3 The part 【Chemistry 14】 refers to the position where the In the formula, R L1c , R L2c and R L3c Each of is independently absent, oxo (=O), halogen, hydroxy, -CN, -C 1 -C 8 Alkyl, -C 1 -C 8 Alkoxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 Alkynyl, C 3 -C 8 Cycloalkyl, 3-8 membered heterocyclyl, C 6 -C 12 aryl or 5-12 membered heteroaryl; 1 -C 8 Alkyl, -C 1 -C 8 Alkoxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 Alkynyl, C 3 -C 8 Cycloalkyl, 3-8 membered heterocyclyl, C 6 -C 12 Each of the aryl and 5- to 12-membered heteroaryl has at least one substituent R Lca optionally replaced by R Lca are independently absent, oxo (=O), halogen, hydroxy, -CN, -C 1 -C 8 Alkyl, -C 1 -C 8 Alkoxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 Alkynyl, C 3 -C 8 Cycloalkyl, 3-8 membered heterocyclyl, C 6 ~C 12 aryl or 5-12 membered heteroaryl; Two R's L1c are taken together with the atoms to which they are attached to form a 3- to 12-membered ring, said ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring contains at least one substituent halogen, hydroxy, -C 1 ~C 8 optionally substituted with alkyl; Two R's L2c are taken together with the atoms to which they are attached to form a 3- to 12-membered ring, said ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring contains at least one substituent halogen, hydroxy, -C 1 ~C 8 optionally substituted with alkyl; Two R's L3c are taken together with the atoms to which they are attached to form a 3- to 12-membered ring, said ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring contains at least one substituent halogen, hydroxy, -C 1 ~C 8 optionally substituted with alkyl; 【Chemistry 15】 teeth, 【Chemistry 16】 Selected from: Z 1 , Z 2 , and Z 3 each independently represents N or CR z However, Z 1 , Z 2 , and Z 3 is not N at the same time; R z is absent, hydrogen, halogen, -C 1-8 Alkyl, -NR Za R Zb , -OR Za , -SR Za , C 3 -C 8 independently selected from cycloalkyl, 3- to 8-membered heterocyclyl, or CN; 1-8 Alkyl, C 3 -C 8 Each of the cycloalkyl and 3- to 8-membered heterocyclyl is selected from at least one R Zc optionally substituted with; The part 【Chemistry 17】 Is, Z 1 , Z 2 Or Z 3 via any one of the above 【Chemistry 18】 Connected to CR z and R z is absent; R Za and R Zb are each independently absent, hydrogen, -C 1 -C 8 Alkyl, C 3 -C 8 Cycloalkyl, 3-8 membered heterocyclyl, C 6 -C 12 aryl, or 5- to 12-membered heteroaryl; 1~8 Alkyl, C 3 ~C 8 Cycloalkyl, 3-8 membered heterocyclyl, C 6 ~C 12 Each of the aryl, or 5- to 12-membered heteroaryl, is preferably a 5- to 12-membered heteroaryl. Zd optionally substituted with; R Zc and R Zd are each independently a halogen, a hydroxyl, or 1 ~C 8 Alkyl, -C 1~8 Alkoxy, C 3 ~C 8 Cycloalkyl, 3-8 membered heterocyclyl, C 6 ~C 12 aryl, or 5-12 membered heteroaryl; R 13 and R 14 are each absent, hydrogen, halogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Alkynyl, -C 1~8 Alkoxy, -C 3 ~C 8 Cycloalkyl, 3- to 8-membered heterocyclyl, -C 6 -C 12 Aryl, 5- to 12-membered heteroaryl, -CN, -SO 2 R 13a , -SO 2 N.R. 13a R 13b , -COR 13a , -CO 2 R 13a , -CONR 13a R 13b , -NR 13a R 13b , -NR 13a C.O.R. 13b , -NR 13a CO 2 R 13b or -NR 13a SO 2 R 13b -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 Alkoxy, -C 3 -C 8 Cycloalkyl, 3- to 8-membered heterocyclyl, -C 6 -C 12 Each of the aryl or 5- to 12-membered heteroaryl is selected from the group consisting of halogen, —C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 3 -C 8 Cycloalkyl, 3-8 membered heterocyclyl, C 6 -C 12 Aryl, 5- to 12-membered heteroaryl, oxo, -CN, -OR 13c , -SO 2 R 13c , -SO 2 N.R. 13c R 13d , -COR 13c , -CO 2 R 13c , -CONR 13c R 13d , -NR 13c R 13d , -NR 13c C.O.R. 13d , -NR 13c CO 2 R 13d or -NR 13c SO 2 R 13d optionally substituted with; In each occurrence, R 13a , R 13b , R 13c and R 13d are each independently absent, hydrogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C 3 -C 8 Cycloalkyl, 3-8 membered heterocyclyl, C 6 -C 12 aryl, or 5-12 membered heteroaryl; L 4 , L 5 and L 6 are each independently absent, a single bond, —O—, or —NR a -, - (CR a R b ) n8 -, -O(CR a R b ) n8 --, --NR a (CR a R b ) n8 - or -C(O)-; In each occurrence, X 1 , X 2 and X 7 Each independently represents -CR a or N; In each occurrence, X 3 , X 4 and X 8 Each independently represents -NR a -, -O-, -S- and -CR a R b - selected from; In each occurrence, X 5 and X 6 are each independently absent, a single bond, —C(O)—, or —NR a - and -O-; In each occurrence, R a and R b are each independently hydrogen, hydroxy, halogen, CN, -C 1 -C 8 Alkyl, -C 1 -C 8 Alkoxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 Alkynyl, -C 3 -C 8 Cycloalkyl, 3- to 8-membered heterocyclyl, -C 6 -C 12 aryl or 5- to 12-membered heteroaryl; 1 -C 8 Alkyl, -C 1 -C 8 Alkoxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 Alkynyl, -C 3 -C 8 Cycloalkyl, 3- to 8-membered heterocyclyl, -C 6 -C 12 Each of the aryl or 5- to 12-membered heteroaryl has at least one substituent, halogen, hydroxy, halogen, -C 1 -C 8 Alkyl, -C 1 -C 8 Alkoxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 Alkynyl, -C 3 -C 8 Cycloalkyl, 3- to 8-membered heterocyclyl, -C 6 -C 12 optionally substituted with aryl or 5-12 membered heteroaryl; or R a and R b are taken together with the carbon atom to which they are attached to form a 3- to 12-membered ring, said ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; said ring contains at least one substituent, halogen, hydroxy, -C 1 ~C 8 Alkyl, -C 2 ~C 8 Alkenyl, -C 2 ~C 8 Alkynyl, -C 1 ~C 8 Alkoxy, -C 2 ~C 8 Alkenyl, -C 2 ~C 8 Alkynyl, C 3 ~C 8 Cycloalkyl, 3-8 membered heterocyclyl, C 6 ~C 12 optionally substituted with aryl or 5-12 membered heteroaryl; m1, m2, m3, and m4 are each independently 0, 1, or 2; provided that m1 + m2 + m3 + m4 ≦ 4; m5, m6, and m7 each independently represent 0 or 1; provided that m5 + m6 + m7 ≧ 1; n1, n2, n3, n4, and n5 are each independently 0, 1, 2, or 3; n6, n7 and n8 are each independently 0, 1, 2, 3 or 4; however, L 1 , L 2 Or L 3 For any one of 1 If N, then X 5 is a single bond, absent, —C(O)—; and / or X 2 If N, then X 6 is a single bond, absent, or -C(O)-; L 1 but 【Chemistry 19】 If X 1 If N, then X 5 is a single bond, is absent, or is —C(O)—, and / or X 3 is -CR a R b - and X 2 If N, then X 6 is a single bond, is absent, or is —C(O)—, and / or X 4 is -CR a R b - and L 2 but 【Chemistry 20】 If X 1 If N, then X 5 is a single bond, is absent, or is —C(O)—, and / or X 3 is -CR a R b - and X 2 If N, then X 6 is a single bond, is absent, or is —C(O)—, and / or X 4 is -CR a R b - and L 3 but 【Chemistry 21】 If X 1 If N, then X 5 is a single bond, is absent, or is —C(O)—, and / or X 3 is -CR a R b - and X 2 If N, then X 6 is a single bond, is absent, or is —C(O)—, and / or X 4 is -CR a R b -
2. 2. The compound according to claim 1, wherein the compound is selected from formula (II): 【Chemical Formula 22】 Here, R 1a , R 1b , R 1c , R 1d , R 2 , R 3 , R 4 , R 5a , R 5b , R 6a , R 6b , R 7a , R 7b , R 8 , R 9 , R 10 , R 11a , R 11b , R 11c , R 11d , R 12a , R 12b , R 12c , R 12d , R 13 , R 14 , L 1 , L 2 , L 3 , L 4 , Z 1 , Z 2 , Z 3 , X 7 , X 8 , m1, m2, m3, m4, m5, m6, m7 and n6 are defined as in claim 1.
3. A compound according to any one of the preceding claims, wherein the compound is selected from formula (III): 【Chemistry 23】 Here, R 1a , R 1b , R 1c , R 1d , R 2 , R 3 , R 4 , R 5a , R 5b , R 6a , R 6b , R 7a , R 7b , R 8 , R 9 , R 10 , R 11a , R 11b , R 11c , R 11d , R 12a , R 12b , R 12c , R 12d , R 13 , L 1 , L 2 , L 3 , L 5 , L 6 , X 8 , m1, m2, m3, m4, m5, m6, m7, n6 and n7 are as defined in any one of the preceding claims.
4. 10. A compound according to any one of the preceding claims, wherein the compound is selected from formula (IV): 【Chemistry 24】 Here, R 1a , R 1b , R 1c , R 1d , R 2 , R 3 , R 4 , R 5a , R 5b , R 6a , R 6b , R 7a , R 7b , R 8 , R 9 , R 10 , R 11a , R 11b , R 11c , R 11d , R 12a , R 12b , R 12c , R 12d , R 13 , L 1 , L 2 , L 3 , L 5 , L 6 , X 8 , m1, m2, m3, m4, m5, m6, m7, n6 and n7 are as defined in any one of the preceding claims.
5. 10. A compound according to any one of the preceding claims, wherein the compound is selected from formula (Va), (Vb), (Vc) or (Vd); 【Chemistry 25】 Here, R 1a , R 1b , R 1c , R 1d , R 2 , R 3 , R 4 , R 5a , R 5b , R 6a , R 6b , R 7a , R 7b , R 8 , R 9 , R 10 , R 11a , R 11b , R 11c , R 11d , R 12a , R 12b , R 12c , R 12d , R 13 , R 14 , L 1 , L 2 , L 3 , L 6 , Z 1 , Z 2 , Z 3 , m1, m2, m3, m4, m5, m6, m7 and n7 are as defined in any one of the preceding claims.
6. 10. A compound according to any one of the preceding claims, wherein the compound is selected from formula (VIa), (VIb), (VIc), (VId) or (VIe): 【Chemistry 26】 Here, R 1a , R 1b , R 1c , R 1d , R 2 , R 3 , R 4 , R 5a , R 5b , R 6a , R 6b , R 7a , R 7b , R 8 , R 9 , R 10 , R 11a , R 11b , R 11c , R 11d , R 12a , R 12b , R 12c , R 12d , R 13 , R 14 , L 1 , L 2 , L 3 , m1, m2, m3, m4, m5, m6, m7 and n7 are as defined in any one of the preceding claims.
7. 10. A compound according to any one of the preceding claims, wherein the compound is selected from formula (VIIa), (VIIb), (VIIc), (VIId) or (VIIe); 【Chemical 27】 Here, R 1a , R 1b , R 1c , R 1d , R 2 , R 3 , R 4 , R 5a , R 5b , R 6a , R 6b , R 7a , R 7b , R 8 , R 9 , R 10 , R 13 , R 14 , L 1 , L 2 , L 3 , m1, m2, m3, m4, m5, m6, m7 and n7 are as defined in any one of the preceding claims.
8. 10. A compound according to any one of the preceding claims, wherein the compound is selected from formula (VIIIa), (VIIIb), (VIIIc) or (VIIId): 【Chemistry 28】 Here, R 1a , R 1b , R 1c , R 1d , R 2 , R 3 , R 4 , R 5a , R 5b , R 6a , R 6b , R 7a , R 7b , R 8 , R 9 , R 10 , R 11b , R 11c , R 11d , R 12b , R 12c , R 12d , R 13 , R 14 , L 2 , L 3 , m2, m3, m4, m6, m7 and degron are as defined in any one of the preceding claims.
9. 2. A compound according to any one of the preceding claims, wherein m1+m2+m3+m4≦3.
10. 2. A compound according to any one of the preceding claims, wherein m1+m2+m3+m4=1, 2 or 3; preferably m1+m2+m3+m4=1 or 2.
11. A compound according to any one of the preceding claims, comprising the moiety 【Chemical 29】 -CH in 2 The compound according to the above, wherein the number of - is 4 or less, preferably 3 or less, and more preferably 2 or less.
12. A compound according to any one of the preceding claims, comprising R 3 and R 4 are each independently hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl; 2-8 Alkenyl, -C 2-8 The alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl is optionally substituted with at least one substituent selected from hydrogen, F, Cl, Br, I, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, or -CN.
13. A compound according to any one of the preceding claims, comprising R 3 and R 4 are each independently hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl, and preferably R 3 is independently methyl or cyclopropyl; R 4 is hydrogen.
14. A compound according to any one of the preceding claims, comprising R 1a , R 1b , R 1c , R 1d , R 5a , R 5b , R 6a , R 6b , R 7a , R 7b , R 2 , R 8 , R 9 and R 10 are each independently hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 alkynyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or -CN; 2-8 Alkenyl, -C 2-8 wherein each of alkynyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl is optionally substituted with at least one substituent selected from hydrogen, F, Cl, Br, I, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, or -CN.
15. A compound according to any one of the preceding claims, comprising R 1a , R 1b , R 1c , R 1d , R 5a , R 5b , R 6a , R 6b , R 7a , R 7b , R 2 , R 8 , R 9 and R 10 are each independently hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -CF 3 , -CHF 2 , -CN, -CH 2 OCH 3 , -CH 2 OCH 2 CH 3 , -CH 2 CH 2 OCH 3 -CH 2 CH 2 OCH 2 CH 3 and preferably, R 1a , R 1b , R 1c , R 1d , R 5a , R 5b , R 6a , R 6b , R 7a , R 7b , R 2 , R 8 , R 9 and R 10 are each independently hydrogen, F, Cl, methyl, methoxy, cyclopropyl, -CF 3 or -CHF 2 , -CH 2 OCH 3 and more preferably, R 2 is hydrogen, methyl, methoxy, cyclopropyl or -CF 3 and R 8 is hydrogen, F, methyl, -CF 3 or -CHF 2 and R 9 is hydrogen or F; R 10 is hydrogen, F, Cl, methyl or -CH 2 OCH 3 and R 1a , R 1b , R 1c , R 1d , R 5a , R 5b , R 6a , R 6b , R 7a and R 7b are each independently hydrogen, F or methyl.
16. 2. A compound according to any one of the preceding claims, comprising (R 1a and R 1b ), (R 1c and R 1d ), (R 5a and R 5b ), (R 6a and R 6b ), (R 7a and R 7b ), (R 1a and R 1c ), (R 1a and R 1d ), (R 1b and R 1c ), (R 1b and R 1d ), (R 1a and R 5a ), (R 1a and R 5b ), (R 1b and R 5a ), (R 1b and R 5b ), (R 5a and R 6a ), (R 5a and R 6b ), (R 5b and R 6a ), (R 5b and R 6b ), (R 6a and R 7a ), (R 6a and R 7b ), (R 6b and R 7a ) or (R 6b and R 7b ), together with the carbon atom to which they are attached, form a 3-, 4-, 5-, 6-, 7-, or 8-membered ring, said ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, said ring being optionally substituted with at least one substituent F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl.
17. A compound according to any one of the preceding claims, wherein the moiety 【Chemistry 30】 but, 【Chemistry 31-1】 【Chemistry 31-2】 The compound is selected from the group consisting of
18. A compound according to any one of the preceding claims, comprising R 11a , R 11b , R 11c , R 11d , R 12a , R 12b , R 12c and R 12d are each independently hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 alkynyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; 2-8 Alkenyl, -C 2-8 Each of alkynyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl is hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 optionally substituted with at least one substituent selected from alkynyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, or -CN; or (R 11a and R 12a ), (R 11b and R 12b ), (R 11c and R 12c ) or (R 11d and R 12d ) taken together with the carbon atom to which they are attached form a 3-, 4-, 5-, 6-, 7-, or 8-membered ring, said ring containing 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; said ring is selected from hydrogen, halogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 The compound is optionally substituted with at least one substituent selected from alkynyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, or -CN.
19. A compound according to any one of the preceding claims, comprising R 11a , R 11b , R 11c , R 11d , R 12a , R 12b , R 12c and R 12d are each independently hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably, R 11a , R 11b , R 11c , R 11d , R 12a , R 12b , R 12c and R 12d are each independently hydrogen, F, Cl, Br, I, methyl, ethyl or propyl; more preferably, R 11a , R 11b , R 11c , R 11d , R 12a , R 12b , R 12c and R 12d are each independently hydrogen or methyl; or (R 11a and R 12a ), (R 11b and R 12b ), (R 11c and R 12c ) or (R 11d and R 12d ) taken together with the carbon atom to which they are attached form a 3-, 4-, 5-, 6-, 7-, or 8-membered ring, said ring containing 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; preferably, (R 11a and R 12a ), (R 11b and R 12b ), (R 11 c and R 12c ) or (R 11d and R 12d ) taken together with the carbon atom to which they are attached form a 3-, 4- or 5-membered cycloalkyl ring.
20. A compound according to any one of the preceding claims, comprising L 1 is -O-, -C(O)-, -N(R a ) -, *L1 -C(O)N(R a ) - **L1 , *L1 -C(O)O- **L1 , *L1 -N(R a ) C(O)- **L1 , *L1 -OC(O)- **L1、 【Hua 32-1】 【Hua 32-2】 Selected from: Here, 【Chemistry 33-1】 【Chemistry 33-2】 Each of the groups is selected from at least one R L1c optionally replaced by The R L1c each independently represents oxo (=O), F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl; said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 Each of alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, and 5- to 12-membered heteroaryl is selected from the group consisting of at least one R Lca optionally replaced by R Lca are independently oxo (=O), F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl; or Two R's L1c form, together with the carbon atom to which they are attached, a 3-, 4-, 5-, 6-, 7-, or 8-membered ring, said ring containing 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; said ring is optionally substituted with at least one substituent F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl; R a is hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl; and the methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 Each of alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl may have at least one substituent, halogen, hydroxy, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 The compound is optionally substituted with alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl.
21. A compound according to any one of the preceding claims, comprising L 1 is -O-, -N(CH 3 )-, -C(O)-, -NH-, *L1 -C(O)N(CH 3 ) - **L1 , *L1 -C(O)NH- **L1 , *L1 -C(O)O- **L1 , *L1 -C(O)N(C 2 H 5 ) - **L1 , *L1 -C(O)N(C 3 H 7 ) - **L1 , *L1 -N(CH 3 ) C(O)- **L1 , *L1 -NHC(O)- **L1 , *L1 -OC(O)- **L1 , *L1 -N(C 2 H 5 ) C(O)- **L1 , *L1 -N(C 3 H 7 ) C(O)- **L1、 【Chemistry 34-1】 【Chemistry 34-2】 【Chemistry 34-3】 【Chemistry 34-4】 【Chemistry 34-5】 【Chemistry 34-6】 【Chemistry 34-7】 【Chemistry 34-8】 The compound is selected from the group consisting of
22. A compound according to any one of the preceding claims, comprising L 2 is -O-, -C(O)-, -N(R a ) -, *L2 -C(O)N(R a ) - **L2 , *L2 -C(O)O- **L2 , *L2 -N(R a ) C(O)- **L2 , *L2 -OC(O)- **L2、 【Chemistry 35-1】 【Chemistry 35-2】 Selected from: Here, 【Hua 36-1】 【Chemistry 36-2】 Each of the groups is selected from at least one R L2c optionally replaced by R L2c each independently represents oxo (=O), F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl; said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 Each of alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, and 5- to 12-membered heteroaryl is selected from the group consisting of at least one R Lca optionally replaced by R Lca are independently oxo (=O), F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl; or Two R's L2c form together with the carbon atoms to which they are attached a 3-, 4-, 5-, 6-, 7-, or 8-membered ring, said ring containing 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; said ring is optionally substituted with at least one substituent F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl; R a is hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl; and the methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 Each of alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl may have at least one substituent, halogen, hydroxy, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 The compound is optionally substituted with alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl.
23. A compound according to any one of the preceding claims, comprising L 2 is -O-, -N(CH 3 )-, -C(O)-, -NH-, *L2 -C(O)N(CH 3 ) - **L2 , *L2 -C(O)NH- **L2 , *L2 -C(O)O- **L2 , *L2 -C(O)N(C 2 H 5 ) - **L2 , *L2 -C(O)N(C 3 H 7 ) - **L2 , *L2 -N(CH 3 ) C(O)- **L2 , *L2 -NHC(O)- **L2 , *L2 -OC(O)- **L2 , *L2 -N(C 2 H 5 ) C(O)- **L2 , *L2 -N(C 3 H 7 ) C(O)- **L2、 【Hua 37-1】 【Hua 37-2】 【Hua 37-3】 【Chemistry 37-4】 【Chemistry 37-5】 【Chemistry 37-6】 【Chemistry 37-7】 The compound is selected from the group consisting of
24. A compound according to any one of the preceding claims, comprising L 3 is -O-, -N(R a )-, -C(O)-, *L3 -C(O)N(R a ) - **L3 , *L3 -C(O)O- **L3 , *L3 -N(R a ) C(O)- **L3 , *L3 -OC(O)- **L3 , 【Hua 38-1】 【Chemistry 38-2】 Selected from: Here, 【Chemistry 39-1】 【Chemistry 39-2】 Each of the groups is selected from at least one R L3c optionally substituted with; The R L3c each independently represents oxo (=O), F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl; said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 Each of alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, and 5- to 12-membered heteroaryl is selected from the group consisting of at least one R Lca optionally replaced by R Lca are independently oxo (=O), F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl; or Two R's L3c form together with the carbon atoms to which they are attached a 3-, 4-, 5-, 6-, 7-, or 8-membered ring, said ring containing 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; said ring is optionally substituted with at least one substituent F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl; R a is hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl; and the methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 Each of alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl may have at least one substituent, halogen, hydroxy, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 The compound is optionally substituted with alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl.
25. A compound according to any one of the preceding claims, comprising L 3 is -O-, -N(CH 3 )-, -C(O)-, -NH-, *L3 -C(O)N(CH 3 ) - **L3 , *L3 -C(O)NH- **L3 , *L3 -C(O)O- **L3 , *L3 -C(O)N(C 2 H 5 ) - **L3 , *L3 -C(O)N(C 3 H 7 ) - **L3 , *L3 -N(CH 3 ) C(O)- **L3 , *L3 -NHC(O)- **L3 , *L3 -OC(O)- **L3 , *L3 -N(C 2 H 5 ) C(O)- **L3 , *L3 -N(C 3 H 7 ) C(O)- **L3 , 【Chemistry 40-1】 【Chemistry 40-2】 【Chemistry 40-3】 【Chemistry 40-4】 【Chemistry 40-5】 【Chemistry 40-6】 【Chemistry 40-7】 【Chemistry 40-8】 The compound is selected from the group consisting of
26. A compound according to any one of the preceding claims, wherein the moiety 【Chemistry 41】 but, 【Chemistry 42-1】 【Chemistry 42-2】 【Chemistry 42-3】 【Chemistry 42-4】 【Chemistry 42-5】 【Chemistry 42-6】 【Chemistry 42-7】 【Chemistry 42-8】 【Chemistry 42-9】 【Chemistry 42-10】 【Chemistry 42-11】 The compound is selected from the group consisting of
27. A compound according to any one of the preceding claims, comprising L 4 is a single bond, -O-, -NR a -, - (CR a R b ) n8 -, -O(CR a R b ) n8 --, --NR a (CR a R b ) n8 - or -C(O)-; In each occurrence, R a and R b are each independently hydrogen, hydroxy, -F, -Cl, -Br, -I, -CN, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl or 5- to 12-membered heteroaryl, and wherein said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 Each of alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl or 5- to 12-membered heteroaryl may have at least one substituent halogen, hydroxy, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 The compound is optionally substituted with alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3-8 membered heterocyclyl, phenyl, or 5-12 membered heteroaryl.
28. A compound according to any one of the preceding claims, comprising L 4 are independently selected from a single bond.
29. A compound according to any one of the preceding claims, comprising X 7 is independently -CR a or N; R a are independently hydrogen, hydroxy, -F, -Cl, -Br, -I, -CN, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl or 5- to 12-membered heteroaryl, and wherein said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 Each of alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl or 5- to 12-membered heteroaryl may have at least one substituent halogen, hydroxy, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 The compound is optionally substituted with alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3-8 membered heterocyclyl, phenyl, or 5-12 membered heteroaryl.
30. A compound according to any one of the preceding claims, comprising X 7 is -CH, -C(CH 3 ), or N; preferably, X 7 is independently selected from -CH.
31. A compound according to any one of the preceding claims, comprising X 8 is independently -NR a -, -O-, -S- and -CR a R b - selected from; In each occurrence, R a and R b are each independently hydrogen, hydroxy, -F, -Cl, -Br, -I, -CN, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl or 5- to 12-membered heteroaryl, and wherein said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 Each of alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl or 5- to 12-membered heteroaryl may have at least one substituent halogen, hydroxy, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 The compound is optionally substituted with alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3-8 membered heterocyclyl, phenyl, or 5-12 membered heteroaryl.
32. A compound according to any one of the preceding claims, wherein X 8 are independently -NH- and -CH 2 -; preferably, X 8 are independently -CH 2 - The compound selected from the group consisting of
33. A compound according to any one of the preceding claims, 【Chemistry 43】 teeth, 【Chemistry 44】 is selected from; preferably 【Chemistry 45】 teeth, 【Chemistry 46】 The compound is selected from the group consisting of
34. A compound according to any one of the preceding claims, comprising Z 1 , Z 2 and Z 3 wherein at most one of the groups is N.
35. A compound according to any one of the preceding claims, comprising Z 1 , Z 2 and Z 3 However, each of them is independently z A compound which is
36. A compound according to any one of the preceding claims, comprising R Z is, in each occurrence, hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -NR Za R Zb , -OR Za , -SR Za , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, or CN; each of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl is independently selected from at least one R Zc optionally substituted with; R Za and R Zb are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl, each of which is selected from at least one substituent R Zd optionally substituted with; R Zc and R Zd are each independently -F, -Cl, -Br, -I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl.
37. A compound according to any one of the preceding claims, comprising R z is H, -CH 3 , -C 2 H 5 , F, -CH 2 F, -CHF 2 , -CF 3 , -OCH 3 , -OC 2 H 5 , -C 3 H 7 , -OCH 2 F, -OCHF 2 , -OCH 2 CF 3 , -OCF 3 , -SCF 3 , -CF 3 or -CH(OH)CH 3 The compound is selected from the group consisting of
38. A compound according to any one of the preceding claims, comprising R 13 and R 14 are each independently hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 2-8 Alkenyl, -C 2-8 alkynyl, 3- to 8-membered heterocyclyl, -C 6 ~C 12 Aryl, 5- to 12-membered heteroaryl, -CN, -SO 2 R 13a , -SO 2 N.R. 13a R 13b , -COR 13a , -CO 2 R 13a , -CONR 13a R 13b , -NR 13a R 13b , -NR 13a C.O.R. 13b , -NR 13a CO 2 R 13b or -NR 13a SO 2 R 13b methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 2-8 Alkenyl, -C 2-8 alkynyl, 3- to 8-membered heterocyclyl, -C 6 ~C 12 Each of aryl and 5- to 12-membered heteroaryl is F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 2-8 Alkenyl, -C 2-8 alkynyl, 3- to 8-membered heterocyclyl, -C 6 -C 12 Aryl, 5- to 12-membered heteroaryl, oxo, -CN, -OR 13c , -SO 2 R 13c , -SO 2 N.R. 13c R 13d , -COR 13c , -CO 2 R 13c , -CONR 13c R 13d , -NR 13c R 13d , -NR 13c C.O.R. 13d , -NR 13c CO 2 R 13d or -NR 13c SO 2 R 13d optionally substituted with; R 13a , R 13b , R 13c and R 13d are each independently hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 2-8 Alkenyl, -C 2-8 alkynyl, 3- to 8-membered heterocyclyl, -C 6 -C 12 The compound is aryl, or 5- to 12-membered heteroaryl.
39. A compound according to any one of the preceding claims, comprising R 13 and R 14 are each independently hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -CN, -CH 2 F, -CHF 2 , -CF 3 , -OCH 2 F, -OCHF 2 , -OCH 2 CF 3 , -OCF 3 , -SCF 3 or phenyl.
40. A compound according to any one of the preceding claims, 【Chemistry 47】 but, 【Chemistry 48】 The compound,
41. A compound according to any one of the preceding claims, comprising L 5 and L 6 each independently represents a single bond, —O—, or —NR a -, - (CR a R b ) n8 -, -O(CR a R b ) n8 --, --NR a (CR a R b ) n8 - or -C(O)-; X 8 is -CR a R b - and In each occurrence, R a and R b are each independently hydrogen, hydroxy, -F, -Cl, -Br, -I, -CN, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl or 5- to 12-membered heteroaryl, and wherein said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 Alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl or 5- to 12-membered heteroaryl may contain at least one substituent halogen, hydroxy, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 The compound is optionally substituted with alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3-8 membered heterocyclyl, phenyl, or 5-12 membered heteroaryl.
42. A compound according to any one of the preceding claims, comprising L 5 and L 6 each independently represents a single bond, 【Chemistry 49】 -O-, -NH-, -NMe-, -N(CH 2 CH 3 ) -, -CH 2 -, -CHF-, -CF 2 -, -C(CH 3 ) 2 - or CO- (preferably L 5 is -CO- or -CH 2 - and L 6 teeth, 【Chemistry 50】 -O-, -NH-, -NMe-, -N(CH 2 CH 3 ) -, -CH 2 -, -CHF-, -CF 2 -, -C(CH 3 ) 2 - or -CO-; Here, X 8 is CH 2 and The compound, wherein n6 is 0 or 1.
43. A compound according to any one of the preceding claims, comprising R 13 are each independently hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 2-8 Alkenyl, -C 2-8 alkynyl, 3- to 8-membered heterocyclyl, -C 6 ~C 12 Aryl, 5- to 12-membered heteroaryl, -CN, -SO 2 R 13a , -SO 2 N.R. 13a R 13b , -COR 13a , -CO 2 R 13a , -CONR 13a R 13b , -NR 13a R 13b , -NR 13a C.O.R. 13b , -NR 13a CO 2 R 13b or -NR 13a SO 2 R 13b methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 2-8 Alkenyl, -C 2-8 alkynyl, 3- to 8-membered heterocyclyl, -C 6 ~C 12 Each of aryl and 5- to 12-membered heteroaryl is F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 2-8 Alkenyl, -C 2-8 alkynyl, 3- to 8-membered heterocyclyl, -C 6 -C 12 Aryl, 5- to 12-membered heteroaryl, oxo, -CN, -OR 13c , -SO 2 R 13c , -SO 2 N.R. 13c R 13d , -COR 13c , -CO 2 R 13c , -CONR 13c R 13d , -NR 13c R 13d , -NR 13c C.O.R. 13d , -NR 13c CO 2 R 13d or -NR 13c SO 2 R 13d optionally substituted with; In each occurrence, R 13a , R 13b , R 13c and R 13d are each independently hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 2-8 Alkenyl, -C 2-8 alkynyl, 3- to 8-membered heterocyclyl, -C 6 -C 12 The compound is aryl, or 5- to 12-membered heteroaryl.
44. A compound according to any one of the preceding claims, comprising R 13 is hydrogen, F, Cl, Br, I, CN, -C 1 -C 8 Alkyl, or -C 1 -C 8 alkoxy, preferably R 13 is hydrogen, F, Cl, Br, I, CN, -Me, -Et, -C 3 H 7 , -C 4 H 9 , -OMe, -OEt, -OC 3 H 7 Or -OC 4 H 9 are independently selected from Here, n 7 is 0, 1, or 2.
45. A compound according to any one of the preceding claims, 【Chemistry 51】 but, 【Chemistry 52】 The compound,
46. A compound according to any one of the preceding claims, comprising L 5 and L 6 each independently represents a single bond, —O—, or —NR a -, - (CR a R b ) n8 -, -O(CR a R b ) n8 --, --NR a (CR a R b ) n8 - or -C(O)-; X 8 is -CR a R b - and In each occurrence, R a and R b are each independently hydrogen, hydroxy, -F, -Cl, -Br, -I, -CN, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl or 5- to 12-membered heteroaryl, and wherein said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 Each of alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl or 5- to 12-membered heteroaryl may have at least one substituent halogen, hydroxy, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, -C 2 -C 8 Alkenyl, -C 2 -C 8 The compound is optionally substituted with alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3-8 membered heterocyclyl, phenyl, or 5-12 membered heteroaryl.
47. A compound according to any one of the preceding claims, comprising L 5 and L 6 each independently represents a single bond, 【Chemistry 53】 -O-, -NH-, -NMe-, -N(CH 2 CH 3 ) -, -CH 2 -, -CHF-, -CF 2 -, -C(CH 3 ) 2 - or -CO- (preferably L 5 and L 6 are each independently -CO- or -CH 2 - is Here, X 8 is CH 2 and The compound, wherein n6 is 0 or 1.
48. A compound according to any one of the preceding claims, comprising R 13 are each independently hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 2-8 Alkenyl, -C 2-8 alkynyl, 3- to 8-membered heterocyclyl, -C 6 ~C 12 Aryl, 5- to 12-membered heteroaryl, -CN, -SO 2 R 13a , -SO 2 N.R. 13a R 13b , -COR 13a , -CO 2 R 13a , -CONR 13a R 13b , -NR 13a R 13b , -NR 13a C.O.R. 13b , -NR 13a CO 2 R 13b or -NR 13a SO 2 R 13b methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 2-8 Alkenyl, -C 2-8 alkynyl, 3- to 8-membered heterocyclyl, -C 6 ~C 12 Each of aryl and 5- to 12-membered heteroaryl is F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 2-8 Alkenyl, -C 2-8 alkynyl, 3- to 8-membered heterocyclyl, -C 6 -C 12 Aryl, 5- to 12-membered heteroaryl, oxo, -CN, -OR 13c , -SO 2 R 13c , -SO 2 N.R. 13c R 13d , -COR 13c , -CO 2 R 13c , -CONR 13c R 13d , -NR 13c R 13d , -NR 13c C.O.R. 13d , -NR 13c CO 2 R 13d or -NR 13c SO 2 R 13d optionally substituted with; In each occurrence, R 13a , R 13b , R 13c and R 13d are each independently hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 2-8 Alkenyl, -C 2-8 alkynyl, 3- to 8-membered heterocyclyl, -C 6 -C 12 The compound is aryl, or 5- to 12-membered heteroaryl.
49. A compound according to any one of the preceding claims, comprising R 13 is hydrogen, F, Cl, Br, I, CN, -C 1 -C 8 Alkyl, or -C 1 -C 8 alkoxy, preferably R 13 is hydrogen, F, Cl, Br, I, CN, -Me, -Et, -C 3 H 7 , -C 4 H 9 , -OMe, -OEt, -OC 3 H 7 Or -OC 4 H 9 are independently selected from Here, n 7 is 0, 1, or 2.
50. A compound according to any one of the preceding claims, 【Chemical 54】 but, 【Chemistry 55】 The compound is selected from the group consisting of
51. A compound according to any one of the preceding claims, wherein the moiety 【Chemistry 56】 but, 【Chemistry 57-1】 【Chemistry 57-2】 The compound,
52. A compound according to any one of the preceding claims selected from: 【Chemistry 58-1】 【Chemistry 58-2】 【Chemistry 58-3】 【Chemistry 58-4】 【Chemistry 58-5】 【Chemistry 58-6】 【Chemistry 58-7】 【Chemistry 58-8】 【Chemistry 58-9】 【Chemistry 58-10】 【Chemistry 58-11】 【Chemistry 58-12】 【Chemistry 58-13】 【Chemistry 58-14】 【Chemistry 58-15】 【Chemistry 58-16】 【Chemistry 58-17】 【Chemistry 58-18】 【Chemistry 58-19】 【Chemistry 58-20】 【Chemistry 58-21】 【Chemistry 58-22】 【Chemistry 58-23】 【Chemistry 58-24】 【Chemistry 58-25】 【Chemistry 58-26】 【Chemistry 58-27】 【Chemistry 58-28】 【Chemistry 58-29】 【Chemistry 58-30】 【Chemistry 58-31】 【Chemistry 58-32】 【Chemistry 58-33】 【Chemistry 58-34】 【Chemistry 58-35】 【Chemistry 58-36】 【Chemistry 58-37】 【Chemistry 58-38】 【Chemistry 58-39】 【Chemistry 58-40】 【Chemistry 58-41】 【Chemistry 58-42】 【Chemistry 58-43】 【Chemistry 58-44】 【Chemistry 58-45】 【Chemistry 58-46】 【Chemistry 58-47】 【Chemistry 58-48】 【Chemistry 58-49】
53. 53. A pharmaceutical composition comprising a compound according to any one of claims 1 to 52, or a pharma- ceutically acceptable salt, stereoisomer, tautomer or prodrug thereof, in association with a pharma- ceutically acceptable excipient.
54. 53. A method of treating a disease that can be affected by EGFR modulation, comprising administering to a subject in need thereof an effective amount of a compound according to any one of claims 1 to 52, or a pharma- ceutically acceptable salt, stereoisomer, tautomer, or prodrug thereof.
55. 53. The method of claim 52, wherein the disease is selected from cancer, preferably pancreatic cancer, breast cancer, glioblastoma multiforme, head and neck cancer, or non-small cell lung cancer.
56. 53. Use of a compound according to any one of claims 1 to 52, or a pharma- ceutically acceptable salt, stereoisomer, tautomer or prodrug thereof, in the preparation of a medicament for the treatment of a disease that may be affected by EGFR modulation.
57. 57. The use according to claim 56, wherein the disease is cancer, preferably pancreatic cancer, breast cancer, glioblastoma multiforme, head and neck cancer, or non-small cell lung cancer.
Citation Information
Patent Citations
Bifunctional compounds targeting EGFR protein degradation
CN114057770A
Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
WO2020051564A1
New macrocyclic compounds and derivatives as EGFR inhibitors
WO2020260252A1
Compound for inhibiting and inducing degradation of EGFR kinase
WO2021121261A1
Protein tyrosine phosphatase degraders and methods of use thereof
WO2021127586A1
